Quarterlytics / Assura

Assura

agr · LSE
Claim this profile
Ticker agr
Exchange LSE
Sector
Industry
Employees 11-50
← All annual reports
FY2016 Annual Report · Assura
Sign in to download
Loading PDF…
Innovating and 
building for the 
future of healthcare

Annual Report 2016

Who we are
Assura is a leading UK healthcare 
REIT and our vision is to be the UK’s 
best developer and owner-manager 
of primary care property

Contents

Financial highlights

Strategic report 
1 
2  Property portfolio
4  Our milestones of the year
6  Chairman’s statement
9  Strategic review
12  Our business model 
14  Strategy 
16  Market
19  Valued over £10 million
20  Focus
22  Expertise
24  Culture
26  Effectiveness
28  Key performance indicators
30  Risk management
38  Business review
44  Sustainability
46  Charities

Governance 
48 

 Chairman’s introduction 
to governance
50  Board of Directors 
52  Corporate Governance
54  Audit Committee Report
57  Nominations Committee Report
58  Remuneration Report
86  Directors’ Report
89 

 Directors’ Responsibility 
Statement

Independent Auditor’s Report

Financial statements
90 
94  Consolidated income statement
95  Consolidated balance sheet 
96 

 Consolidated statement of 
changes in equity

Our strategies

To achieve our vision we  
have four strategic priorities:
Focus 
Maintaining a strategic focus  
on a highly attractive market 
Read more on p20

Expertise
Responding to the NHS agenda 
Read more on p22 

Culture
Investing in our people
Read more on p24

97  Consolidated cash flow statement 
98  Notes to the accounts
117  Company financial statements
123  Glossary
125  Corporate information

Effectiveness 
Leveraging our team’s skills  
to maximum advantage
Read more on p26 

 
Financial highlights

2014

2015

2016

2014

2015

2016

2014

2015

2016

2014

2015

2016

2014

2015

2016

656.7

925.3

Investment property

£1,109.4m

1,109.4

 19.9%

43.4 

44.9 

46.1

Adjusted EPRA NAV

46.1p

 2.7%

Net rental income

£58.4m

58.4

 21.2%

Underlying profit

£28.3m

28.3

 78.0%

Total dividends paid

£27.2m

 88.9%

27.2 

37.8 

48.2 

10.9 

15.9 

7.2 

14.4 

Our investment case

By following our strategies we can deliver long-term 
shareholder value through:

 ■ Low volatility of property returns

 ■ Low default risk

 ■ Linkage to cost inflation

 ■ Scalable, internally managed model

 ■ Covered, progressive dividends

 ■ Excellent risk adjusted returns.

Read more on p14

Assura plc Annual Report 2016  1

Strategic reportFinancial statements Governance www.assuraplc.com 
Property portfolio

Expanding our portfolio to support  
the primary healthcare infrastructure

A   
Alwoodley Medical Centre,  
Leeds
Completed in March 2016 to accommodate the 
former Moorcroft and Nursery Lane surgeries. 
The premises provide an excellent range of 
primary care services as well as a new X-ray  
unit on behalf of NHS Harrogate.

B   
Fleetwood Health and Wellbeing Centre, 
Fleetwood
Acquired in March 2016 this 5,857 square  
metre modern purpose built premises offers 
multiple services and treats a list size of over 
12,000 patients.

C   
Frome Medical Practice,  
Frome
This 4,087 square metre building is an example 
of the latest design in primary care premises. 
Together with 61 consulting rooms, the centre 
contains an education room, tutorial room and 
fully furnished operating theatre with the highest 
grade air extraction plant.

D   
Claremont Medical Centre,  
Surbiton
Acquired as part of Abbey Healthcare  
Group, the practice offers extensive primary 
care services and has a list size of over  
10,000 patients.

E   
Malmesbury Primary Care Centre, 
Malmesbury
The recently acquired centre opened by His 
Royal Highness The Prince of Wales in 2008 
includes an integrated pharmacy and makes 
up part of a primary care village which includes 
sheltered housing.

F   
Urmston Group Practice,  
Urmston
Completed in February 2016, this mixed use 
scheme provides 1,048 square metres of high 
quality healthcare space and resources to the  
local community. The building includes a minor 
operation suite and multi-purpose clinical rooms 
as well as additional retail units and residential 
accommodation for Trafford Housing Trust.

Portfolio analysis by capital value

Portfolio analysis by region

Portfolio analysis by tenant covenant

 Number of 
 properties

Total 
value
£m

Total 
value
%

 Number of 
 properties

Total 
value
£m

Total 
value
%

<£1m

£1–5m

£5–10m

>£10m

60

39.7

204

515.5

40

17

281.4

251.4

4

47

26

23

North

South

Midlands

Scotland

321 1,088.0

100

Wales

GPs

NHS body

Pharmacy

Other

126

466.0

95

62

19

19

309.4

220.9

37.2

54.5

43

29

20

3

5

321 1,088.0

100

Total 
rent roll
£m

Total 
rent roll
%

44.1

11.6

4.8

3.3

69

18

8

5

63.8

100

2  Assura plc Annual Report 2016

www.assuraplc.com11

6

1

1

18

6

2

21

5

2

41

4

11

1

2

6
A

3

B

8

F

7

2

14

1

9

21

3

20

7

1

5

E

C

30

D

9

3

2

8

3

3

Value of property:

  >£10m
  £5–10m

  £1–5m

  <£1m

Note: size of marker 
indicates number of 
properties of that 
category in the 
applicable region

22

4

2

1

3

2

1

Assura plc Annual Report 2016  3

Strategic reportFinancial statements Governance www.assuraplc.comOur milestones of the year

Developing and maintaining 
customer relationships

JUNE 2015

Property Developer of the Year  
In June Assura was awarded Property 
Developer of the Year at the prestigious 
Health Investor awards. Property Director 
Andrew Darke collected the award.

JULY 2015 

Media City rugby event 
July saw the first event of the Assura 
Challenge take place at The Pitch at Media 
City UK. Assura’s charities, Salford Red Devils 
Foundation and the Warrington Wolves 
Foundation, joined forces in an excellent “Play 
Touch Rugby” league tournament including 
Assura and seven other local businesses.

JULY 2015 

Frome Medical Practice acquisition  
In July we acquired Frome Medical Practice. 
The practice, located in Somerset, is 
adjacent to the community hospital and 
offers over 23 additional services including 
physiotherapy and minor surgery. 

Read more on p46

  Read more at www.assuraplc.com

JANUARY 2016 

FEBRUARY 2016 

Malmesbury Primary Care 
Centre acquisition 
In January we acquired Malmesbury Primary 
Care Centre. The centre, located in Wiltshire, 
offers over 21 additional services and makes 
up part of a primary care village which includes 
a pharmacy and sheltered housing. 

Completion of Urmston development 
In February we completed the forward funded mixed use scheme for 
Urmston Group Practice. The new development provides 1,048 square 
metres of high quality healthcare space and resource to the local 
community. The building includes a minor operation suite and 
multi-purpose clinical rooms that enable the delivery of GP services  
and GP training facilities, as well as additional retail units and residential 
accommodation for Trafford Housing Trust.

4  Assura plc Annual Report 2016

www.assuraplc.com 
 
NOVEMBER 2015 

NOVEMBER 2015 

DECEMBER 2015 

Abbey Healthcare Group acquisition 
November saw us acquire Abbey Healthcare 
Group Limited and Abbey Healthcare Property 
Investments Limited, owner companies of 
three primary care premises. The premises, 
located in Surbiton, Milton Keynes and 
Kilmeny, provide GP services for over 
30,000 patients.

£300 million equity raise 
In November we successfully completed 
an equity raise of £300 million, net of expenses. 
The equity raise financed multiple acquisitions 
and enabled us to repay £181 million of 
long-term debt and reduce our overall 
debt by 36% since 31 March 2015. 

Read more on p9

Assura enters the FTSE 250 Index 
December saw us join the London Stock 
Exchange’s FTSE 250 Index following three 
years of significant growth. 

FEBRUARY 2016 

Acquisition of Well Street Surgery, Hackney 
In February we completed the acquisition of Well Street Surgery, Hackney. The 
centre delivers a multitude of services including antenatal, diabetes clinic, drug 
misuse and dermatology. The ground floor includes a large community room and 
provides modern kitchen facilities to run classes for the local population, providing 
food education courses on how, and where, to shop for food in the locality and, 
subsequently, cooking classes.

MARCH 2016 

Completion of Ashby de la 
Zouch development  
In March we completed the forward funded 
development for Castle Medical Group. The 
development, called Ascebi House, includes 
modern compliant general practice rooms, 
space for staff training, a patient records room 
and an integrated pharmacy. The site even 
includes an environmentally friendly bat box. 

Assura plc Annual Report 2016  5

Strategic reportFinancial statements Governance www.assuraplc.com 
Chairman’s statement

We have a unique proposition 
in our sector as developer, 
landlord and asset manager

 “The overwhelming need in this 
country for improved primary 
care premises underpins the 
future of Assura”

SIMON LAFFIN
EXECUTIVE CHAIRMAN

DEAR SHAREHOLDER
It has been another busy and successful 
year for Assura, and a year in which 
we have continued the Group’s strong 
growth. We have significantly grown our 
property portfolio this year both through 
acquisitions and new developments. 
Thanks to the continued support of 
our shareholders, we were able to raise 
£300 million, net of expenses, in an equity 
raise this year to fund our investment 
programme. We are well advanced in 
implementing our plan to use these 
proceeds. Since the fund raise, we have 
made property additions of £79 million, 
reduced net debt by £193 million and 
we have a pipeline of further property 
acquisitions and developments of 
£134 million. Our gearing is now at 30%, 
well within our reduced target range. 
We are now the UK’s largest developer 
and owner-manager of primary healthcare 
property, and entered the FTSE 250 in 
December last year and have a market 
cap of £950 million. 

As we announced in March this year, 
Graham Roberts, our Chief Executive 
since 2012, is currently on a leave of 

6  Assura plc Annual Report 2016

absence, receiving treatment for cancer 
and so, for the time being, I have assumed 
the role of Executive Chairman. This will 
ensure that we continue to exercise our 
agreed strategy and drive superior risk 
adjusted returns for our shareholders.

Rent roll

£63.8m

 up 15% 

Quarterly dividend per share

0.55p

 up 10% 

A key part of this strategy is our 
unique proposition of offering all of the 
elements of the property service for GPs, 
which enables us to offer GPs a long-
term partner approach throughout the 
lifecycle of a medical centre. Our ability 
to “develop, invest and manage” gives us 
a crucial advantage when securing new 
development opportunities and other 
asset management initiatives. Moreover, 
it provides a highly scalable model that 
means as we grow, the benefits of scale 
accrue to shareholders, and drive our 
progressive dividend policy. 

The efficacy of this model has been 
illustrated in the year as we have increased 
our rent roll by 15% to £63.8 million, our 
underlying profit by 78% to £28.3 million 
and our dividends paid during the year 
by 89% to £27.2 million. 

www.assuraplc.comLoan to value

30%

Capital invested in past four years

£500m

Market developments
We continued to engage widely with 
the NHS and the Government throughout 
the course of the year to make the case 
for further investment in primary care 
infrastructure, primarily through the 
British Property Federation’s Healthcare 
Committee. The recognition of the 
importance of this investment by the 
NHS can be seen in its recent publication 
of the General Practice Forward View, 
which announced increased funding 
for “staff, technology and premises”.

Everyone accepts that the increasing 
health needs of a growing and ageing 
population are putting a strain on the 
public purse. There is a shortage of  
GPs, and secondary health (i.e. hospital) 
resources are both expensive and 
overstretched. According to a recent 
report from the think tank Reform,  
a GP appointment each costs £21.  
If that patient chooses instead to go 
to a hospital A&E department, that visit 
costs almost six times more, an average 
of £124. Patients prefer to access health 
treatment from their primary practitioner 
and the primary care treatment costs 
the NHS significantly less as well. The 
Government needs to take a long-term 
view of health service provision in the UK. 
This would require recruiting more GPs, 
and funding modern flexible properties 
for those GPs to work in. Scarce GP 
resources can be leveraged by providing 
additional co-located services across 
a wide range of health and social care 
professionals, such as diagnostics, 
self-help and outpatient services which 
improve the care pathway. This will help 

to reduce the pressures and financial 
burdens elsewhere in the NHS and 
improve the patient experience. The 
benefits of this model are explicitly 
recognised in the General Practice 
Forward View report. Replacing some 
expensive secondary care with enhanced 
primary care would save the NHS large 
sums of money, and improve the 
patient experience. 

It is clear that excellent primary care 
requires modern buildings and fit-out. 
Doctors need hygienic, warm and 
sound-proof facilities, as demanded by 
the Care Quality Commission. About half 
of all GP surgeries cannot provide this  
in their current premises, and so require 
redevelopment. Such redevelopment 
gives Clinical Commissioning Groups  
the opportunity to bring a variety of 
community care services under one roof 
and so offer a more complete service. 
Property management is an essential 
part of the NHS provision for the future.

The UK has a unique model for primary 
care property. All new developments have 
to be approved by the NHS. Completed 
properties are then valued and rents 
agreed with the District Valuer, an 
HMRC employee. The Government 
therefore can ensure value for money from 
any private investment. In turn, the NHS 
commissioning body offers developers 
a long (typically 21 or 25 year) contract, 
which is set at a rent that takes account 
of both the lease length and the strength 
of the ultimate Government backstop. 

“Excellent primary care requires  
modern buildings”

Assura plc Annual Report 2016  7

Strategic reportFinancial statements Governance www.assuraplc.comChairman’s statement continued

The result is that GPs, and ultimately 
the NHS, pay a very competitive rent that 
is lower than it otherwise would be. The 
system enables the NHS to call on private 
money for new developments, avoiding 
any need for Government capital 
investment. It is a highly efficient and cost 
effective model for the private sector 
funding of state medical infrastructure.

Shareholders
We are committed to the highest 
standards of financial transparency and 
believe a significant investment in investor 
relations activity is a key responsibility for 
any public company. We have held 119 
meetings with investors during the year 
and I am delighted to welcome a number 
of new shareholders onto our register. We 
are very grateful to our shareholders for 
the level of support demonstrated during 
the year which enabled us to increase our 
equity base by 60%. We successfully met 
the criteria for inclusion in the FTSE 250 
Index in December 2015 and this provides 
further exposure for the Company to an 
enlarged group of investors. 

Dividends
We are committed to providing our 
shareholders with superior risk adjusted 
returns and a key component of this return 
is a growing, covered dividend. In January 
2016 we increased our quarterly dividend 
payment by 10% to 0.55 pence per share 
or 2.2 pence per share on an annualised 
basis. We also took the opportunity in 
January to provide our shareholders with 
the flexibility of receiving their dividends in 
shares through a scrip alternative share 
scheme. This has been taken up by 13% 
of our shareholders, which underlines the 
value of the scheme.

Our people and the Board
We have 34 people in Assura and, on 
behalf of the Board, I would like to thank 
them all for their hard work, dedication 
and contribution to the success of the 
business over such a busy year for 
the Company. 

The future
Over the past four years we have invested 
£500 million capital and £3.3 million in 
the maintenance of the UK’s primary 
care estate. Thanks to the support of our 
shareholders, we have built the strongest 
balance sheet in the sector and we plan 
to continue deploying this capital in UK 
primary care. Our in-house management 
team intends to continue delivering 
excellent customer service and operational 
excellence for the nation’s GPs, while 
maximising the value of our portfolio 
through asset management initiatives. 

Rent review increases have been 
relatively low in the last few years, 
due to both low general inflation 
and the scarcity of comparative new 
developments. However, yields have 
strengthened somewhat over that period, 
reflecting the long-term attractiveness 
of the sector to investors. The Board 
believes that when the NHS steps up 
its approvals for new developments, 
as surely it must, rental growth will 
accelerate. The overwhelming need in 
this country for improved primary care 
premises underpins the future of Assura.

SIMON LAFFIN 
EXECUTIVE CHAIRMAN
17 May 2016

8  Assura plc Annual Report 2016

www.assuraplc.comStrategic review

We have delivered growth in our 
investment portfolio of 20%

“Our portfolio is well placed 
to capture rental growth once 
new developments recommence”

JONATHAN MURPHY
FINANCE DIRECTOR

Underlying profit

£28.3m

 up 78% 

Dividends paid

£27.2m

 up 89% 

Building scale
Assura continues to grow profitably.  
In the year we completed £141 million of 
property additions, which was the largest 
contributor to the £184 million increase 
in investment property in the year. This 
has enabled our rent roll to grow by 15% 
to £63.8 million. In turn, this has been 
passed on to a 78% growth in underlying 
profit to £28.3 million and 89% growth in 
dividends paid in the year to £27.2 million. 

The attractiveness of our sector is 
becoming more widely understood 
and as such Assura’s portfolio expansion 
has been achieved against a backdrop 
of an increasingly competitive market. 
Our strong brand recognition, substantial 
experience in the sector and our reputation 
in the GP community have allowed us to 
successfully secure these opportunities. The 
primary care property market remains highly 
fragmented. Our portfolio of 321 medical 
centres compares with a total UK market of 
close to 9,000 buildings. A large number of 
these buildings would not meet our exacting 
investment criteria, although there remains 
a significant number of potential individual 
asset acquisition opportunities.

This year, our growth has been achieved 
predominantly through single asset 
purchases and without the benefit of large 
scale portfolio acquisitions as in prior years. 
This has been achieved through targeted 
marketing and promotional activities that 
focused on those medical centres that 
represent the key premises in their local 
health economy. 

Driving investment in primary 
care property
The equity fund raise of £300 million, net 
of expenses, in October 2015 was key to 
delivering this substantial investment. We 
are grateful to our shareholders for their 
support and the level of investor demand 
enabled us to secure an increase in our 
equity base of 60%. 

Since the fund raise we have been focused 
on the stated twin objectives of making 
further additions to our property portfolio 
and reducing our borrowings. Since 
October we have secured further property 
additions of £79 million at a yield on cost of 
5.1% and a weighted average unexpired 
lease term of 20.3 years. In addition to the 

Assura plc Annual Report 2016  9

Strategic reportFinancial statements Governance www.assuraplc.comStrategic review continued

Rental income
The key driver of our property return is 
the income from our long-term leases, 
and in the year, rental growth was 1.2% 
from settled rent reviews, ahead of CPI 
inflation at 0.6%. Most of our rent reviews 
are on an open market basis, set by 
reference to rental awards agreed with 
the District Valuer on new schemes. This 
means that they are influenced by land 
and construction cost inflation over the 
medium term. Over recent years there 
has been significant inflation in these 
costs, but this increased cost is not yet 
fully reflected in our passing rents as the 
slowdown in new schemes has reduced 
the evidence of that inflation.

Our portfolio is well placed to capture  
this rental growth once new developments 
recommence and this gives us confidence 
for the medium term prospects for rental 
growth in our sector.

Capital growth
The balance of the return is generated 
from capital growth, which has seen a 
like-for-like valuation growth of 4.8% in 
the past year. This increase has primarily 
come from a movement in yields with our 
net equivalent yield moving by 25 basis 
points in the past year. This relatively 
moderate repricing over the past year 
still leaves our yields maintaining a 
premium over fixed return gilts in 
excess of 330 basis points.

completed transactions we also have a 
further pipeline of individual development 
opportunities and acquisitions of more than 
£134 million. 

Our second key objective was to 
reduce our borrowings and we revised 
our target loan to value range to between 
40% and 50%. Since we closed the  
year at 30%, this provides us with the 
financial flexibility to take advantage  
of future acquisition and development 
opportunities. We plan to maintain this 
target range over the medium term.

Delivering long-term 
outperformance in 
property returns
The enlarged property portfolio has 
delivered a Total Property Return of 
8.9%. Assura is a constituent of the IPD 
All Healthcare Index and over the last five 
years we have delivered a return of 8.8% 
against the index of 6.9%. This level of 
consistent outperformance over a long 
period is a testament to the skills and 
dedication of our property team and  
to the specialist knowledge we have  
in our sector.

In November 2015 we negotiated the 
redemption of £181 million of long-term, 
fixed rate loans with Aviva, with an 
average interest rate of 5.4%. This was 
achieved with associated break costs 
of £34 million, which were significantly 
below our initial estimated costs of 
£40 million. At the year end we had 
borrowings of £373 million with an 
average interest rate of 4.8% and 
a weighted maturity of 10.2 years.

One of our stated intentions from the  
fund raise was to enable improvements 
in both terms and pricing for future funding. 
The increased scale and balance sheet 
strength of the business makes us more 
attractive to capital markets and to a 
broader range of both bank and non-
bank funders. 

After the year end, we secured a new 
£200 million unsecured revolving credit 
facility with a club of four banks. This 
unsecured facility replaces our existing 
£120 million facility and will provide us 
with the maximum operational flexibility 
together with a significant saving on 
transaction costs in financing properties. 
This has been achieved at an initial 
margin of 150 basis points, at a rate 
of 2.09%, significantly below that of 
the Aviva debt that it partially replaces.

Our 321 medical centres have a rent roll 
of £63.8 million with a geographically 
diverse portfolio serving in excess 
of 3 million patients. Our investment 
approach is to identify those assets 
we believe are best in class in their local 
catchment areas. By acquiring those 
assets that provide a broad range of 
services to their local communities, 
we believe these will provide greater 
prospects for lease renewal on expiry 
and so drive greater property returns 
over the long term. 

A good example of this approach 
can be seen in our acquisition of 
Frome Medical Practice. This centre 
serves 30,000 patients and contains 
61 consulting rooms, an education 
suite and fully furnished operating 
theatre. This infrastructure supports 
a broad range of services including 
pharmacy, opticians and mental health 
services in addition to the GP practices. 

For key properties, we are not afraid 
to acquire shorter leases, and use our 
property skills to redevelop or enhance 
the premises, whilst seeking to regear  
the lease to a longer period.

10  Assura plc Annual Report 2016

www.assuraplc.comEPRA cost ratio

16.5%

Total Property Return

8.9%

Our team of portfolio and investment 
managers has responsibility for 
identifying value enhancing asset 
management opportunities, such as 
lease extensions and redevelopments 
within our existing estate, as well as 
new acquisition opportunities.

This structure enables us to ensure 
that we can maximise the efficiency with 
which we can translate increased rental 
income into underlying profit and hence 
dividends. In the year we have delivered 
78% growth in underlying profit to 
£28.3 million. This has been achieved 
from 20% growth in our investment 
property value and a reduction in our 
EPRA Cost Ratio from 17.7% to 16.5%. 

The overall impact of all of these factors 
has enabled us to increase our dividends 
paid by 89% from £14.4 million  
to £27.2 million.

Developing our people
One of our core strategic priorities is 
enhancing our business culture and we 
are committed to the development and 
training of our people. We have a small 
head office team of 34 people and crucial 
to our success is developing the skills of 
our team. We have eight people currently 
undergoing formal training. We have 
strengthened the team in the year through 
the recruitment of Orla Ball as Company 
Secretary and In-House Counsel. 

We also add value through developing 
properties ourselves rather than relying 
solely on third party developers and 
managers. We completed one development 
during the year at a total development cost 
of £3.8 million. This has added £0.3 million 
to our annual rent roll. Our in-house 
development capability gives us the 
opportunity to source new premises at 
levels significantly cheaper than we could 
achieve through purchasing completed 
properties from developers. On a typical 
scheme we are able to source a 
development at a 1% higher yield on cost 
than for an equivalent property acquired in 
the investment market. In addition, by being 
involved as a developer, long-term landlord 
and asset manager we are able to build 
effective long-term relationships with our 
GPs and this provides us with a unique 
positioning and market insight in our sector.

The level of development expenditure in 
the year is significantly below the levels 
we would normally expect. This reflects 
the reduced level of developments across 
the sector, although we have sourced 
three new developments under forward 
funding agreements bringing the value 
of completions during the year to 
£16.4 million. We remain positive that the 
substantial requirement for investment in 
primary care infrastructure will lead to an 
increase in developments in the future. 

Maximising operational 
efficiency
The £141 million of property additions  
have been incorporated by our in-house 
property management team whilst 
maintaining our continued focus on 
tenant satisfaction. In our annual tenant 
satisfaction survey over 90% of our 
tenants said they would recommend us as 
potential landlords to other GPs. Our GPs 
remain our greatest source of referrals for 
new business. We remain focused on 
understanding their evolving needs and 
demands, so we can be at the forefront 
of the significant investment required 
in improving premises in the future. 

Assura plc Annual Report 2016  11

Strategic reportFinancial statements Governance www.assuraplc.com 
Our business model

A simple business model to deliver 
superior risk adjusted returns

What we need 

Customer relationships
Knowledge of GPs’ evolving requirements 
through our involvement in the design 
and management of medical centres 
gives us a unique insight into their 
property needs.

Assets
Our bespoke medical centres are 
constructed in locations that are crucial 
to the local health economy and to the 
highest sustainability standards.

People
Our small team of 34 people 
covers the key skills of real estate 
ownership and includes asset and 
property management, development, 
investment, marketing and financing.

Partners
We maintain strategic partnerships  
with the leading architectural practice 
in the sector and a number of specialist 
healthcare developers to complement 
our in-house expertise.

Capital
The support of our shareholders, banking 
partners and bondholders is crucial to 
sustaining our investment in the UK’s 
health infrastructure.

What we do

Develop

Invest

Manage 

Our strategic priorities

Focus

Read more on p20

Expertise 

Read more on p22

Maintaining a strategic focus on a highly  
attractive market 

Responding to the NHS agenda 

12  Assura plc Annual Report 2016

www.assuraplc.comWe develop, invest and manage a portfolio of 
primary care medical centres across the UK

We aim to generate attractive financial and social 
returns for our shareholders and wider stakeholders 
by investing in high quality, sustainable medical 
centres that provide crucial infrastructure for 
their local health economy

Develop
Our team of development managers work with our 
design and development partners to provide bespoke, 
community-led property solutions for each of our 
healthcare partners. We monitor and manage the 
process from design through to delivery of the 
completed building. 

Invest
As a long-term investor we are committed to any new 
development being constructed to the highest possible 
standards and to its ongoing efficient operation and 
maintenance. We support the evolving requirements 
of the GPs through lease renewals, property extensions 
or co-locating appropriate partners such as pharmacies. 

Manage 
Our team of property surveyors manage the medical 
centres and their efficient operation through frequent 
liaison with our tenants. This integrated approach enables 
us to capture more development and other added value 
opportunities. Our internally managed structure provides 
a highly scalable model that means as we grow the 
benefits of scale accrue to shareholders and help drive 
our progressive dividend policy.

The value 
we create

Key beneficiaries of our value creation:

GP customers
Our purpose built medical centres provide  
the essential infrastructure to allow GPs  
to provide a broader range of healthcare  
services in the community.  

Communities
£29,520 plus employee time donated to  
our local charity partners. Our medical centres 
provide a crucial community resource to aid 
improved health outcomes in their locations.

Employees
Over £2.6 million paid to our employees. 
In addition Assura actively promotes training 
and development for our staff.

Shareholders
£27.2 million paid as dividends to shareholders  
during the year.  
Dividends per share of 2.05 pence.  
Earnings per share of 2.2 pence.

Suppliers
Over £47.9 million paid to suppliers of  
materials and services. Our construction  
and management contracts are often with 
local suppliers to promote sustainability.

Government
Over £5.5 million paid in taxes to UK Government.

Culture

Read more on p24

Effectiveness

Read more on p26

Investing in our people

Leveraging our team’s skills to maximum advantage 

Assura plc Annual Report 2016  13

Strategic reportFinancial statements Governance www.assuraplc.comStrategy

Four key priorities to sustain 
performance for the long term

Strategic priority

Performance in 2016

Priorities for 2017

Key risks

Focus

Assura has a deep understanding of the  
economic dynamics of healthcare real estate. 
By building on the knowledge and expertise of 
our team and engagement with our healthcare 
partners we believe we can generate superior 
Total Property Return through a strategic focus 
on a highly attractive market.

  Read more on p20

Expertise

The Assura brand has a strong reputation for 
innovation derived from our bespoke designs 
for our medical centres. Our designs have an 
emphasis on flexibility and adaptability to 
ensure that the buildings can adapt to the 
changing NHS agenda.

  Read more on p22

Culture

We pride ourselves on our commitment to 
the highest possible standards in everything 
we do, our commitment to the sustainability 
agenda, the personal development of our 
teams and our role in spearheading 
investment in social infrastructure.

  Read more on p24

Effectiveness

We are committed to supporting the NHS 
in tackling the major underinvestment in UK 
primary care property and utilising our skills 
and capital in achieving this. We have the 
right team to source and manage these 
opportunities and the right plans to leverage 
our team’s skills to maximum advantage.

  Read more on p26

14  Assura plc Annual Report 2016

 ■  Delivered rental growth  
of 1.2% from settled 
rent reviews.

 ■ Drive development 

opportunities to support 
rental growth evidence.

 ■ 20% growth in investment 
property to £1,109 million. 

 ■ Total Property 
Return of 8.9%.

 ■  Outperformed the IPD All 
Healthcare Index by 1.9%.

 ■ Investment managers 
to focus on asset 
enhancement opportunities.

 ■  Continue to seek growth 
opportunities through 
acquisitions and purchase 
and leasebacks.

 ■  Engaged with senior NHS 
leaders and politicians to 
support transforming 
primary care property. 

 ■  Delivered four newly 

constructed bespoke 
GP-led medical centres.

 ■  Promote benefits of 

investment in primary care 
infrastructure for the NHS.

 ■ Build on a strong brand with 
GPs to be at the forefront of 
new development planning.

 ■  One of our four newly 
constructed medical 
centres achieved  
BREEAM Excellent, with 
the remainder achieving 
Very Good.

 ■ Develop zero carbon 

medical centre of the future 
for the NHS.

 ■ Further investment in our 

team’s development.

 ■ Property additions of 
56 medical centres 
(£141 million).

 ■ EPRA Cost Ratio reduced 

from 17.7% to 16.5%.

 ■ Accounting return has 
fallen to 7.2%, which 
reflects one-off costs 
from restructuring debt 
and new equity issuance.

 ■ Seek further opportunities 
to expand the portfolio.

 ■ Continue to promote 

the Company to a wide 
shareholder base and 
a diverse group of 
debt funders.

 ■ Achieve further scale 
benefits, particularly 
through reduced cost 
of debt.

 ■ The development pipeline remains subdued and continued 

uncertainty over NHS approval processes for new developments 

could lead to further delays in re-building this pipeline.

 ■ The market is becoming increasingly competitive but  

our strong brand and reputation as a long-term investor  

in the sector means we are well placed to secure further 

attractive opportunities.

Property return

KPIs

2016

2015

 8.9%

 7.8%

 ■ Further changes to the organisational structures or policies of 

the NHS could lead to delays to further investment in primary 

care infrastructure. However, the current Government remains 

committed to increased funding for the NHS and an increasing 

role for primary care service provision.

% NHS tenant covenant

2016

2015

2016

2015

2016

2015

 87.3%

 86.8%

 B

 B

 7.2%

 7.7%

 ■ Sustainable development and building design is an  

area of constant change and we are required to ensure  

that we are fully up to date with the latest technologies  

and innovations.

Average EPC rating

 ■ Maintaining cost discipline as the business expands will  

be crucial in ensuring that we continue to reduce our overall 

EPRA Cost Ratio. Included within this metric is the cost of 

vacant space and so letting this available space will improve 

this cost metric.

 ■ We have been successful in securing both equity and debt capital 

for supporting the expansion of the business although there is no 

certainty that future expansion will be supported in the same way. 

We believe the fundamentals of the business remain very strong 

and attractive to both equity and debt funders. 

Accounting return

www.assuraplc.com ■  Delivered rental growth  

 ■ Drive development 

of 1.2% from settled 

rent reviews.

opportunities to support 

rental growth evidence.

 ■ 20% growth in investment 

 ■ Investment managers 

property to £1,109 million. 

to focus on asset 

 ■ Total Property 

Return of 8.9%.

 ■  Outperformed the IPD All 

Healthcare Index by 1.9%.

enhancement opportunities.

 ■  Continue to seek growth 

opportunities through 

acquisitions and purchase 

and leasebacks.

 ■  Engaged with senior NHS 

 ■  Promote benefits of 

leaders and politicians to 

investment in primary care 

support transforming 

primary care property. 

 ■  Delivered four newly 

constructed bespoke 

GP-led medical centres.

infrastructure for the NHS.

 ■ Build on a strong brand with 

GPs to be at the forefront of 

new development planning.

Focus

Assura has a deep understanding of the  

economic dynamics of healthcare real estate. 

By building on the knowledge and expertise of 

our team and engagement with our healthcare 

partners we believe we can generate superior 

Total Property Return through a strategic focus 

on a highly attractive market.

  Read more on p20

Expertise

The Assura brand has a strong reputation for 

innovation derived from our bespoke designs 

for our medical centres. Our designs have an 

emphasis on flexibility and adaptability to 

ensure that the buildings can adapt to the 

changing NHS agenda.

  Read more on p22

Culture

We pride ourselves on our commitment to 

the highest possible standards in everything 

we do, our commitment to the sustainability 

agenda, the personal development of our 

teams and our role in spearheading 

investment in social infrastructure.

  Read more on p24

Effectiveness

We are committed to supporting the NHS 

in tackling the major underinvestment in UK 

primary care property and utilising our skills 

and capital in achieving this. We have the 

right team to source and manage these 

opportunities and the right plans to leverage 

our team’s skills to maximum advantage.

  Read more on p26

Strategic priority

Performance in 2016

Priorities for 2017

Key risks

 ■ The development pipeline remains subdued and continued 

uncertainty over NHS approval processes for new developments 
could lead to further delays in re-building this pipeline.

 ■ The market is becoming increasingly competitive but  

our strong brand and reputation as a long-term investor  
in the sector means we are well placed to secure further 
attractive opportunities.

KPIs

Property return

2016

2015

 8.9%

 7.8%

 ■ Further changes to the organisational structures or policies of 
the NHS could lead to delays to further investment in primary 
care infrastructure. However, the current Government remains 
committed to increased funding for the NHS and an increasing 
role for primary care service provision.

% NHS tenant covenant

2016

2015

 87.3%

 86.8%

 ■  One of our four newly 

 ■ Develop zero carbon 

constructed medical 

centres achieved  

BREEAM Excellent, with 

the remainder achieving 

Very Good.

medical centre of the future 

for the NHS.

 ■ Further investment in our 

team’s development.

 ■ Sustainable development and building design is an  

area of constant change and we are required to ensure  
that we are fully up to date with the latest technologies  
and innovations.

Average EPC rating

2016

2015

 B

 B

 ■ Property additions of 

 ■ Seek further opportunities 

56 medical centres 

(£141 million).

to expand the portfolio.

 ■ Continue to promote 

 ■ EPRA Cost Ratio reduced 

the Company to a wide 

from 17.7% to 16.5%.

 ■ Accounting return has 

fallen to 7.2%, which 

reflects one-off costs 

shareholder base and 

a diverse group of 

debt funders.

 ■ Achieve further scale 

from restructuring debt 

benefits, particularly 

and new equity issuance.

through reduced cost 

of debt.

 ■ Maintaining cost discipline as the business expands will  

be crucial in ensuring that we continue to reduce our overall 
EPRA Cost Ratio. Included within this metric is the cost of 
vacant space and so letting this available space will improve 
this cost metric.

 ■ We have been successful in securing both equity and debt capital 
for supporting the expansion of the business although there is no 
certainty that future expansion will be supported in the same way. 
We believe the fundamentals of the business remain very strong 
and attractive to both equity and debt funders. 

Accounting return

2016

2015

 7.2%

 7.7%

Assura plc Annual Report 2016  15

Strategic reportFinancial statements Governance www.assuraplc.comMarket

Long-term track record and strong 
relationships with the NHS and GPs

“A secure and predictable 
income stream, with an 
underpinning of inflation 
linkage, is a highly 
attractive proposition”

ANDREW DARKE
PROPERTY DIRECTOR

Market outlook
The primary care sector is characterised 
by strong real estate fundamentals: 
secure occupier covenants, minimal 
development risk, restricted supply with 
no speculative development and long 
leases without breaks. In addition, the 
underlying open market rent review 
mechanism most common in the sector 
has provided inflation tracking returns 
over the medium term.

A secure and predictable income stream, 
with an underpinning of inflation linkage, 
is a highly attractive proposition for an 
investor who is looking for an alternative 
investment in real estate, with different 
characteristics to mainstream sectors, 
such as residential, retail or office. 
The relative stability and quality of the 
underlying income stream are particularly 
relevant at a time of macro-economic 
uncertainties in the global economy 
and in the UK’s relationship with Europe. 
In addition, the sector is experiencing 
increasing demand at a time when 
supply has been heavily restricted by 
the approval processes of the NHS. 
There are increasing signs that this latter 
situation is improving and the unblocking 

of the significant investment required 
in primary care property will become 
more likely.

The relative attractiveness of our asset 
class is shown in the chart (see page 17) 
from IPD that shows the overall return 
and the level of volatility of that return since 
its inception to 2015. Primary healthcare 
provides both the second highest level 
of return and the lowest level of volatility 
over that period. If you put those two 
factors together, then primary healthcare 
provides the best risk adjusted return over 
a nine-year time horizon.

Increasing demand
Assura as a developer and investor 
in primary care property provides 
bespoke, purpose built premises that 
meet the evolving needs of GPs as 
they look to meet the increasing health 
requirements of the UK population.

of additional services that are available 
in our modern purpose built premises.  
In the 2014 BMA Survey of GP practices 
40% of GPs stated that their premises 
were not fit for purpose. 

The demands on our health service are 
increasing with a greater requirement  
for treatment of patients with long-term 
conditions, now accounting for 50% of 
GP appointments. Across the system, 
such patients consume 70% of health 
and social care spending. This is a rising 
trend. By 2018, the number of people 
with multiple long-term health conditions 
will rise to 2.9 million – an increase of 
1 million since 2008.

The Office for National Statistics has 
recently updated its population forecasts 
for the next 25 years. These highlight 
both a growth in overall population 
and significant changes in age profile. 

GPs are the cornerstone of the UK health 
model and provide consultations with 
over 1.3 million patients every day. Many 
of these consultations take place in 
outdated and unsuitable premises that 
are not able to provide the broad range 

The demographic profile forecast 
for the country in 2039 represents a 
considerable national challenge. The 
number of people aged 75 or over is 
expected to be 90% higher at 9.9 million 
people and the number of people over 85 

16  Assura plc Annual Report 2016

www.assuraplc.comis set to more than double to 3.6 million. 
This elderly age group have many chronic 
conditions that force them to be major 
consumers of healthcare resources.  
On average the over 85s visit their  
GP 13 times a year. 

The population is also expected to 
continue to grow with one of Western 
Europe’s highest birth rates, and more 
children will add to the demands on 
primary care. These demographic  
trends highlight the challenges faced  
by the NHS and point to the need for a 
sustained investment programme. GPs 
need fit for purpose buildings to deliver 
more and better services to a growing 
and more demanding patient population.

The increasing role of the primary care 
sector and the importance of greater 
service provision in the community are 
well recognised by the NHS as highlighted 

in the NHS England “General Practice 
Forward View” report. The report commits 
to increased funding for GP services of 
£2.4 billion annually by 2021. This report 
from the NHS explicitly recognises the 
need for investment in staff, technology 
and premises. As part of its proposals 
this replaces the £1 billion Primary Care 
Transformation Fund, which provides 
capital for GP premises to support the 
greater provision of services, extended 
opening hours and new ways of working, 
with an Estates and Technology 
Transformation Fund (Primary Care). This 
revised fund has a further £250 million 
and an extension in its duration of two 
years, though the detailed guidelines 
and criteria for project selection are still 
being clarified. However, the need for 
investment is clear and the desire for this 
to transform the delivery of primary care 
is also evident across the GP community. 
The delivery of these projects and their 

1.3m

In 2039 the number of people 
aged 75 or over is expected to be 
90% higher at 9.9 million people

2.9m

On average the over 85s visit 
their GP 13 times a year

Risk reward spectrum
Nine-year Total Return vs standard deviation 2007–2015  
(since the inception of the IPD Healthcare Index)

Assura plc Annual Report 2016  17

EquitiesOfficeIndustrialAll propertyRetailRisk (standard deviation)increased riskreduced riskSOURCE: IPD UK Annual Property Index; MSCI; J. P. Morgan 7-10yrTotal Return (per annum)1618141012864200%1%2%3%4%5%6%7%8%9%10%All HealthcareResidential indexBondsPrimaryHealthcareStrategic reportFinancial statements Governance www.assuraplc.comMarket continued

timing remains uncertain though we 
continue to work with GPs across the 
country on submissions to secure 
approval for relevant projects.

A further development is the increasing 
coordination of health and social care 
and the greater involvement of GPs in  
this service provision, as evidenced 
by the recent announcement of the 
devolved healthcare budget for Greater 
Manchester, so-called “Devo Manc”.  
This provides a unified funding model 
for primary care, secondary care and 
social care and has seen the £6 billion 
budget devolved to Greater Manchester. 
The Greater Manchester Health and 
Social Care Devolution Strategic Plan 
(December 2015) identifies the need for 
greater provision of community-based 
and preventative services outside of 
the hospital sector and places a strong 
emphasis on the role of GPs in delivering 
these services. However, this will require 
significant investment in primary care 
infrastructure to enable this greater range 
of services to be provided in the 
community setting. 

The NHS recognises that it needs to 
meet the increasing health needs of a 
larger and ageing population through  
a more efficient model than is currently 
practised. Devo Manc represents one 
possible way of tackling the issues. There 
are also a large number of other models 
of service delivery being trialed across the 
country and these are approaching the 
same issues from a number of different 
angles. Some initiatives are looking at 
grouping GPs together in Federations, 
others at GPs working under NHS 
Foundation Trusts and working more 
cooperatively with the hospital sector.

Whatever model or range of models is 
ultimately selected for service delivery, 
modern fit for purpose premises will be 
needed to enable a wider range of services 
to be provided by a broader range of 
medical practitioners. A recent study 
highlighted how a primary care-led urgent 
care service was able to offer urgent care 
at a third of the cost of the local A&E 
services. It is also highlighted that some 
commentators believe as much as 50% of 
the current appointments fulfilled by GPs 
could be handled by alternative medical 

Net initial yield movement

practitioners such as pharmacists and 
nurses. Co-located practices in larger, 
modern buildings are best placed to facilitate 
this shift in the model of service delivery.

These market dynamics make for a very 
attractive long-term opportunity and as 
the largest investor developer of primary 
care infrastructure we stand ready to play 
an even larger role in supporting the NHS. 

Market overview
The continuing attractiveness of our 
sector for its security and longevity of 
income has seen yields tightened with  
a movement of 27 basis points on a net 
initial basis and 25 basis points on our 
net equivalent yield. 

The chart on the left illustrates the 
movement in our net initial yield as 
against the IPD monthly UK index  
and the 15-year gilt.

Our sector is distinct from the wider 
commercial property market and returns 
are not subject to the same cyclicality. 
This chart highlights that yields have 
been extremely stable and have not 
moved as much as the wider market, 
despite the fact that the quality and 
longevity of our cash flows are arguably 
significantly more attractive than a 
UK-wide benchmark index. It is notable 
that the recent volatility in the wider 
commercial property market has not 
impacted our valuations. We continue to 
see value in this market and are actively 
looking for investment opportunities at 
the current pricing levels.

18  Assura plc Annual Report 2016

 IPD monthly UK index initial yield         Assura net initial yield          15-year gilt0Jun06Jun07Mar08Mar10Mar09Mar11Mar12Mar13Mar14Mar15Mar1612345678%www.assuraplc.comValued over £10 million

2

3

6

1

4

5

Building

Aspen Centre, The  2

Beam Street Medical Centre

Bonnyrigg Medical Centre

Church View Medical Centre

Eaglebridge Health and Wellbeing Centre  1

Fleetwood Health and Wellbeing Centre 

Freshney Green Primary Care Centre  4

Frome Medical Centre

Gloucester

Nantwich

Bonnyrigg

South Kirkby

Crewe

Fleetwood

Grimsby

Frome

Market Drayton Primary Care Centre

Market Drayton

Moor Park Health Leisure Centre  6

North Ormesby Health Village

One Life Building  3

Severn Fields Health Village  5

South Bar House

Todmorden Medical Centre

Turnpike House Medical Centre

Waters Green Medical Centre 

Blackpool

North Ormesby

Middlesbrough

Shrewsbury

Banbury

Todmorden

Worcester

Macclesfield

Town

Build date

Square  
metres

List size

NHS %

2014

2008

2005

2013

2007

2012

2009

2012

2005

2011

2005

2005

2012

2009

2008

2006

2006

3,481

3,322

4,074

2,812

6,261

5,857

6,796

4,087

3,667

5,217

7,652

3,327

6,086

3,691

4,467

4,257

6,007

21,182

24,050

21,535

13,587

42,367

12,048

29,926

29,115

17,470

26,679

21,854

9,630

16,883

34,458

13,480

26,721

61,016

93%

89%

98%

90%

91%

91%

86%

83%

91%

96%

65%

94%

94%

89%

92%

91%

94%

Assura plc Annual Report 2016  19

Strategic reportFinancial statements Governance www.assuraplc.comFocus

Maintaining a strategic focus 
on a highly attractive market

20  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.comFocus 

Additions to the portfolio
The investment team has added 
some key properties to the portfolio 
during the year. These include standing 
investments in Ardrossan, North Ayrshire 
for £3.4 million and Frome (pictured 
below), Wiltshire for £15.5 million and 
a purchase and leaseback in Kington, 
Herefordshire for £6.7 million.

Close working relationships
The knowledge and expertise of the 
investment team is vital in satisfying GPs 
looking to sell their premises that Assura 
is the preferred partner as landlord for 
the practice. By building close working 
relationships with GPs, Assura is able 
to secure investment opportunities on 
competitive terms.

Assura’s investment team
The availability of fewer portfolios of 
medical centres has resulted in an 
increase in individual asset purchases 
during the year. This has required a 
greater level of investment manager 
time. As a result, the investment team 
was strengthened at the outset of the 
year with the addition of two specialist 
investment managers. All four individuals 
have specific territories to cover across 
the UK and work closely with the 
marketing team to identify and target 
properties which would enhance the 
existing portfolio. 

Assura’s investment team: 
Adam Lowe, Robert Lawton, 
Amanda Roddy, Alexander Taylor

 “ Our knowledge and 

experience ensures that we 
create a positive and long-
lasting relationship with GPs 
and meet their current and 
future premises aspirations”

ROBERT LAWTON
INVESTMENT MANAGER

Strategic reportFinancial statements Governance www.assuraplc.comExpertise

Responding to the NHS agenda

22  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.comExpertise 

  “ It is widely acknowledged that sustainable 
development must address climate change 
issues and reduce the amount of carbon 
produced in construction”

PAUL WARWICK 
DEVELOPMENT MANAGER

The concept
As the leading primary care property 
developer in the healthcare sector,  
Assura has been working to develop  
the concept of zero energy healthcare 
premises. Bringing together existing 
sustainable design practices and 
construction techniques, the concept 
aims to deliver premises with negligible 
energy use, aiming to reduce running 
costs for our tenants. 

Why it is needed
It is widely acknowledged that sustainable 
development must address climate 
change issues and reduce the amount 
of carbon produced in construction. 

The Energy Performance of Buildings 
Directive set a target for all newly built 
premises to achieve nearly zero carbon 
status by 2020 and although the deadline 
is subject to fluctuation it is inevitable that 
such a target must be achieved in the 
medium term. As a responsible developer 
Assura aims to be proactive in exceeding 
this target and in doing so provide added 
value to our tenants and shareholders. 

What we have done so far
The team has set about designing 
exemplar healthcare premises with a 
commitment to sustainability with the 
aim of creating bespoke premises that 
offer minimal running costs, flexibility to 

meet the changing demands of primary 
healthcare and offering users the ability 
to control and maintain environmental 
comfort within their building. 

Our implementation
Having demonstrated the feasibility  
of the concept we have taken this  
a step further and have now begun 
to incorporate these principles into 
new schemes in our development 
programme. NHS sign off is awaited  
for the first of these schemes, which  
is expected to be on site in July 2016. 

Ardudwy Health Centre, Harlech
Assura’s most sustainable property to date with an EPC rating of A+

Assura plc Annual Report 2016  23

Strategic reportFinancial statements Governance www.assuraplc.comCulture

Investing in our people

24  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.comCulture 

Assura’s culture
Assura is committed to nurturing 
and developing our talent, creating 
a sustainable workforce with the right 
mix of capabilities and providing a 
great place to work. As a result staff 
turnover is exceptionally low with only 
one resignation in the last three years.

We focus on employee wellbeing 
and benefits include private medical 
insurance, half price gym membership 
and a Group Income Protection Plan. 
Assura also operates a cycle to work 
scheme which several staff members 
participate in.

We encourage all members of staff 
to reach their full potential. We support 
those staff who wish to undertake 
relevant training via study support 
and paid study leave and currently have 
eight members training for professional 
qualifications including accountancy, 
chartered secretarial, chartered surveyor 
and marketing. We also seek to promote 
from within and there have been several 
internal promotions during the past 
few years.

 “ I joined Assura in 2012 and was promoted 
into the marketing function in 2014 where  
I am undertaking a Chartered Institute  
of Marketing qualification”

FRANCESCA HARRIS  
MARKETING COORDINATOR

Gender diversity is important and the 
structure and gender makeup of the 
Board, senior leadership team and 
employee workforce is shown on  
page 87.

All of the above help us to attract, 
engage and grow our people to enable 
the effective delivery of the Group’s 
strategy over the long term. 

Our members currently in training: 
Zoe Roberts, Demi Clarke, Kirsty Brady, 
Anna Meredith, Guy Redman, Orla Ball, 
Francesca Harris, Hannah Winstanley

www.assuraplc.com

  25

Strategic reportFinancial statements Governance Effectiveness

Leveraging our team’s skills 
to maximum advantage

26  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.comEffectiveness

Internal management structure 
Assura’s in-house team of property 
professionals has the skills to identify and 
maximise the opportunities in our sector. 

A specialist dedicated team is on 
hand to deal efficiently and effectively 
with all matters, whether it be a day 
to day matter, a new acquisition as  
a result of purchase and leaseback  
or a development.

Our service 
Our culture of providing first class  
service to GPs and health professionals 
is at the forefront of our business and 
we constantly review the property team to 
deliver a service worthy of recommendation.

Improving team structure 
This year we have continued to invest  
in the professional development of the 
property team. It is structured into North 
and South with each regional team 
having all three disciplines of portfolio/
property manager, investment and 
development surveyors. 

Having a regional focus provides greater 
continuity of care to our tenants in all 
aspects of their premises’ needs.

The improved structure promotes more 
efficient team working whilst ensuring  
our occupiers, patients and local 
communities reap the benefits.

“Assura undertakes active tenant 
relationship management and as a 
specialist healthcare provider, we are 
able to understand the needs and 
requirements of our GP customers”

ROGER THOMPSON MRICS 
SENIOR PORTFOLIO MANAGER

Roger Thompson MRICS 
Senior Portfolio Manager

  27

Strategic reportFinancial statements Governance www.assuraplc.comKey performance indicators

Our vision is to be the UK’s best 
developer and owner-manager  
of primary care property

Strategic priority

KPI and benchmark

Explanation

Performance

Focus
Maintaining a strategic focus on a 
highly attractive market

  Read more on p20

Expertise
Responding to the NHS agenda

  Read more on p22

Culture
Investing in our people

  Read more on p24

Effectiveness
Leveraging our team’s skills to 
maximum advantage

  Read more on p26

28  Assura plc Annual Report 2016

Rental growth  
from rent reviews
1.2%

 2015: 1.3%

IPD five-year  
Total Return
8.8%

 IPD: 6.9%

Total Property Return
8.9%

 2015: 7.8%

Lease length
14.0 years
 2015: 14.4 years

Complete developments
£16.4m 4 sites

 2015: £22.8m 4 sites

% of tenant covenant 
NHS/GP
87%
 2015: 87%

Developments  
on site
£13.5m 2 sites
 2015: £22.2m 5 sites

BREEAM rating achieved on developments –  
Very Good or better
100%
 2015: 100%

Average EPC rating

B
 2015: B

Total Accounting Return
7.2%

 2015: 7.7%

Total Shareholder Return
(11.4)%
 2015: 49.9%

EPRA Cost Ratio
16.5%

 2015: 17.7%

Underlying profit per share
2.2p

 2015: 2.1p

Rental growth is the weighted average annualised uplift 

We have delivered rental growth of 1.2% which is ahead 

in rent reviews settled in the year.

of CPI inflation over the period.

Total Property Return measures the overall return 

generated by our properties on a debt free basis. It is 

calculated as the net rental income generated by the 

portfolio plus the change in our market values, divided 

by opening property assets plus additions.

We measure our performance against the All Healthcare 

Benchmark as calculated by IPD.

The weighted average unexpired lease term (“WAULT”) 

provides the average period until the first available break 

in our underlying property leases calculated on the basis 

of the weighted average of the underlying rent. 

Complete developments are the number and valuation 

on completion of completed developments during 

the year. 

Tenant covenant is the proportion of our rent roll that 

is paid directly by GPs or NHS bodies.

Developments on site are the number and estimated 

valuation on completion of developments currently 

commenced at the year end.

The rate of growth has been slowing, though with 

construction cost inflation returning we believe  

medium-term prospects will recover.

Over the last five years, our Total Return of 8.8% per annum 

has outperformed the All Healthcare Benchmark of 6.9%. 

This has been achieved with low volatility of returns and is 

ahead of our estimated cost of equity.

We have continued to deliver a Total Property Return 

in excess of our net initial yield from delivering capital 

growth from our investment portfolio.

Our lease length of 14.0 years provides a high level 

of income certainty to underpin investor returns. 

An effective NHS backing for 87% of our income provides 

low default risk at a premium to the equivalent gilt rates.

The value of completed schemes has decreased during 

the year to £16.4 million. This reflects the reduced level 

of activity across the sector.

The slowdown in development activity across the sector 

has reduced the number of schemes on site. We currently 

have a pipeline in excess of 11 schemes and £41 million.

BREEAM is the world’s foremost environmental 

assessment method and ratings for buildings, and sets 

One of our developments achieved a rating of Excellent 

in the current year with the remaining three achieving  

the standard for best practice in sustainable building design, 

a Very Good rating. 

The average EPC rating was a B, which is our target  

for new developments.

construction and operation. It has become one of the 

most comprehensive and widely recognised measures 

of a building’s environmental performance. 

An Energy Performance Certificate (“EPC”) is an 

assessment based on the construction and type of 

property and relevant fittings such as heating systems, 

insulation or double glazing.

Total Accounting Return is the movement on EPRA 

NAV for the year plus the dividends paid, divided by 

the opening EPRA NAV for the year.  

TSR is the movement in the share price for the period 

plus the dividends paid, divided by the opening share 

price for the year.  

EPRA Cost Ratio is the total administrative costs for 

the year divided by gross rental income. 

Underlying profit per share is underlying profit divided  

by the average number of shares in issue.

Our Total Accounting Return has fallen slightly in the year 

reflecting the one-off costs of equity issuance and debt 

restructuring.

TSR has fallen in the year reflecting the movement in the 

ratio of the share price to EPRA NAV. At 31 March 2016 

our premium to EPRA NAV was 15% (2015: 38.5%).

The integration of the 56 property additions has been 

achieved efficiently, which has contributed to a reduction 

in the EPRA cost ratio to 16.5%.

Underlying profit per share has increased to 2.2 pence 

per share despite a 60% increase in our issued shares.

www.assuraplc.com 
 
In order to be the best, we need to 
demonstrate that we can consistently 
outperform over time. In order to measure 
ourselves against this objective we have a 
wide range of key performance indicators 
(“KPIs”). These can be distilled into three key 
areas. Firstly, Total Property Return, which 
measures our success in choosing the right 
investments and managing these over time. 
Secondly, Total Accounting Return, which 
measures the returns we have delivered 
to our shareholders in the form of dividends 
paid and our growth in net asset 

value (“NAV”). Lastly, we consider Total 
Shareholder Return (“TSR”) as measured by 
the stock market, which reflects the value 
of dividends paid and the relative movement 
in our share price over the period. 

These measures are complementary and 
should build on each other although the 
share price movement is also affected by 
other external factors outside of our control. 
By managing the Property Return and 
Accounting Return over the medium term 
we should be able to deliver a superior TSR 
to our investors.

This overriding objective is reflected in the 
long-term management incentive scheme, 
the Value Creation Plan (“VCP”), which 
provides incentives to management based 
on the TSR delivered to investors over 
a five-year time horizon. This is explained in 
more detail in the Remuneration Committee 
report on pages 58 to 85. 

In order to achieve these objectives we have 
four strategic priorities and how we monitor 
ourselves against them is outlined below:

Strategic priority

KPI and benchmark

Explanation

Performance

Focus

Maintaining a strategic focus on a 

highly attractive market

  Read more on p20

Expertise

Responding to the NHS agenda

  Read more on p22

Culture

Investing in our people

  Read more on p24

Effectiveness

Leveraging our team’s skills to 

maximum advantage

  Read more on p26

Rental growth  

from rent reviews

1.2%

 2015: 1.3%

IPD five-year  

Total Return

8.8%

 IPD: 6.9%

Total Property Return

8.9%

 2015: 7.8%

Lease length

Complete developments

14.0 years

 2015: 14.4 years

£16.4m 4 sites

 2015: £22.8m 4 sites

% of tenant covenant 

Developments  

NHS/GP

87%

 2015: 87%

on site

£13.5m 2 sites

 2015: £22.2m 5 sites

BREEAM rating achieved on developments –  

Very Good or better

100%

 2015: 100%

Average EPC rating

B

 2015: B

Rental growth is the weighted average annualised uplift 
in rent reviews settled in the year.

We have delivered rental growth of 1.2% which is ahead 
of CPI inflation over the period.

Total Property Return measures the overall return 
generated by our properties on a debt free basis. It is 
calculated as the net rental income generated by the 
portfolio plus the change in our market values, divided 
by opening property assets plus additions.

We measure our performance against the All Healthcare 
Benchmark as calculated by IPD.

The weighted average unexpired lease term (“WAULT”) 
provides the average period until the first available break 
in our underlying property leases calculated on the basis 
of the weighted average of the underlying rent. 

Complete developments are the number and valuation 
on completion of completed developments during 
the year. 

Tenant covenant is the proportion of our rent roll that 
is paid directly by GPs or NHS bodies.

Developments on site are the number and estimated 
valuation on completion of developments currently 
commenced at the year end.

BREEAM is the world’s foremost environmental 
assessment method and ratings for buildings, and sets 
the standard for best practice in sustainable building design, 
construction and operation. It has become one of the 
most comprehensive and widely recognised measures 
of a building’s environmental performance. 

An Energy Performance Certificate (“EPC”) is an 
assessment based on the construction and type of 
property and relevant fittings such as heating systems, 
insulation or double glazing.

The rate of growth has been slowing, though with 
construction cost inflation returning we believe  
medium-term prospects will recover.

Over the last five years, our Total Return of 8.8% per annum 
has outperformed the All Healthcare Benchmark of 6.9%. 
This has been achieved with low volatility of returns and is 
ahead of our estimated cost of equity.

We have continued to deliver a Total Property Return 
in excess of our net initial yield from delivering capital 
growth from our investment portfolio.

Our lease length of 14.0 years provides a high level 
of income certainty to underpin investor returns. 

An effective NHS backing for 87% of our income provides 
low default risk at a premium to the equivalent gilt rates.

The value of completed schemes has decreased during 
the year to £16.4 million. This reflects the reduced level 
of activity across the sector.

The slowdown in development activity across the sector 
has reduced the number of schemes on site. We currently 
have a pipeline in excess of 11 schemes and £41 million.

One of our developments achieved a rating of Excellent 
in the current year with the remaining three achieving  
a Very Good rating. 

The average EPC rating was a B, which is our target  
for new developments.

Total Accounting Return

Total Shareholder Return

7.2%

 2015: 7.7%

(11.4)%

 2015: 49.9%

EPRA Cost Ratio

Underlying profit per share

16.5%

 2015: 17.7%

2.2p

 2015: 2.1p

Total Accounting Return is the movement on EPRA 
NAV for the year plus the dividends paid, divided by 
the opening EPRA NAV for the year.  

TSR is the movement in the share price for the period 
plus the dividends paid, divided by the opening share 
price for the year.  

EPRA Cost Ratio is the total administrative costs for 
the year divided by gross rental income. 

Underlying profit per share is underlying profit divided  
by the average number of shares in issue.

Our Total Accounting Return has fallen slightly in the year 
reflecting the one-off costs of equity issuance and debt 
restructuring.

TSR has fallen in the year reflecting the movement in the 
ratio of the share price to EPRA NAV. At 31 March 2016 
our premium to EPRA NAV was 15% (2015: 38.5%).

The integration of the 56 property additions has been 
achieved efficiently, which has contributed to a reduction 
in the EPRA cost ratio to 16.5%.

Underlying profit per share has increased to 2.2 pence 
per share despite a 60% increase in our issued shares.

Assura plc Annual Report 2016  29

Strategic reportFinancial statements Governance www.assuraplc.com 
 
Risk management

Effective risk management is crucial 
in delivering our strategic objectives

Committee reports to the Audit Committee, 
which regularly monitors risk management 
and internal control systems and reports 
to the Board. 

The Board has carried out a robust 
assessment of the principal risks facing 
the business. These are the risks which 
would threaten its business model, future 
performance, solvency or liquidity and 
are summarised on pages 33 to 37. 

The Board has also considered which 
of the Group’s strategic objectives may 
be affected by these risks and their 
findings are set out in the table below.

Risk management is the responsibility 
of the Board which sets the risk 
appetite and tolerances for the 
business, determines the natures 
and extent of the principal risks the 
Company is willing to take in achieving 
its strategic objectives and ensures 
that risk management and internal 
controls are embedded in the 
business’s operations. 

 ■ Control risk – by clear management 

controls and Board reporting

 ■ Gearing risk – we maintain an 

appropriate range of lenders and debt 
maturities with variable rate debt being 
restricted to one third of our loan book, 
on gearing up to 50% loan to value

 ■ Political risk – which could limit future 
growth but does not affect the current 
business assets. 

We target above market, risk adjusted 
returns in our chosen healthcare real 
estate assets, by developing assets 
ourselves (as opposed to purchasing 
only completed developments) and using 
debt to gear returns up to 50% loan to 
value. However, we seek to avoid, trap 
or heavily mitigate risks in all other areas 
of the business including:

 ■ Property event risk – by full insurance 

cover, full due diligence and committed 
funds for acquisitions 

 ■ Development risk – by only undertaking 
developments where there is already 
an agreement for lease in place

A formal Risk Committee was established 
during the year and all staff were interviewed 
to check that every risk was captured. The 
materiality and severity of each risk were 
assessed as to their likelihood of happening 
in the next 12 months and likely financial 
impact. Key risk indicators (how we trap 
risks) and assurance that effective controls 
were in place were noted for each risk. 

The Risk Committee meets at least four 
times a year, to review the risk register, 
identify emerging risks and conduct “deep 
dives” into individual risks to ensure that 
sound assurance is in place. The Risk 

i

c
g
e
t
a
r
t
S

Changes to government policy

Competitor threat

Reduction in investor demand

Failure to deploy capital

Failure to communicate

i

l Reduction in availability and/or increase in cost of finance
a
c
n
a
n
F

Failure to maintain capital structure and gearing

i

k
s

i
r

l

a
p
c
n

i

i
r
P

Development overspend

Key staff dependency

Underperformance of assets

l

a
n
o
i
t
a
r
e
p
O

30  Assura plc Annual Report 2016

Focus

Expertise

Culture Effectiveness

Strategic objective

•
•
•
•
•
•
•

•
•
•

•

•
•

•
•

•

•

•
•
•
•
•
•
•

•
•
•

www.assuraplc.com 
TOP-DOWN

BOTTOM-UP

Strategic risk management

Operational risk management

BOARD  
AND AUDIT 
COMMITTEE

Review external environment

Set risk appetite and parameters

Determine strategic  
action points

Assess effectiveness  
of risk management systems

Report principal risks

Direct delivery of  
strategic actions

Monitor key risk indicators

SENIOR 
LEADERSHIP 
TEAM

Consider completeness of identified  
risks and adequacy  
of mitigating actions

Consider aggregation of risk exposures 
across the business

Execute strategic actions

Report on key risk indicators

RISK 
COMMITTEE

Report priority and  
emerging risks

Identify, evaluate, prioritise,  
mitigate and monitor operational  
risks recorded in risk register

Assura plc Annual Report 2016  31

Strategic reportFinancial statements Governance www.assuraplc.comRisk management continued

Viability statement
In accordance with provision C.2.2 of the 
UK Corporate Governance Code 2014, 
the Board has conducted a review of the 
Company’s current position and principal 
risks to assess the Company’s longer-
term viability. 

A five-year period is considered appropriate 
for this review as this corresponds with the 
Company’s strategic planning timeframe. In 
addition, the long-term nature of leases and 
debt facilities supports an assessment over 
this period. 

Company forecasts are prepared using 
a comprehensive financial model which 
projects the income statement, balance 
sheet, cash flows and key performance 
indicators over the relevant timeframe. 
The model allows various assumptions 
to be applied and altered in respect 
of factors such as level of investment, 
investment yield, availability and cost 
of finance, rental growth and potential 
movements in interest rates and 
property valuations. 

Having made reference to the principal 
risks facing the Company, as laid out on 
pages 33 to 37, sensitivities which are 
considered severe but within the realms 
of possibility have been applied to the 
assumptions to review the potential 
impact on the Company results and 
financial position. Specific sensitivities 
applied include increases in interest 
rates, a prolonged downturn in property 
investment valuations, an increased 
risk of tenant default and a sustained 
absence of rent review growth. This 
assessment has not assumed any 
significant changes to government 
policy with respect to NHS Estates 
strategy or the GP reimbursement model.

Based on this consideration of principal 
risks and the forecasting exercise 
completed, the Board has a reasonable 
expectation that the Company will be 
able to continue in operation and meet its 
liabilities as they fall due over the five-year 
period assessed. The Board considers 
that the long-term nature of the leases 
and financing arrangements in place 
means that the business model would 
remain viable in the event that further 
growth of the business was not achieved. 

32  Assura plc Annual Report 2016

www.assuraplc.com New

 No change

 Low

 Medium

 High

Movement in year 
and net risk rating

No change

Medium

Strategic risks
Changes to government policy

Risk

Avoid

Trap

Mitigate

The Board monitors 
changes in government 
policy and management 
reports to the Board at 
every meeting.

The Group proactively 
engages with the 
Government over policy 
that could impact the 
business, both directly 
and through the 
Healthcare Committee 
of the British Property 
Federation.

Reduced funding for 
primary care premises’ 
expenditure could lead 
to a reduction in our 
development pipeline 
and growth prospects.

A change to the 
reimbursement 
mechanism for GPs 
could lead to a change 
in the risk profile of our 
underlying tenants.

Comment
The increased provision of healthcare services in the community is a stated policy objective of the current Government and 
so a reduction in funding to this sector is considered unlikely.

The reimbursement mechanism is not currently under review. Any change would probably result in an increased cost to the 
NHS in the future supply of primary care properties, reducing healthcare opportunities in the community.

Competitor threat

Risk

Avoid

Trap

Mitigate

Increased competition 
from new purchasers 
could lead to a 
reduction in our ability to 
acquire new properties 
and a general increase 
in prices across 
the sector.

We maintain our 
specialist knowledge, 
team structure 
and strong brand 
recognition with GPs.

The Board receives 
regular property 
reports, highlighting 
where we have lost 
out to competitors 
and when new entrants 
are identified.

The market is 
increasingly competitive 
and every proposed 
transaction is reviewed 
by our Investment 
Committee to ensure 
that the prospective 
returns are adequate.

Movement in year 
and net risk rating

No change

Medium

Comment
A further significant increase in asset prices increases the risk of these returns not achieving our required level and our rate 
of acquisitions slowing significantly. 

We have made substantial additions to our portfolio during the year and we remain confident in our ability to continue to do so.

Assura plc Annual Report 2016  33

Strategic reportFinancial statements Governance www.assuraplc.comRisk management continued

Strategic risks continued
Reduction in investor demand

Risk

Avoid

Trap

Mitigate

We are open in 
communicating our 
strategy to investors 
and maintain a loan 
to value range which 
is acceptable 
to the market.

The overall economy 
and its impact on the 
Group’s operations are 
regularly assessed and 
considered in reviewing 
the Group’s strategy.

The Board receives 
regular reports on 
investor relations and 
the development of 
our share register.

We successfully raised 
£300 million, net of 
expenses, in the market 
during the year.

The dividend yield and 
the underlying strength 
of the cash flows 
supporting it remain 
attractive relative to 
other asset classes.

Reduced investor 
demand for UK primary 
care property could 
lead to a reduction in 
asset valuations and a 
fall in future profits.

This could arise from:

 ■ Changes in 
NHS policy

 ■ Health of the UK 

economy

 ■ Availability of finance

 ■ Relative 

attractiveness of 
other asset classes.

Movement in year 
and net risk rating

No change

Medium

Comment
The fundamentals for our sector remain very strong and the longevity and security of our cash flows has continued to generate 
strong investor demand for our shares in the past year. 

Failure to deploy capital

Risk

Avoid

Trap

Mitigate

Movement in year 
and net risk rating

A shortage of 
development or 
acquisition opportunities 
could result in a drag 
on operating cash and 
reduced investor 
confidence. 

Our specialist 
knowledge, team 
structure and strong 
brand recognition with 
GPs reduce this 
overall risk. 

The Board reviews the 
development and 
acquisition pipeline at 
every Board meeting.

Management bonus 
schemes reward 
successful new 
developments 
and acquisitions.

New

Low

Comment
We have made substantial additions to our portfolio during the year and we remain confident in our ability to continue to do so.

We are well advanced in implementing our plan to use the proceeds from the recent fund raise. 

34  Assura plc Annual Report 2016

www.assuraplc.com New

 No change

 Low

 Medium

 High

Movement in year 
and net risk rating

No change

Low

Movement in year 
and net risk rating

No change

Low

Failure to communicate

Risk

Avoid

Trap

Mitigate

Failure to adequately 
communicate the 
Company’s strategy 
and explain 
performance may 
result in an increased 
disconnect between 
investors’ perceptions 
of value and actual 
performance.

Strategic priorities 
are clearly articulated 
in corporate 
communications 
and the Group’s 
performance is 
transparently reported.

We communicate 
regularly with investors 
and analysts. 

The Board receives 
regular reports on 
investor attitudes 
and the market.

The Group maintains 
close links with its 
two brokers, who 
communicate investor 
thoughts and concerns.

Investor communication, 
particularly through 
face to face meetings, 
remains a key priority. 

Comment 
Some 119 meetings have been held during the year, including 19 meetings with potential investors.

Financial risks
Reduction in availability and/or increase in cost of finance 

Risk

Avoid

Trap

Mitigate

The Group has 
predominantly 
long-term facilities 
which reduce these 
refinancing risks.

The Group regularly 
monitors and manages 
its refinancing profile 
and cash requirements.

The Group actively 
engages with a range 
of funders to ensure a 
breadth of funder and 
maturity profiles. 

We continue to explore 
financing options with 
other lenders as well 
as maintaining strong 
relationships with 
existing lenders.

A reduction in 
available financing 
could adversely affect 
the Group’s ability to 
source new funding 
and refinance 
existing facilities.

This could delay 
or prevent the 
development of 
new premises.

Increasing financing 
costs could increase 
the overall cost of debt 
to the Group and so 
reduce underlying 
profits.

Comment
The current appetite for lending into the sector is very strong, given the quality of the underlying cash flows.

Assura plc Annual Report 2016  35

Strategic reportFinancial statements Governance www.assuraplc.comRisk management continued

Financial risks continued
Failure to maintain capital structure and gearing

Risk

Avoid

Trap

Mitigate

Property valuations are 
inherently uncertain and 
subject to significant 
judgement.

Valuations and 
yields are regularly 
benchmarked against 
comparable portfolios. 

The Group engages 
two external valuers 
to review property 
valuations. 

A fall in property 
values or income 
could adversely affect 
bank covenants.

Breach of covenants 
could lead to forced 
asset disposals which 
could reduce the 
Group’s net assets 
and profitability.

The valuations are 
formally reviewed by 
the Board twice a year.

Covenant headroom 
and gearing are 
regularly monitored with 
reference to possible 
valuation movements 
and future expenditure.

The Board regularly 
reviews the capital 
structure of the Group.

The Board has 
established a target 
range for a net loan 
to value ratio over the 
medium term of 40% 
to 50%. The current 
position of 30% is lower 
than our target range 
and will increase as 
we invest in our 
short-term pipeline.

All financial forecasting, 
including for new 
acquisitions, considers 
gearing and covenant 
headroom.

Movement in year 
and net risk rating

No change

Low

Comment
Following the successful equity fund raising last year the level of gearing has reduced significantly and thus improved 
covenant headroom. 

Operational risks
Development overspend 

Risk

Avoid

Trap

Mitigate

Development risk could 
adversely impact the 
performance of the 
Group as a result of 
cost overruns and 
delays on new projects.

The Group has 
a dedicated 
and experienced 
development 
management team.

The Group’s policy 
is to engage in 
developments that are 
substantially pre-let with 
fixed price or capped 
price build contracts.

A high level of due 
diligence is undertaken 
before works commence 
and detailed designs are 
negotiated to prevent 
variations.

Regular reviews are 
conducted of latest cost 
estimates as each 
project progresses.

We remain confident 
of our ability to manage 
this risk through our 
experienced team of 
development surveyors 
and reduce the potential 
risk through the use of 
fixed price contracts 
and the use of 
performance bonds. 
A performance bond 
insures against the risk 
of the main contractor 
becoming insolvent.

Movement in year 
and net risk rating

No change

Medium

Comment
The potential impact of this has not changed during the year as the number of developments remains at a historically low level. 

36  Assura plc Annual Report 2016

www.assuraplc.com New

 No change

 Low

 Medium

 High

Movement in year 
and net risk rating

No change

Medium

Key staff dependency

Risk

Avoid

Trap

Mitigate

Failure to recruit, 
develop and retain 
staff and Directors 
with the right skills and 
experience may result 
in underperformance.

Competitive salary 
and benefit packages 
are aligned with 
appropriate peer 
groups and periodically 
benchmarked.

Professional 
development and 
training are encouraged 
and costs are met by 
the Group.

Succession plans 
are in place for each 
department.

Long-term incentive 
plans span five-year 
periods to encourage 
retention of key staff.

Succession planning, 
team structure and 
skill set are regularly 
evaluated and planned. 

An enhanced 
performance 
appraisal process 
was successfully 
implemented during 
the year and this two 
way discussion forum 
identifies employee 
aspirations and any 
dissatisfaction.

All employee 
resignations are 
reported to each 
Board meeting.

Comment
Eight members of staff are currently working towards a professional qualification. 

Staff turnover is very low, currently running at 3%.

Underperformance of assets

Risk

Avoid

Trap

Mitigate

Not all rent reviews 
are upwards only and 
challenges to reviews 
and appeals could lead 
to lack of rental growth.

The Group engages 
experienced third 
parties to conduct 
rent reviews.

Leases are carefully 
reviewed on acquisition 
and the Group does not 
acquire leases with a 
tenant right to trigger a 
downward rent review.

The Group targets 
RPI reviews for new 
leases but if this is 
unachievable then open 
market upwards only 
reviews or open market 
landlord trigger only 
reviews are accepted.

Comment
Approximately 26% of leases have fixed uplifts or are linked to RPI.

Movement in year 
and net risk rating

New

Medium

Assura plc Annual Report 2016  37

Strategic reportFinancial statements Governance www.assuraplc.comBusiness review

Proceeds from equity raise substantially 
invested and we are well positioned for 
further growth

At 31 March 2016 our portfolio of 
completed investment properties was 
valued at a total of £1,088 million (2015: 
£908 million), which produced a net initial 
yield (“NIY”) of 5.29% (2015: 5.56%). Taking 
account of potential lettings of unoccupied 
space and any uplift to current market rents 
on review, our valuers assess the net 
equivalent yield to be 5.52% (2015: 5.77%). 
Adjusting this Royal Institution of Chartered 
Surveyors standard measure to reflect the 
advanced payment of rents, the true 
equivalent yield is 5.72% (2015: 5.98%). 

Our EPRA NIY, based on our passing 
rent roll and latest annual direct property 
costs, was 5.23% (2015: 5.43%).

Net rental income 

Valuation movement 

2016 
£m

58.4 

36.4

Total Property Return 

94.8 

2015 
£m

48.2

21.4

69.6

Expressed as a percentage of opening 
investment property plus additions, Total 
Property Return was 8.9% compared with 
7.8% in 2015.

Our annualised Total Return over the 
last five years as calculated by IPD was 
8.8% compared with the IPD All Healthcare 
Benchmark of 6.9% over the same period.

The valuation gain in the year of £36.4 million 
represents a 4.8% uplift on a like-for-like 
basis and has arisen as a result of the 
downward pressure on yields with increased 
competition for acquiring assets in the 
sector. Despite the downward pressure, the 
NIY on our assets continues to represent a 
substantial premium over the 15-year gilt 
which traded at 1.96% at 31 March 2016.

The bulk of the growth in our investment 
portfolio has come from the acquisition  
of 52 properties, seeing us invest  
£124.5 million during the year. The two 
largest acquisitions were the Fleetwood 
Health and Wellbeing Centre for 
£16.7 million and the Frome Medical 
Practice for £15.5 million. Further 
information on properties valued over 
£10 million is provided on page 19.

Investment and 
development activity
Despite the recent hiatus in NHS 
development approvals we have invested 
substantially during the year, with this 
expenditure split between investments  
in completed properties, developments, 
forward funding projects, extensions and 
fit-out costs enabling vacant space to be 
let as follows:

Acquisition of completed 
medical centres

Developments/forward funding 
arrangements

Like-for-like portfolio 
(improvements)

Total capital expenditure

2016
£m

124.5

17.7

2.7

144.9

Despite the continued delay in NHS 
approval of new developments, we 
have completed four developments 
during the year (three under forward 
funding agreements) with a total 
development cost of £15.5 million. This 
has added £0.9 million to our annual rent 
roll and generated a 5.7% yield on cost.

We recorded an unrealised revaluation 
surplus of £0.7 million during the year 
in respect of investment property under 
construction (2015: deficit of £0.9 million). 

As at 31 March 2016, we had two 
developments on site under forward 
funding agreements, with a total committed 
investment value of £13.5 million, and a 
further five which we would hope to be on 
site shortly (estimated cost of £17.1 million).

Portfolio as at 31 March 2016: £1,088 million 
(2015: £908 million)

Our business is based on our investment portfolio 
of 321 properties. This has a passing rent roll of 
£63.8 million (2015: £55.6 million), 87% of which 
is underpinned by the NHS. The WAULT is 
14.0 years and 87% of the rent roll will still be 
contracted in 2026.

Portfolio analysis by capital value

 Number of 
 properties

Total 
value
£m

Total 
value
%

<£1m

£1–5m

£5–10m

>£10m

60

39.7

204

515.5

40

17

281.4

251.4

4

47

26

23

321 1,088.0

100

38  Assura plc Annual Report 2016

www.assuraplc.comGrowth in completed investment 
property portfolio

£180m

Growth in EPRA NAV per share

2.7%

Net profit for the year

£27.9m

Live developments

Estimated 
completion 
date

Kidderminster August 2016

Bewdley

November 2016

% NHS

86%

90%

Development 
costs

Costs 
to date

Size

£6.6m

£6.9m

£4.2m 2,203 sqm

£4.3m 2,014 sqm

Portfolio management 
We have continued to deliver rental 
growth and have successfully concluded 
133 rent reviews during the year to 
generate a weighted average annual rent 
increase of 1.20% (2015: 1.27%) on those 
properties. Our portfolio benefits from 
a 26% weighting in fixed and RPI uplifts 
which generated an average uplift of 
1.93% during the year. The majority of 
our portfolio is subject to open market 
reviews and these have generated an 
average uplift of 0.69% during the year.

We work very hard at developing and 
maintaining customer relationships. 
This approach is carried across the 
range of services we provide both during 
development and after completion, as a 
portfolio manager. We have a dedicated 
team of portfolio managers who are in 
regular communication with our customers 
and we monitor progress through regular 
customer satisfaction surveys.  

During the year we have successfully 
secured 13 new tenancies with an  
annual rent roll of £0.5 million covering 
4,430 square metres. In addition we  
have significantly extended the lease  
on eight properties.

Our EPRA Vacancy Rate was 3.0% 
(2015: 3.2%) which has decreased  
during the year reflecting the team’s 
success with letting initiatives during the 
year. Our vacancy rate is extremely low 
due to the long nature of our leases  
and only developing buildings that are 
substantially pre-let. All of our vacant 
space, where not reserved as potential 
expansion space for the GP tenants, 
relates to areas of buildings for 
complementary services and letting  
this space remains a key focus for  
the current year.

Portfolio analysis by region

Portfolio analysis by tenant covenant

 Number of 
 properties

Total 
value
£m

Total 
value
%

North

South

Midlands

Scotland

Wales

GPs

NHS body

Pharmacy

Other

126

466.0

95

62

19

19

309.4

220.9

37.2

54.5

43

29

20

3

5

321 1,088.0

100

Total 
rent roll
£m

Total 
rent roll
%

44.1

11.6

4.8

3.3

69

18

8

5

63.8

100

Assura plc Annual Report 2016  39

Strategic reportFinancial statements Governance www.assuraplc.comBusiness review continued

Administrative expenses
The Group measures its operating 
efficiency as the proportion of 
administrative costs to the average 
gross investment property value. This 
ratio during the year was 0.60% (2015: 
0.72%) and administrative costs stood 
at £6.1 million (2015: £5.7 million).

We continue to hold discussions with 
lenders to broaden our base of lenders, 
who have maintained their appetite to 
lend into our sector, and to ensure 
facilities are in place to support future 
acquisitions. At 31 March 2016, we 
had undrawn facilities and cash of 
£118.7 million. 

Underlying profit

Net rental income 

Administrative 
expenses 

2016 
£m

58.4

(6.1) 

Net finance costs 

(24.0) 

Underlying profit 

28.3

2015
 £m

48.2

(5.7)

(26.6)

15.9

The movement in underlying profit can be 
summarised as follows:

Financing 
statistics 

Net debt 

2016 

2015

£327.9m £450.0m

Weighted average 
debt maturity 

10.2 
years 

11.9
years

Weighted average 
interest rate 

% of debt at fixed/
capped rates 

Interest cover1 

Loan to value 

4.84% 

5.28%

Year ended 31 March 2015 

88% 

218% 

30% 

100%

160%

48%

Net rental income 

Administrative expenses 

Net finance costs 

Year ended 31 March 2016 

£m

15.9

10.2

(0.4)

2.6

28.3

Note
1.  Interest cover is the number of times net 
interest payable is covered by underlying 
profit before net interest.

Our loan to value ratio currently stands  
at 30%, which is lower than our target 
range of 40%-50% and will increase as 
we invest in our pipeline in the short term. 
88% of the debt facilities are fixed with 
a weighted average debt maturity of 
10.2 years compared with a WAULT 
of 14.0 years, which highlights the 
security of the cash flows of the business.

Details of the facilities and their covenants 
are set out in Note 17 to the accounts.

Net finance costs in the year amounted 
to £24.0 million (2015: £26.6 million) 
before early repayment costs.

Underlying profit has grown 78% to  
£28.3 million in the year to 31 March  
2016 following the property acquisitions 
completed during the year.

Underlying profit differs from EPRA 
earnings as it excludes accounting 
adjustments such as IFRS 2 charges 
for share-based payments and one-
off expenses that we consider to be 
exceptional and not reflective of 
continuing underlying performance.

Earnings per share
The basic earnings per share (“EPS”)  
on profit for the year was 2.2 pence 
(2015: 4.9 pence).

EPRA EPS, which excludes the net 
impact of valuation movements and 
gains on disposal, was 2.0 pence 
(2015: 2.1 pence).

We also analyse cost performance 
by reference to our EPRA Cost Ratios 
(including and excluding direct vacancy 
costs) which were 16.5% and 16.0% 
respectively (2015: 17.7% and 16.3%). 
This is now our key KPI as reported 
on page 28.

Financing
From a financing perspective, the 
highlight of the year was the successful 
equity issuance in October 2015, which 
raised proceeds of £300 million, net 
of expenses.

Our focus since then has been on 
investing the proceeds in primary care 
property but we have also made some 
adjustments to our lending arrangements 
to increase flexibility and take advantage 
of attractive interest rates which remain 
at historically low levels. 

In November 2015 we repaid £181 million 
of long-term debt held by Aviva Commercial 
Finance along with the associated early 
repayment costs of £34.1 million.

Further to this we announce today that 
the Group has signed a new £200 million 
revolving credit facility on an unsecured 
basis to replace the existing facility. The 
initial margin is 150 basis points and the 
facility increases operational flexibility and 
reduces transaction costs associated with 
financing properties.

40  Assura plc Annual Report 2016

www.assuraplc.com 
Underlying profit per share omits 
accounting adjustments and certain 
exceptional items and has increased 
to 2.2 pence (2015: 2.1 pence). The 
key variable is the cost of the long-term 
incentive plan which vested in full during 
the year, which reflected the strong 
performance of the business over the 
past four years. 

Based on calculations completed in 
accordance with IAS 33, share-based 
payment schemes are currently expected 
to be dilutive to EPS, with 11.2 million 
new shares expected to be issued based 
on the average share price for the three 
months to 31 March 2016. The following 
illustration is an extraction. Further details 
to the accounts are provided in Note 7.

EPS measure 

Basic 

Diluted

Profit for year 

EPRA 

Underlying 

2.2p 

2.0p 

2.2p 

2.1p

2.0p

2.2p

Dividends
Total dividends paid in the year to 31 March 
2016 were £27.2 million or 2.05 pence 
per share (2015: 1.85 pence per share). 
In January 2016 we introduced a scrip 
dividend alternative for shareholders, 
an option that was exercised by 9.9% of 
shareholders at the first opportunity and 
13.3% for the April 2016 dividend. 

As a result of brought forward tax losses 
all dividends paid during the year were 
normal dividends (non-PID) with an 
associated tax credit.

We remain committed to maintaining a 
covered dividend that is progressive broadly 
in line with underlying rental growth.

The table below illustrates our cash flows 
over the period:

Net assets
EPRA NAV movement

2016 
£m

66.5 

22.9 

(26.3) 

2015
 £m

38.6

16.9

(14.4)

EPRA NAV at 
31 March 2015 

Underlying profit 

Capital 
(revaluations and 
capital gains) 

Dividends 

(17.7) 

(14.0)

1.5 

(0.2) 

4.2

0.1

Early repayment 
costs

Other 

EPRA NAV at 
31 March 2016 

Pence 
per share

£m

452.4 

28.3 

44.9

2.2

36.5 

(27.2) 

(34.1)

(7.1) 

2.8

(2.1)

0.6

(2.6)

0.3

754.5 

46.1

(122.5) 

(64.3)

Equity issuance 

305.7 

Opening cash 

Net cash flow 
from operations 

Dividends paid 

Investment:

Property and 
business 
acquisitions 

Development 
expenditure 

Sale of properties 

Other 

Financing:

Net proceeds 
from equity 
issuance

Net borrowings 
movement

Closing cash

299.1

173.5

(179.0)

44.3

(74.1)

66.5

Net cash flow from operations differs 
from underlying profit due to movements 
in working capital balances.

Property additions during the year were 
£127.2 million, although the cash outflow 
was only £122.5 million after taking into 
account shares issued as consideration 
(£4.2 million), and net working capital 
assumed (£0.5 million).

Our Total Accounting Return per share 
for the year ended 31 March 2016 is 7.2% 
of which 2.05 pence per share (4.6%) 
has been distributed to shareholders 
and 1.2 pence per share (2.7%) is the 
movement on EPRA NAV including an 
element of dilution associated with the 
equity issuance in October 2015.

The equity issuance saw the Company 
raise proceeds of £300 million, net of 
issuance expenses. In addition, the 
Company issued a total of 7,650,749 
shares split between three corporate 
acquisitions over the course of the year. 
These shares issued as part consideration 
were priced based on the market value 
of the Company shares at the time 
of completion.

Assura plc Annual Report 2016  41

Strategic reportFinancial statements Governance www.assuraplc.comBusiness review continued

EPRA performance measures

The European Public Real Estate Association (“EPRA”) 
has published Best Practice Recommendations with 
the aim of improving the transparency, comparability 
and relevance of financial reporting within the real 
estate sector across Europe.

This section details the rationale for each 
performance measure as well as our 
performance against each measure.

Summary table

EPRA EPS (p) 

2016 

2.0p 

2015

2.1p

EPRA NAV (p) 

46.1p 

44.9p

EPRA NNNAV (p) 

42.4p 

35.9p

EPRA NIY (%) 

5.23% 

5.43%

EPRA “topped-up” 
NIY (%) 

5.23% 

5.43%

EPRA Vacancy Rate 

3.0% 

3.2%

EPRA Cost Ratio 
(including direct 
vacancy costs) (%) 

EPRA Cost Ratio 
(excluding direct 
vacancy costs) (%) 

16.5% 

17.7%

16.0% 

16.3%

EPRA NAV

46.1p

 2015: 44.9p

EPRA NNNAV

42.4p

 2015: 35.9p

Definition
NAV adjusted to include properties 
and other investment interests at fair 
value and to exclude certain items not 
expected to crystallise in a long-term 
investment property business.

Purpose 
Makes adjustments to IFRS NAV to 
provide stakeholders with the most 
relevant information on the fair value 
of the assets and liabilities with a true 
real estate investment company with 
a long-term investment strategy.

The calculation of EPRA NAV is shown 
in Note 8 to the accounts.

Definition
EPRA NAV adjusted to include the 
fair values of (i) financial instruments, 
(ii) debt and (iii) deferred taxes.

Purpose
Makes adjustments to EPRA NAV to 
provide stakeholders with the most 
relevant information on the current fair 
value of all the assets and liabilities 
within a real estate company.

The calculation of EPRA NNNAV is 
shown in Note 8 to the accounts.

EPRA EPS

2.0p

 2015: 2.1p

Diluted EPRA EPS

2.0p

 2015: 2.0p

Definition
Earnings from operational activities.

Purpose
A key measure of a company’s underlying 
operating results and an indication of 
the extent to which current dividend 
payments are supported by earnings.

The calculation of EPRA EPS and 
diluted EPRA EPS are shown in Note 7 
to the accounts.

42  Assura plc Annual Report 2016

www.assuraplc.comEPRA NIY 

5.23%

 2015: 5.43%

EPRA “topped-up” NIY

5.23%

 2015: 5.43%

Definition – EPRA NIY
Annualised rental income based on 
the cash rents passing at the balance 
sheet date, less non-recoverable property 
operating expenses, divided by the 
market value of the property, increased 
with (estimated) purchasers’ costs.

Definition – EPRA “topped-up” NIY
This measure incorporates an adjustment 
to the EPRA NIY in respect of the expiration 
of rent free periods (or other unexpired 
lease incentives such as discounted rent 
periods and step rents).

Purpose 
A comparable measure for portfolio 
valuations, this measure should make it 
easier for investors to judge for themselves 
how the valuation compares with that of 
portfolios in other listed companies.

EPRA Vacancy Rate

3.0%

 2015: 3.2%

Definition
Estimated rental value (“ERV”) of vacant 
space divided by ERV of the whole portfolio.

Purpose
A “pure” (%) measure of investment property 
space that is vacant, based on ERV.

2016 
£m

2015 
£m

EPRA Cost Ratio 
(Including direct vacancy costs)

Investment property  1,107.6 

925.3

Less developments 

(9.7) 

(6.7)

Completed 
investment property 
portfolio

Allowance for 
estimated 
purchasers’ costs 

Gross up completed 
investment property 
– B 

Annualised cash 
passing rental income

Property outgoings 

Annualised net rents 
– A 

Notional rent 
expiration of rent free 
periods or other 
incentives 

Topped up 
annualised rent – C

1,097.9 

918.6

71.7 

52.7

1,169.6 

971.3

63.8 

(2.6) 

55.6

(2.9)

61.2 

52.7

– 

–

61.2 

52.7

EPRA NIY – A/B (%) 

5.23 

5.43

EPRA “topped up” 
NIY – C/B (%) 

5.23 

5.43

2016 

2015

ERV of vacant space (£m)

2.0 

1.9

ERV of completed 
property portfolio (£m) 

66.5 

EPRA Vacancy Rate (%) 

3.0 

57.9

3.2

16.5%

 2015: 17.7%

EPRA Cost Ratio 
Excluding direct vacancy costs

16.0%

 2015: 16.3%

Definition
Administrative and operating costs 
(including and excluding direct vacancy 
costs) divided by gross rental income.

Purpose
A key measure to enable meaningful 
measurement of the changes in a 
company’s operating costs.

2016
 £m

2015 
£m

2.6 

6.1 

1.9 

2.9

5.7

0.7

(0.2) 

(0.2)

Direct property costs 

Administrative expenses 

Share-based payment costs 

Net service charge  
costs/fees 

Exclude:

Ground rent costs 

(0.4) 

(0.3)

EPRA costs (inc direct 
vacancy costs) – A 

10.0 

8.8

Direct vacancy costs 

(0.3) 

(0.7)

EPRA costs (exc direct 
vacancy costs) – B 

Gross rental income  
less ground rent costs  
(per IFRS) 

9.7 

8.1

60.6  49.8

Gross rental income – C 

60.6  49.8

EPRA Cost Ratio (inc direct 
vacancy costs) – A/C 

16.5% 17.7%

EPRA Cost Ratio (exc direct 
vacancy costs) – B/C 

16.0%  16.3%

Assura plc Annual Report 2016  43

Strategic reportFinancial statements Governance www.assuraplc.com 
Sustainability

 As part of our strategic priority of culture  
we pride ourselves on our commitment to 
the sustainability agenda and the personal 
development of our team.

Environmental policy
The Group is committed to minimising 
the environmental impact of its activities 
and achieving continual improvement in 
its environmental performance by:

 ■ Openly addressing the environmental 
risks of the work carried out, and 
identifying and managing the 
environmental risks associated with 
the business on an ongoing basis 

 ■ Setting and reviewing annual 

environmental objectives and targets, 
and monitoring performance 

 ■ Complying with applicable environmental 

legislation and other requirements 
relevant to the Group’s operations

 ■ Gaining certification to the ISO14001: 
2004 management standard and 
carrying out regular internal and external 
audits to ensure good performance and 
identify opportunities for improvement 

 ■ Working with partners, sub-contractors 

and suppliers to promote good 
environmental management and 
performance

 ■ Reducing the environmental 

impacts of new developments by 
achieving a BREEAM Excellent 
rating where possible 

 ■ Reducing the environmental impacts 
of all owned and leased premises by 
adopting or promoting reasonable 
controls for preventing pollution, 

44  Assura plc Annual Report 2016

improving resource efficiency, reducing 
waste and reducing the Group’s 
carbon footprint 

 ■ Training employees appropriately and 
promoting environmental awareness 
and commitment amongst all staff. 
This policy is reviewed and updated 
annually by the Board and is available 
to the public, on our website  
www.assuraplc.com.

Castle Medical Group, Ashby de la Zouch 
Bat box

Social and community matters
Assura operates in a responsible, 
professional, ethical and reliable manner 
and is trusted as a provider of services 
and facilities. Reflecting our commitment 
to the sustainability agenda, Assura has 
aligned itself with the wider corporate 
and social responsibility interests of 
the NHS. Accordingly, the Group has 
a formal Environmental Management 
System and has gained accreditation 
to the ISO14001: 2004 standard. 

www.assuraplc.comThe Group’s role in developing new 
medical facilities in the community, 
thereby bringing services closer to the 
patient, helps to improve quality of life. 
In developing a new medical centre, 
the Group enters into consultation with 
local communities. Many of the Group’s 
developments are part of regeneration 
schemes that also enhance the non-
medical facilities for local communities. 

A current example of work in this area 
is the recently completed development 
at Ashby de la Zouch which achieved 
a BREEAM Very Good rating. This 
development has a habitat improvement 
scheme and photovoltaic panels. 

Assura supports charities close to 
its Warrington head office which are 
heavily involved with local communities.

Assura is a founder member of the Social 
Stock Exchange (“SSE”).

The SSE showcases Social Impact 
Businesses that have taken the step to 
evidence their impact via the publication 
of an Impact Report. A Social Impact 
Business is one that uses commercial 
models to organise, mobilise and manage 
a for-profit business that delivers social 
and environmental change.

The aim of the SSE is to provide 
stakeholders with the information 
they need to identify and compare 
organisations that deliver value to 
society and the environment.

Health and safety 
The Group is committed to maintain 
safe working environments, and regularly 
undertakes programmes to identify, 
evaluate and reduce risk in the work place 
and on site. Risk reviews, supported by 
executive management reporting, are 
presented to the Board on a regular basis.

100% 

of developments in the year achieved  
a BREEAM rating of Very Good or 
Excellent

8 

members of staff training to gain  
professional qualifications

Victoria Park Health 
Centre, Leicester
Landscaped 
sustainable drainage 
wetland area

Assura plc Annual Report 2016  45

Strategic reportFinancial statements Governance www.assuraplc.comCharities

In April Assura commenced its support of the 
Warrington Wolves Charitable Foundation and 
the Salford Red Devils Foundation.

Warrington Wolves and Salford 
Red Devils Foundation
The Warrington Wolves Charitable 
Foundation is the community arm of the 
Rugby League club. By using the power 
of sport it is able to engage and change 
lives. The Foundation delivers sports, 
lifestyle, education, training, arts and 
inclusion activities. Salford Red Devils 
Foundation is a registered charity with 
a remit to deliver sport, health and 
education-based activities for the benefit 
of all, regardless of background and 
ability, across Greater Manchester and 
beyond. Based at the AJ Bell Stadium, 
Salford Red Devils Foundation uses the 
vehicle of professional sport to engage 
thousands of people each year in 
community clubs, classrooms, school 
playing fields and businesses through 
a delivery team of teachers, healthcare 
professionals and sports coaches.

To kick off the support of these 
two charities the Assura Challenge 
commenced. This divided Assura’s staff 
members into two teams, half supporting 
Warrington and the other half Salford, 
with the aim to raise the most amount 
of money possible. Several events were 
organised during the year by Assura in a 
bid to raise money. The first of these was 
the Touch Rugby event in July. This event 
brought together touch rugby teams from 
Assura’s corporate advisors in a fiercely 
competitive battle. The second event 
was held in September when Assura 
organised a rugby themed charity lunch 
in Manchester on the eve of the Rugby 
Union World Cup. Angela Powers from 

Sky Sports presented a Q&A session 
with several personalities from the world 
of Rugby League and Rugby Union. 

Finally, two members of staff ran the 
Warrington half marathon in September 
for the foundations. In total £13,300 was 
raised during 2015/16 for the charities 
with more events planned for 2016/17.

   For further information, please 
go to www.wolvesfoundation.com 
www.salfordreddevilsfoundation.co.uk

46  Assura plc Annual Report 2016

www.assuraplc.com 
 
Assura Challenge 
Touch Rugby event 
Held at Media City Salford 
in July 2015

Our charities for 2016/17
During the forthcoming year all 
of our chosen charities will be 
local. We will continue to support 
the Warrington Wolves Charitable 
Foundation and Salford Red Devils 
Foundation and in addition the 
Warrington Hospital branch of 
Life after Loss which was chosen 
by our staff to be our next charity.

Life After Loss is a charity which supports 
those affected by pregnancy or infant loss. 

The organisation was founded in 2006. Our 
support will fund much needed equipment 
such as a fetal cardiotocography monitor.

 For further information, please 
go to www.lifeafterloss.org.uk

Brainwave
Brainwave is a charity that exists 
to help children with disabilities and 
developmental delay achieve their 
full potential. The children they 
work with have a range of conditions 
including autism, brain injuries 
such as cerebral palsy and genetic 
conditions such as Down’s syndrome. 
The centre we are supporting 
is in Birchwood, Warrington.

Thanks to its supporters and dedicated 
therapy teams, Brainwave now impacts 
on the lives of over 600 children with 
additional needs. Brainwave’s growth 
and regional outreach have been driven 
by the commitment to bring measurable 
improvements to the lives of children with 
physical, sensory, learning, cognitive and 
behavioural difficulties. 

Key to ongoing success of the three 
centres is the ability for the charity to 
raise funds. As well as providing a financial 
donation, Assura has supported several 
of Brainwave’s events during the last 
12 months. 

   For further information, please 
go to www.brainwave.org

Assura plc Annual Report 2016  47

Strategic reportFinancial statements Governance www.assuraplc.com 
Chairman’s introduction to governance

The Board has an effective, well- 
balanced structure, which draws  
on a wealth and variety of experience 

SIMON LAFFIN
EXECUTIVE CHAIRMAN

DEAR SHAREHOLDER
The Board is committed to maintaining 
the highest standards of Corporate 
Governance. 

This year, we have enhanced our 
approach to risk management and have 
adopted the revised statement of going 
concern and statement of longer-term 
viability, as discussed elsewhere in  
this report.

The Board continues to believe that  
it has an effective, well-balanced 
structure, which includes a group of 
Non-Executives who collectively draw  
on a wealth and variety of skills and 
experience as shown on pages 50 
and 51, thus providing for effective 
decision making. 

An internal evaluation was carried out 
during the year. A questionnaire was 
circulated to the Board, Company 
Secretary and Executive Committee 
members, asking a range of questions 
about how each perceived the Board to 
be operating and how individuals were 

contributing. I collated the results and 
spoke to individuals separately, reporting 
back the findings to both the Board and 
the executive committee. The feedback 
was almost universally positive, more so 
than the previous year. The only 
significant points to arise were:

 ■ An opportunity for enhanced non-
financial performance measures

 ■ The need for further succession 

planning for all roles at the  
appropriate time. 

The Board was content, given the small 
size of the Board and its perceived 
successful nature that this year’s review 
was conducted internally and at no cost. 
We shall however review in the new year 
whether to employ an independent 
external agency to assist the process.

The Board culture is one of openness, 
mutual respect and constructive debate. 
Comprehensive Board papers are 
circulated in advance to allow members 
to consider fully. Quality of papers had 
been raised in the previous year’s Board 

48  Assura plc Annual Report 2016

review, and this was addressed this year 
to the satisfaction of Directors. I consider 
that all the Directors continue to devote 
sufficient time to discharging their duties 
to a high standard and remain committed 
to their roles.

In March 2016, our Chief Executive, 
Graham Roberts, was given a leave of 
absence as he received treatment for 
cancer. I therefore took on temporarily 
the role of Executive Chairman, pending 
a resolution of Graham’s health. The Board 
then reviewed and approved the relevant 
roles of the executives and myself in order 
that responsibilities remained clear and 
unambiguous, with appropriate checks 
and balances. In particular, we instituted 
a formal fortnightly Executive Board 
meeting, consisting of our Finance Director 
(Jonathan Murphy), Property Director 
(Andrew Darke), and chaired by me, 
with our Company Secretary (Orla Ball) 
providing legal counsel and minutes. This 
Executive Board issues its minutes and 
also verbally reports to the main Board. 
The independent Non-Executive Directors 
are content that satisfactory governance 
procedures and controls are being 
maintained during this period of absence.

In accordance with Corporate 
Governance best practice, it is the 
Company’s policy that all Directors will 
submit themselves for re-election at the 
2016 Annual General Meeting (“AGM”).

The Board has engaged widely with 
shareholders during the year. We are 
delighted to welcome so many new 
shareholders to our register and are 
grateful for the significant support we 
received during our fund raising in 
October 2015. Effective communication 
with investors is a key strategic priority 
and no fewer than 119 investor meetings 
have been held during the year. All 
shareholders are encouraged to attend 
the AGM in July where the Directors and 
executive team will be available to meet 
shareholders directly and to discuss any 
matters of importance. 

www.assuraplc.comBoard strengths

SIMON LAFFIN
EXECUTIVE CHAIRMAN

 ■ Experienced Chairman

 ■ Strategy

 ■ Finance

COMPOSITION 
OF THE BOARD

1

2

2

–

–

1

4

Chairman’s responsibilities

 ■ The effective running of the Board, 
ensuring that the Directors receive 
accurate and timely information to 
enable debate and high quality 
decision making

 ■ Promoting high standards of 

Corporate Governance

 ■ Ensuring that the Board agendas 
take full account of the important 
issues facing the Company and 
the concerns of all Board members

 ■ Ensuring, as Chairman of the 

Nominations Committee, that there 
are Board succession plans in place 
in order to retain and build an 
effective and complementary Board.

GRAHAM ROBERTS
CHIEF EXECUTIVE

 ■ Real Estate

 ■ Capital Markets

 ■ Investment

JENEFER GREENWOOD
NON-EXECUTIVE DIRECTOR

 ■ Real Estate

 ■ Customer Focus

 ■ Marketing

  Executive Chairman
  Executive Director
  Non-Executive Director

Composition of the Board

Chairman

Executive

Independent Non-Executive 

Length of tenure of Directors

One year

Two years

Three years

Four years

JONATHAN MURPHY
FINANCE DIRECTOR

 ■ Corporate Finance

 ■ Accounting and Reporting

 ■ Risk Management

DAVID RICHARDSON
SENIOR INDEPENDENT DIRECTOR

 ■ Finance and Accounting

 ■ Mergers and Acquisitions

 ■ Corporate Governance

Chief Executive’s 
responsibilities

 ■ Running the Company’s business

 ■ Implementing the business strategy

 ■ Regularly updating the Board on 
progress against approved plans

 ■ Providing effective leadership of 

the Executive Board to achieve the 
agreed strategies and objectives.

Assura plc Annual Report 2016  49

Strategic reportFinancial statements Governance www.assuraplc.comBoard of Directors

SIMON LAFFIN
EXECUTIVE CHAIRMAN
Simon Laffin is the Chairman of Assura. 
Simon is also Non-Executive Chairman 
of Flybe Group plc and a Non-Executive 
Director of Watkin Jones plc. Previously 
he served as Chairman of Hozelock 
Group and a Non-Executive Director of 
Quintain Estates and Development plc, 
Mitchells & Butlers plc, Aegis Group plc 
and Northern Rock plc (as part of the 
rescue team). 

Between 1995 and 2004 he was Group 
Chief Financial Officer of UK grocery 
retailer Safeway plc (which he joined in 
1990) and was latterly also responsible 
for property. Prior to that, he held a 
variety of finance and management roles 
in Mars Confectionery, Rank Xerox and 
BP. He is a qualified accountant.

GRAHAM ROBERTS
CHIEF EXECUTIVE
Graham Roberts is Chief Executive of 
Assura. Graham was Finance Director 
at The British Land Company PLC from 
2002 to 2011, and before that was 
Senior Partner for real estate at Arthur 
Andersen, where he also led the public 
sector assurance practice, which 
included clients such as NHS Estates 
and a number of NHS trusts. 

His early career was at Binder Hamlyn. 
He is currently a Non-Executive Director 
at Balfour Beatty plc and is Chairman 
of its Audit Committee.

Graham is currently taking a leave 
of absence due to illness.

JONATHAN MURPHY
FINANCE DIRECTOR
Jonathan Murphy is the Finance Director 
of Assura. Jonathan was previously 
Finance Director of the fund management 
business of Brooks Macdonald Group 
plc, having joined as a result of the 
acquisition of Braemar Group plc in 2010, 
where he was Finance Director for four 
years. Jonathan was previously Managing 
Director for the property management 
business of Brooks Macdonald. 

His earlier career included commercial 
and strategic roles at Spirit Group 
and Vodafone. Jonathan qualified 
as a Chartered Accountant with 
PricewaterhouseCoopers, holding 
management roles in both the UK and 
Asia. Jonathan holds an MBA from IESE, 
the leading European Business School 
in Barcelona.

Appointed
August 2011

Appointed
March 2012

Appointed
January 2013

Board meetings and attendance
Board meeting 
Audit Committee 
Remuneration Committee 
Nominations Committee (Chair) 

11/11
5/5
5/5
2/2

Independent
Not applicable

Board meetings and attendance
Board meeting 
Nominations Committee 

10/11
2/2

Board meetings and attendance
Board meeting 

11/11

Independent
Not applicable

Independent
Not applicable

50  Assura plc Annual Report 2016

www.assuraplc.comJENEFER GREENWOOD
NON-EXECUTIVE DIRECTOR
Jenefer Greenwood is a Chartered 
Surveyor who started her career 
at Hillier Parker in 1978, becoming 
Executive Director and Head of Retail 
on merger with CBRE. Jenefer worked 
for Grosvenor Estate from 2003 
until 2012. 

DAVID RICHARDSON
SENIOR INDEPENDENT 
DIRECTOR
David is currently Chairman of BBGI 
SICAV SA and a Board member of The 
Edrington Group. Previously he spent 22 
years at Whitbread Plc where he was the 
Strategic Planning Director for eight years 
and the Finance Director for four years. 

Jenefer sits on fund supervisory 
boards of INTERNOS Global Investors 
and was appointed to the Board of DCH 
Group in August 2014 and chairs the 
Remuneration Committee. 

She has previously served on the Board 
of The Crown Estate and chaired its 
Remuneration Committee. She has held 
positions as Chair of the National Skills 
Academy for Retail and President of the 
British Council of Shopping Centres.

At Whitbread he played a pivotal role 
in transforming the Group from a brewing 
and pubs company into a market leader 
in hotels, restaurants and leisure clubs. 
Following this he has held a number 
of Non-Executive roles in FTSE listed 
companies including Serco Group plc, 
Forth Ports plc (now called Forth Ports 
Ltd), Tomkins plc (now called Gates 
Worldwide Limited), Dairy Crest plc 
and De Vere Group plc. He is a 
Chartered Accountant. 

Appointed
May 2012

Appointed
January 2012

Board meetings and attendance
Board meeting 
Audit Committee 
Remuneration Committee (Chair) 
Nominations Committee 

Board meetings and attendance
Board meeting 
Audit Committee (Chair) 
Remuneration Committee 
Nominations Committee 

11/11
5/5
5/5
2/2

11/11
5/5
5/5
2/2

Independent
Yes

Independent
Yes

Assura plc Annual Report 2016  51

Strategic reportFinancial statements Governance www.assuraplc.comJuly 2015 AGM – key highlights
 ■ All resolutions passed.

 ■ Full Director attendance.

 ■ 751 million to 756 million votes cast 

for each resolution.

 ■ All Directors retired and were  

re-elected to the Board.

 ■ Remuneration report resolution passed 
with 99.45% of votes cast in favour.

Corporate Governance

Statement of compliance 
with the UK Corporate 
Governance Code
In accordance with the Listing Rules 
of the UK Listing Authority, the Company 
confirms that throughout the year ended 
31 March 2016 and as at the date of this 
Annual Report it was compliant with all the 
relevant provisions as set out in the UK 
Corporate Governance Code published 
in September 2014 (“the Code”) save as 
referred to in the Chairman’s Statement 
on page 48 where Mr Laffin became 
Executive Chairman during Mr Roberts’ 
period of leave due to illness. 

Role of the Board
The Company has an effective Board 
which is collectively responsible for the 
long-term success of the Company by 
directing and supervising the activity of  
the Company. The Board has approved a 
schedule of matters reserved for decision 
by the Board. This includes all corporate 
acquisitions or corporate disposals, debt 
raising above £50 million, the Remuneration 
Policy, the annual budget approval and 
amendments to delegated authorities.  
The Board meets at least six times per year 
for scheduled meetings. It also meets as 
required to consider any important or 
urgent business. 

The Directors acknowledge their 
responsibility for preparing the Annual 
Report and Accounts and consider that 
the Annual Report, taken as a whole, is 
fair, balanced and understandable and 
provides shareholders with the necessary 
information to assess the Company’s 
position and performance, business 
model and strategy.

The Board considers that Jenefer 
Greenwood and David Richardson 
are independent having regard to 
their character and judgement and 
the fact that there are no relationships 
or circumstances which could 
affect their judgement.

Shareholder relations
The Board welcomes open 
communication with its shareholders 
and works with its stockbrokers 
Liberum Capital and Stifel to ensure that 
an appropriate level of communication 
is maintained. The dialogue with 
shareholders is facilitated by a series 
of investor relations mechanisms, 
including regular meetings between senior 
members of the Company’s executive 
management with institutional investors 
and sales teams and industry/sector 
analysts. Feedback from these meetings 
is regularly relayed to the Board in order 
to ensure that all Board members, and 
Non-Executive Directors in particular, 
develop an understanding of the views 
of major shareholders. This process 
augments the regular dissemination of 
annual reports and other market updates. 
Copies of these announcements and any 
accompanying presentational materials 
are available on the Company’s website 
at www.assuraplc.com. 

The Board responds to ad hoc requests 
for information from shareholders and 
all shareholders have access to the 
Board and senior management, with 
an opportunity to raise questions, at the 
AGM and other shareholder meetings.

52  Assura plc Annual Report 2016

www.assuraplc.comBOARD

Audit Committee

Nominations Committee

Remuneration Committee

Read more on p54

Read more on p57

Read more on p58

To assist in its Corporate Governance 
responsibilities, the Board has established 
standing Committees. All Non-Executive 
Directors and the Chairman served on all 
Committees. This was appropriate given 
the relatively small size of the Board. Each 
Committee follows Terms of Reference 
which are reviewed annually and are 
available on the Company’s website. 
Simon Laffin stepped down from 
the Audit Committee on becoming 
Executive Chairman. 

On appointment, new Directors receive 
a full briefing on the role, duties and 
responsibilities of a Director of a listed 
company, and on the Company and its 
Board. An induction pack with important 
information is provided. Training needs 
are reviewed annually as part of the 
Board evaluation.

Each Board member is permitted to 
take professional advice on any matter 
which relates to their position, role and 
responsibilities as a Director at the cost 
of the Company and have access to the 
advice and services of the Company 
Secretary who advises the Board on 
Corporate Governance matters. 

Assura plc Annual Report 2016  53

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
Corporate Governance continued

Audit Committee Report

Audit Committee 
members

 ■ David Richardson (Chairman)

 ■ Simon Laffin1

 ■ Jenefer Greenwood

Number of meetings in the year: five

1.   Stepped down on becoming  

Executive Chairman

Responsibilities
Financial statements 
and reports
 ■ To monitor the integrity of the half 

year and annual financial statements 
before submission to the Board, 
reviewing significant financial reporting 
matters and judgements focusing 
particularly on matters of material 
financial impact.

 ■ To review the effectiveness of the 

Company’s system of internal control.

 ■ To conduct an annual review of 
the need to establish an internal 
audit function.

 ■ To discuss the issues arising from 

the interim and final audits.

 ■ To monitor and review annually the 
auditor’s independence, objectivity 
and effectiveness.

 ■ To develop and implement the policy 
for provision of non-audit services by 
the external auditor.

 ■ To make recommendations to the 
Board in relation to the selection 
process for the appointment of the 
external auditor.

54  Assura plc Annual Report 2016

Additional attendees – 
as appropriate
Deloitte LLP 
PwC LLP
Savills LLP and Jones Lang LaSalle
Graham Roberts – Chief Executive
Jonathan Murphy – Finance Director
Paul Carroll – Financial Controller
David Purcell – Group Finance Manager
Andrew Darke – Property Director  
Orla Ball – Company Secretary

Key activities of the Committee
Financial statements 
and reports
 ■ Reviewed the Annual Report 
and financial statements and 
half year financial report and 
made recommendations to the 
Board regarding the approval 
of these documents.

 ■ Received a recommendation from the 
Property Director on the appointment 
of the firms to carry out the valuation 
in 2016 following a review.

Review of risk management 
and internal controls
 ■ Reviewed the effectiveness of the 

Prospectus and working 
capital reports
 ■ Reviewed the prospectus published 

during the year with particular 
emphasis on reviewing the work 
undertaken by PwC to review the 
assessment of the Board that the 
Group’s working capital was sufficient 
to support the business at the date 
of the prospectus.

Review of external audit
 ■ Reviewed, considered and agreed the 
scope and fees for the audit work to 
be undertaken by the external auditor. 

 ■ Reviewed the effectiveness, 
performance and fees of the 
external auditor.

Review of external valuers
 ■ Received presentations from both 

Company’s internal controls and risk 
management processes and the 
disclosures made in the Annual Report.

 ■ Received the minutes from the Risk 

Committee and reviewed the principal 
risks derived from the risk register 
along with any movement in those 
risks in the year. 

 ■ Reviewed the appropriateness of the 
accounting policies and the design 
and operation of the internal controls.

Others
 ■ Monitored compliance with 

the REIT rules.

 ■ Reviewed the effectiveness 

of the Committee.

 ■ Reviewed the requirement for 

an internal audit function.

 ■ Reviewed the viability statement 

and supporting evidence.

valuers and raised queries on these.

 ■ Reviewed the approved treasury 

 ■ Reviewed the effectiveness, 
performance and fees of the 
external valuers.

counterparties.

www.assuraplc.comDEAR SHAREHOLDER
As Chairman of the Audit Committee, 
I have pleasure in setting out below the 
formal report on its activities for the year 
ended 31 March 2016.

The Company is mindful of the 
UK Corporate Governance Code’s 
new requirements in relation to risk and 
the monitoring of internal control systems. 
During 2015 the Committee and the Board 
reviewed the Group’s risk management 
framework and approved the establishment 
of and Terms of Reference for a new 
Risk Committee reporting to the Audit 
Committee. Having monitored the Group’s 
risk management and internal control 
systems, the Committee has not identified 
any significant failings or weakness in these 
control systems during the year. 

You will also note from the report that 
the Company engaged PwC during the 
year to undertake the role of reporting 
accountant in association with the 
prospectus published during the 
year in accordance with UK Listing 
Authority requirements. 

The Committee performs a detailed 
review of the content and tone of the 
Annual Report and half year results and 
has satisfied itself that there are robust 
controls over the accuracy and consistency 
of the information presented. Accordingly 
the Committee has advised the Board that 
the Annual Report taken as a whole is 
“fair, balanced and understandable” and 
provides the information necessary for 
the shareholders to assess the Company’s 
position and performance, business model 
and strategy.

Significant financial 
reporting matters
 ■ Valuation of investment properties 

including those under construction – 
valuations and yields are discussed with 
management and benchmarked against 
comparable portfolios. The two external 
valuers present to and are challenged by 
the Committee on their valuations. 

 ■ Validity of the going concern basis and 
the availability of finance going forward 
– the Committee considers the financing 
requirements of the Group in the context 
of committed facilities and evaluates 
management’s assessment of going 
concern and the assumptions made. 
The external auditor also reports to 
the Committee following its review.

 ■ Accounting for the corporate property 
acquisitions completed during the year 
– the Group made four property 
acquisitions through corporate vehicles 
during the year and each one has been 
categorised as a property acquisition as 
they involved acquiring income producing 
property assets without associated 
employees or ancillary income streams. 
This accounting treatment and their 
inclusion in the Group’s property portfolio 
valuation is key to an understanding of 
the financial statements for the year. We 
discussed the accounting treatments 
with Deloitte LLP, both before and after 
its audit work, and the valuations with 
Messrs Jones Lang LaSalle and Savills 
LLP at the conclusion of their work. We 
satisfied ourselves that all aspects were 
properly treated.

 ■ Viability statement – the Committee 

considered the proposed draft Viability 
Statement and the supporting analysis 
produced by management and 
approved the statement for inclusion in 
the 2016 report. The statement appears 
on page 32.

Assura plc Annual Report 2016  55

Strategic reportFinancial statements Governance www.assuraplc.comCorporate Governance continued

Audit Committee Report continued

The FRC’s Audit Quality Review Team 
reviewed Deloitte’s audit of the 2015 
financial statements as part of their 
annual inspection of audit firms. Their 
review focused on identifying areas for 
improvements rather than highlighting 
areas performed to or above the expected 
level. The Committee received a full copy  
of the findings of the Audit Quality Review 
Team and discussed these with Deloitte. 
Some matters were identified as requiring 
improvement and we have agreed an 
action plan with Deloitte to ensure the 
matters identified by the AQR have been 
addressed in the audit of the Company’s 
31 March 2016 financial statements. The 
Audit Committee is also satisfied that there 
is nothing within the report which might 
have a bearing on the audit appointment.

Deloitte was appointed following a 
competitive tender in March 2012 and 
pursuant to the Competition and Markets 
Authority Order, the latest date by which 
the Company is required to tender and 
appoint an external auditor is for the 
financial year beginning 1 April 2022. 
We will make a statement on future audit 
plans in the Annual Report for the financial 
year ended 31 March 2017.

DAVID RICHARDSON
CHAIRMAN OF THE  
AUDIT COMMITTEE

We are satisfied that there were no matters 
arising from each of the above that we wish 
to draw to the attention of the shareholders.

Internal controls
The Group’s internal control systems 
include a detailed authorisation process, 
formal documentation of all transactions, 
a robust system of financial planning 
(including cash flow forecasting and 
scenario testing) and a robust appraisal 
process for all property investments.

Internal audit
The Audit Committee is satisfied that 
the current level of control and risk 
management within the business 
adequately meets the Group’s current 
needs. The Committee considers that 
the additional cost of an internal audit 
department is not currently justified.

Audit/non-audit fees payable 
to external auditor
The external auditor did not carry out any 
non-audit services this year. The fees paid 
to the external auditor are disclosed in 
Note 4(a) to the audited accounts.

Effectiveness of external 
audit process
The Committee assessed the 
effectiveness of the external audit 
process, initially reviewing and challenging 
the audit planning memorandum prepared 
by Deloitte and then monitoring fulfilment 
of this plan. The Committee received 
regular feedback from management on 
the service and support provided by 
Deloitte and concluded that the external 
audit was carried out efficiently and 
effectively with objective, independent 
challenge. Accordingly the Committee 
recommends Deloitte’s re-appointment 
at the 2016 AGM. 

56  Assura plc Annual Report 2016

www.assuraplc.comNominations Committee Report

Nominations 
Committee members

Attendees
Orla Ball – Company Secretary

 ■ Simon Laffin (Chairman)

 ■ David Richardson

 ■ Jenefer Greenwood

 ■ Graham Roberts

Number of meetings in the year: two

Responsibilities
The Terms of Reference, which are 
reviewed annually (and are available to 
view on the Company website), require 
the Committee to meet at least once 
per year. 

Key issues
 ■ Re-election of all Directors at the 

July 2015 AGM.

 ■ Review of succession planning.

 ■ Review of Board composition, 
Committee composition and 
Committee Chairmanship.

 ■ Consideration of training needs 

and skills updating.

 ■ Board performance evaluation.

 ■ Considered and confirmed that 
the Non-Executive Directors 
were independent.

Key activities of the Committee
Board and Committee changes
There have been no appointments to the 
Board or Board Committees during the year. 

Board performance evaluation 
The Board has reviewed its performance, 
and the performance of its Committees  
and individual Directors based on an 
internal evaluation carried out by the 
Chairman in November 2015 where Board 
and Executive Board members and the 
Company Secretary completed a detailed 
questionnaire. The Board concluded 
that its access to relevant information is 
good, discussions are carried out in an 
appropriate manner, the strategy and goals 
of the Company are clear and the Board is 
appraised promptly and fully of investor 
views. The Board continues to have an 
appropriate mix of skills and experience  
and discussions around the boardroom 
table are constructive and challenging.  
The Nominations Committee also met in  
the absence of the Chairman to appraise 
the Chairman’s performance. There were 
no major changes adopted in the way 
the Board operates. The Board also 
concluded that no further appointments 
were necessary at this time. 

Commitments of the Chairman
Simon Laffin is also Non-Executive 
Chairman of Flybe Group plc and Non-
Executive Director at Watkins Jones plc. Mr 
Laffin manages his time effectively in order 
to allocate sufficient time to each of his roles.

Policies
The Board believes that a diverse 
workforce and management team improve 
the culture of the organisation and add 
value to the business as a whole.

The Board targeted having at least 20% 
female representation which was 
achieved in 2012.

The Committee will continue to consider 
gender and wider aspects of diversity 
such as experience, nationality, disability 
and age when recommending any future 
Board appointments. Final appointments 
will always be made on merit.

Succession planning
Succession planning was a focus of the 
Committee during 2015 and a formal 
report on succession plans for the Board, 
Executive Directors and senior members 
of staff was prepared and reviewed. 
Consideration was given to short-term 
cover as well as development of talent 
within the business to fill more senior 
roles over the medium and long term, 
acknowledging that given the size of 
the workforce there will not be successors 
for every senior role. The Committee will 
continue to monitor this area in 2016. 

SIMON LAFFIN
CHAIRMAN OF THE 
NOMINATIONS COMMITTEE

Assura plc Annual Report 2016  57

Strategic reportFinancial statements Governance www.assuraplc.com 
Remuneration Report

Remuneration 
Committee members

 ■ Jenefer Greenwood (Chairman)

 ■ Simon Laffin

 ■ David Richardson

Number of meetings in the year: five

Additional attendees – 
as appropriate
Graham Roberts – Chief Executive
Orla Ball – Company Secretary 
FIT Remuneration Consultants LLP 
PwC LLP

 ■ Confirmation of third and final vesting 
of Executive Recruitment Plan (“ERP”)

 ■ Review of the Directors’ Remuneration 

Policy

 ■ Design of new Performance Share Plan

 ■ Review and allocation of staff awards 

under the VCP.

Responsibilities
The Terms of Reference, which are 
reviewed annually (and are available to 
view on the Company website), require 
the Committee to meet at least once 
per year.

The Committee’s activities during the 
year included:

 ■ Consideration of objectives and targets 

for annual bonuses

 ■ Consideration of annual pay awards 

and bonuses

 ■ Approval of increase in staff pension 
contributions (company and personal)

 ■ Review and agreement of changes 

to allocation basis for the staff 
bonus pool

58  Assura plc Annual Report 2016

www.assuraplc.comNew Policy
Shareholder approval was obtained at the 2014 AGM for our existing Remuneration 
Policy, the main features of which are as follows:

Element of pay

Policy/Positioning

2015/16

Fixed pay (e.g. salary, 
pension)

Conservatively positioned 
(salary set at lower quartile 
to median)

Graham Roberts:
 ■ Base salary: £321,500

 ■ Pension: 20% 

Annual bonus

Median

Long-term incentives

Remuneration is geared 
towards long-term 
performance – upper 
quartile

Jonathan Murphy:
 ■ Base salary: £215,000

 ■ Pension: 13.5%

Graham Roberts – 100% 
salary max
Jonathan Murphy – 50% 
salary max

Value Creation Plan – 
page 79

DEAR SHAREHOLDER
Introduction
On behalf of the Board, I am pleased 
to introduce the Directors’ Remuneration 
Report for the year ended 31 March 
2016. This report has been prepared 
by the Remuneration Committee 
(“the Committee”) and approved by the 
Board. The report is split into two parts:

 ■ The Annual Report on Remuneration 
– which sets out payments and awards 
made to the Directors and details the 
link between Company performance 
and remuneration for the 2015/16 
financial year. 

 ■ The Directors’ Remuneration Policy 
– which sets out a new remuneration 
policy which we propose applies for 
2016/17 and the subsequent two years. 

The proposed Directors’ Remuneration 
Policy will be subject to a binding vote 
at the AGM on 19 July 2016. This new 
Policy, if approved by shareholders, will 
last for a period of three years from the 
forthcoming AGM or until another Policy 
is approved in a general meeting. The 
Annual Report on Remuneration will be 
subject to an advisory shareholder vote 
at the forthcoming AGM.

Assura plc Annual Report 2016  59

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

The vesting of VCP awards has led the 
Remuneration Committee to consider 
how best to continue to link remuneration 
to Assura’s long-term performance and, 
indeed, whether the underlying principles 
that have shaped Assura’s approach 
to executive remuneration remain 
appropriate as the Company moves 
into the next stage of its development. 

As a result, the Committee has 
conducted a review of its Executive 
Director remuneration policy and 
practices. This review was undertaken 
in the context of continued strong 
performance at Assura. As a result of 
various capital raises, we believe we have 
the strongest balance sheet in the sector, 
making us attractive to both our potential 
property partners amongst GPs and the 
NHS and our equity and debt funders. In 
addition, this strengthened balance sheet 
together with the longevity and security 
of our property cash flows underpins our 
progressive dividend policy and leaves us 
well placed to take advantage of further 
investment opportunities. As set out on 
page 1, key financial highlights in the 
year include:

 ■ Investment property up 19.9% 

to £1,109.4 million

 ■ Adjusted EPRA NAV up 2.7% 

to 46.1 pence

 ■ Net rental income up 21.2% 

to £58.4 million

 ■ Underlying profit up 78.0% 

to £28.3 million

Since its establishment in 2012, the VCP 
has been the vehicle through which the 
link between long-term performance and 
remuneration has been delivered. The 
structure of the VCP is explained later in 
this report but, in essence, involved a 
one-off award of units that convert into 
nil-cost options based on performance 
against an absolute TSR-based 
condition. This plan was shaped to a 
large extent by the circumstances that 
prevailed at its launch in 2012, at which 
point there was a need to incentivise 
Assura’s then new management team 
– headed by Graham Roberts – to 
implement successfully the Company’s 
new business strategy.

The VCP has achieved this primary 
purpose and has, therefore, served 
the Company and shareholders 
well. Reflecting Assura’s impressive 
performance over recent years, at 
the first VCP Measurement Date 
(20 August 2015), it was determined 
that Assura’s absolute TSR had grown by 
approximately 100% from the first trading 
day of the 2012/13 financial year, which 
resulted in all units effectively converting 
in full into nil-cost options over virtually 
the maximum 25 million shares allowed 
under the VCP. More particularly, Graham 
Roberts’ units converted into nil-cost 
options over 11.8 million shares, with 
Jonathan Murphy’s equivalent being  
5.2 million shares. Under the terms of 
the VCP, 50% of these nil-cost options 
became exercisable immediately, with 
25% becoming exercisable three months 
after the announcement of the 2016 
results and the remaining 25% three 
months after the announcement of the 
2017 results (provided in both cases that 
the relevant minimum TSR thresholds 
are still achieved at those dates). 

60  Assura plc Annual Report 2016

www.assuraplc.comThe key outputs from the Committee’s 
review were as follows:

Fixed pay
Fixed pay (e.g. base salary, pension 
and benefits) was very conservatively 
positioned against companies of a 
comparable size. It is considered 
appropriate to retain this below median 
positioning for now. Consequently, for 
2016/17 Graham Roberts’ salary will be 
increased by 1.5% to £326,400, with 
Jonathan Murphy’s salary increased 
by 9.3% to £235,000. 

Jonathan’s higher increase reflects the fact 
that, despite increases made over recent 
years, his salary remained significantly 
below the average commanded by similar 
post-holders. The Committee is entirely 
comfortable that this increase is appropriate, 
given Jonathan’s continued strong 
performance, together with the fact that 
even his new salary remains in line only with 
lower quartile comparators, and is, therefore, 
consistent with the existing policy. Pension/
benefits will remain unchanged.

Annual bonus
Our current policy is to offer a median 
level of bonus opportunity. This policy 
will continue. However, our review 
clearly showed that Jonathan Murphy’s 
current bonus opportunity of 50% of 
salary does not accord with our policy, 
being substantially below median. 
Consequently, his bonus opportunity 
will be increased to 75% of salary. 
Other outputs from the review relating 
to annual bonus were as follows:

 ■ We will retain the current approach to 
bonus target setting and assessment. 
Therefore, as stated in last year’s DRR, 
the performance objectives set under 
the annual bonus will continue to relate 
to matters such as value-added 
opportunities (within the portfolio and 
from market activity), financial targets, 
customer satisfaction, etc.

 ■ Noting best/market practice, a deferred 
share element will be introduced into 
the annual bonus plan, under which 
up to 50% of any bonus earned by an 
Executive Director will be deferred into 
shares for two years to the extent that 
the Executive Director does not already 
hold shares worth at least 300% 
of salary.

 ■ Clawback/malus provisions should 

continue to apply. 

Long-term incentives
Mindful of the fact that the VCP is 
expected to vest in full in August 2017 
(assuming satisfaction of the threshold 
return hurdle at that time), the Committee 
believes it important that a new long-term 
incentive opportunity is created for the 
Company’s well-regarded, highly 
performing management team. However, 
rather than adopting another one-off/
end-to-end plan such as the VCP, the 
Committee considers it appropriate to 
adopt a more market standard approach 
to long-term incentive provision going 
forward, under which more modest 
regular annual awards are made which 
vest subject to performance over rolling 
three-year periods.

Therefore, the Committee is seeking 
shareholder approval at the 2016 AGM 
to establish a new Assura Performance 
Share Plan (“PSP”). The PSP will be of 
fairly standard design, in that awards of 
free shares can (in the normal course) be 
made worth up to 150% of salary each 
year which vest three years later subject 
to (i) continued employment, (ii) the 
satisfaction of performance conditions 
and (iii) a two-year post vesting holding 
period (unless shares worth 300% of 
salary are already held). Malus/clawback 
provisions will also apply to the new PSP 
which will be established in tandem with 
the adoption of an enhanced share 
ownership guideline (increasing from 
100% to 300% of salary).

Assura plc Annual Report 2016  61

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

In conclusion
I trust you find this report helpful 
and informative, and agree that the 
changes we are proposing to our Policy, 
which have been the subject of a prior 
consultation with some of our major 
shareholders, are appropriate and very 
much in the long-term interests of our 
shareholders. I look forward to receiving 
your support for the three remuneration-
related resolutions (i.e. the vote on the 
new Policy, new PSP and Implementation 
Report) which will be tabled at our 
forthcoming AGM.

JENEFER GREENWOOD
CHAIRMAN OF THE REMUNERATION 
COMMITTEE

Other Policy features
No other substantive changes are to be 
made to the existing Policy. 

Other Committee activities 
during the year 
In addition to conducting the Policy 
review, the other key decisions made by 
the Committee during and in relation to 
the 2015/16 financial year include:

 ■ Reflecting another year of strong 

performance, the Executive Directors 
earned a bonus equal to 71% and 
100% respectively of the maximum for 
2015/16 (71% of salary for the Chief 
Executive and 50% for the Finance 
Director). Further details of how this 
bonus outturn was calculated can be 
found on page 78.

 ■ As described above, performance 
against the targets applying to the 
VCP awards was calculated at the 
first Measurement Date, resulting in 
effectively full provisional vesting of 
awards and, therefore, full conversion 
of units into nil-cost options.

 ■ Confirming of third and final vesting 
of the ERP for Jonathan Murphy in 
January 2016. 

When considering which performance 
conditions should be used to determine 
vesting of PSP awards, the Committee 
noted that the use of absolute targets in the 
VCP provided the management team with 
a simple, transparent long-term incentive 
opportunity that was directly aligned 
with value creation for shareholders. 
Consequently, the Committee wishes 
to retain the use of absolute targets in the 
new PSP. We are aware of the preference 
of some shareholders for relative targets 
(e.g. relative TSR, relative TPR/NAV 
performance versus an IPD Index). 
However, the Committee does not believe 
that, in its niche asset class, there are 
sufficient listed comparators against 
which it would be meaningful to compare 
Assura’s TSR performance. Other property 
companies, outside of primary care, 
have different characteristics that make it 
inappropriate to use them as a benchmark. 
Investors will often buy Assura precisely to 
tap into this non-conforming asset class. 
The IPD All Healthcare Index, which could 
be potentially the most relevant benchmark 
to use for a relative Total Property Return 
context, is somewhat dominated by Assura 
itself making up some 25% of the index. 
This index also includes significant 
non-related asset classes, such as care 
homes, which again renders it a rather 
crude relative performance measure.

As a result, the Committee believes that 
the best approach would be to continue 
to use absolute targets for the PSP. 
However, rather than solely using 
absolute TSR targets (as was the case 
with the VCP), the Committee intends to 
use a blend of absolute TSR and NAV per 
share growth targets, thereby providing 
a more rounded assessment of overall 
performance in a simple, transparent 
fashion. Further details of these targets 
can be found on page 85, with a full 
summary of the PSP as a whole found 
in the Notice of AGM. 

62  Assura plc Annual Report 2016

www.assuraplc.comOur goal is to maximise returns for 
shareholders over the long term. Our 
success is measured by three KPIs: 

 ■ Total Property Return – measuring 
income and capital appreciation 
generated from the portfolio.

 ■ Total Accounting Return – measuring 

total reported returns for the Company 
after all overheads and including the 
effect of leverage.

 ■ Total Shareholder Return – the 

dividend and capital appreciation 
experienced by shareholders. 

Our remuneration arrangements either 
directly or indirectly encourage delivery  
of outstanding performance against 
these KPIs. The table below shows 
progress on the three KPIs over the  
period since inception of the VCP:

Measure

Total Property Return

Total Accounting Return

Total Shareholder Return

Since
 1 April 
2012

24.7%

44.9%

94.1%

INTRODUCTION
This report contains the material 
required to be set out as the Directors’ 
Remuneration Report for the purposes 
of Part 4 of the Large and Medium-sized 
Companies and Groups (Accounts 
and Reports) (Amendment) Regulations 
2013, which amended the Large and 
Medium-sized Companies and Groups 
(Accounts and Reports) Regulations 
2008 (“the Regulations”). 

Part A represents the Directors’ 
Remuneration Policy. This is a new 
Policy for which shareholder approval 
is being sought at the 2016 AGM and 
will, if approved, take effect immediately 
after the 2016 AGM.

Part B constitutes the implementation 
sections of the Remuneration Report 
(“Implementation Report”). The auditor 
has reported on certain parts of the 
Implementation Report and stated whether, 
in their opinion, those parts have been 
properly prepared in accordance with the 
Companies Act 2006. Those parts of the 
Implementation Report which have been 
subject to audit are clearly indicated.

PART A: DIRECTORS’ 
REMUNERATION POLICY 
The Directors’ Remuneration 
Policy as set out in this section of the 
Remuneration Report will replace the 
existing Policy which was approved by 
shareholders at the 2014 AGM and will 
take effect for all payments made to 
Directors from the date of the 2016 
AGM. The Policy has been developed 
with regard to the UK Corporate 
Governance Code and is felt to be 
appropriate to support the long-term 
success of the Company while ensuring 
that it does not promote inappropriate 
risk taking. More particularly, the Policy 
is framed to support the Company’s 
strategic drivers, which are set out on 
pages 14 and 15. The Committee aims 
for the Policy and its use of performance 
metrics to support shareholder value 
creation by incentivising sustainable 
performance consistent with the 
strategic drivers and appropriate risk 
management, and that:

 ■ The interests of shareholders and 
management should be aligned

 ■ Excessive risk taking should be 
discouraged and effective risk 
management given due consideration

 ■ It should retain and motivate, 

based on selection and interpretation 
of appropriate benchmarks

 ■ Poor performance should not 

be rewarded

 ■ The long-term interests of the 

Company should be promoted.

Assura plc Annual Report 2016  63

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Based on the above, the new Policy is set out below:

Objective and link  
to strategy

Fixed remuneration

Base salary 
Core element of remuneration 
set at a level that recognises 
the size and complexity of the 
Company and when combined 
with the performance-based 
variable remuneration potential 
can attract and retain 
Executive Directors of the 
quality to execute the strategy.

Operation

Maximum opportunity

Performance measurement 
and assessment

None.

Any increase in salary for 
Executive Directors will take 
into account salary levels 
of comparable companies 
within the FTSE Real Estate 
Investment Trusts and FTSE 
Real Estate Investment 
Services sectors, and 
companies of comparable 
size and complexity.

In the normal course of 
events, increases in the 
Executive Directors’ salaries 
will not exceed the average 
increase for employees, 
save where there is a clear 
misalignment with market levels. 
However, individuals who are 
recruited or promoted to the 
Board may, on occasion, have 
their salaries set below the 
targeted Policy level until they 
become established in their 
role. In such cases subsequent 
increases in salary may be 
higher than the average until the 
target positioning is achieved.

An Executive Director’s base 
salary is considered by the 
Committee on appointment 
and then reviewed periodically 
or when an individual changes 
position or responsibility.

Any changes normally take 
effect from 1 April each year.

When making a determination 
as to the appropriate salary 
level, the Committee first 
considers remuneration 
practices within the Group 
as a whole and, where 
considered relevant, 
conducts objective research 
on companies within the 
Company’s peer group.

It should be noted that the 
results of any benchmarking 
will only be one of many 
factors taken into account 
by the Committee. Other 
factors include:

 ■ Individual performance 

and experience

 ■ Pay and conditions for 
employees across 
the Group

 ■ The general performance 

of the Company

 ■ The economic environment.

No recovery provisions apply 
to base salary.

64  Assura plc Annual Report 2016

www.assuraplc.comOperation

Maximum opportunity

Performance measurement 
and assessment

None.

Benefit values vary year on 
year depending on premiums 
and the maximum value is the 
cost of the provision of these 
benefits. The Committee will 
monitor the costs of benefits 
in practice and will ensure 
that the overall costs do not 
increase by more than the 
Committee considers 
appropriate given all 
the circumstances.

Objective and link  
to strategy

Benefits 
The Company provides 
benefits in line with 
market practice.

Pension 
The Company provides a 
level of pension contribution 
in order to be competitive and 
to ensure that it has the 
ability to recruit and retain 
Executive Directors.

Executive Directors may 
receive a benefit package 
which includes:

 ■  Health insurance

 ■ Death in service benefits

 ■ Company car allowance

 ■ Other benefits as provided 

from time to time.

Benefits are reviewed 
periodically to ensure that they 
remain market competitive.

The payments are not included 
in salary for the purposes of 
calculating any benefit or level 
of participation in incentive 
arrangements.

No recovery provisions apply  
to benefits.

Executive Directors can receive 
pension contributions to 
personal pension arrangements 
or, if a Director is impacted by 
annual or lifetime limits on 
contribution levels to qualifying 
pension plans, the balance  
(or all) can be paid as a cash 
supplement. Pension related 
payments are not included for 
the purposes of calculating any 
benefit or level of participation  
in incentive arrangements.  
No recovery provisions apply.

None.

The maximum employer’s 
contribution is 20% of 
base salary for the Chief 
Executive and 13.5% for 
the Finance Director.

Assura plc Annual Report 2016  65

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Objective and link  
to strategy

Operation

Maximum opportunity

Performance measurement 
and assessment

Performance-based variable remuneration

Bonus 
Incentivises the achievement 
of a range of performance 
targets that are key to the 
success of the Company.

Awards may be made 
annually.

The performance period is 
one financial year. Payouts 
may be made in a mix of 
cash and deferred shares 
determined by the Committee 
following the financial year 
end, based on achievement 
against a range of financial 
and strategic targets.

Where an element of bonus 
is payable as deferred shares, 
individuals may be able to 
receive a dividend equivalent 
in cash or shares equal to the 
value of dividends which 
would have accrued during 
the vesting period.

The Committee views the 
performance targets for the 
bonus plan as commercially 
sensitive and that it would be 
detrimental to the interests of 
the Company to disclose them 
before the start of the financial 
year. Appropriate details of the 
targets will be disclosed after 
the end of the relevant 
financial year in that year’s 
Remuneration Report, except 
where their disclosure remains 
commercially sensitive. 

Bonus payments are not 
pensionable, but are subject 
to clawback provisions.

The maximum annual bonus 
for Executive Directors is 
100% of salary. At threshold 
performance 0% of maximum 
can be earned.

Performance measures are set 
annually based on a number 
of financial and strategic 
measures which may include 
(but are not limited to):

At target up to 75% of 
maximum can be earned.

 ■ Delivering specific added 

value activities

 ■ Delivering financial goals

 ■ Improving operational 

performance

 ■ Developing the performance 

capability of the team.

The Committee has the 
discretion to vary the 
performance targets 
depending on economic 
conditions and Company 
specific circumstances that 
may occur during the year.

At the end of each financial 
year the Committee takes 
into account the Company’s 
financial performance and 
achievement against key 
short-term objectives 
established  
at the beginning of the year. 
This involves establishing in 
advance what constitutes 
success for good, strong or 
outstanding performance. It is 
the Committee’s approach to 
view the performance in the 
round at the end of the year, 
taking into account extraneous 
events and changing priorities, 
where relevant.

66  Assura plc Annual Report 2016

www.assuraplc.comObjective and link  
to strategy

Long-term incentives 
To motivate and incentivise 
delivery of sustained 
performance over the long 
term, and to promote 
alignment with shareholders’ 
interests, the Company 
intends to operate the 
Performance Share 
Plan (“PSP”). 

Operation

Maximum opportunity

In the normal course, the 
PSP allows for awards over 
shares with a maximum value 
of 150% of base salary per 
financial year. However, 
the Committee retains the 
flexibility to grant awards 
in excess of this amount, 
up to 300% of salary, if the 
Committee considers that 
it is in shareholders’ interests 
to do so (e.g. if exceptional 
circumstances exist relating 
to a recruitment).

Awards under the PSP may be 
granted as nil/nominal cost 
options or conditional awards 
which vest to the extent 
performance conditions are 
satisfied over a period of at 
least three years, with a post 
vesting holding period also 
potentially applying. Vested 
awards may also be settled 
in cash.

The PSP rules allow that 
the number of shares subject 
to vested PSP awards may 
be increased to reflect the 
value of dividends that would 
have been paid in respect 
of any ex-dividend dates 
falling between the grant 
of awards and the expiry  
of any vesting period (or 
applicable holding period). 

Clawback and malus 
provisions apply to 
PSP awards.

Performance measurement 
and assessment

The Committee may set such 
performance conditions on 
PSP awards as it considers 
appropriate (whether financial 
or non-financial and whether 
corporate, divisional or individual).

Performance periods may 
be over such periods as the 
Committee selects at grant, 
which will not be less than 
(but may be longer than) 
three years.

No more than 25% of awards 
vest for attaining the threshold 
level of performance conditions.

In addition, while performance 
measures and targets used in 
the PSP will generally remain 
unaltered, if in the Committee’s 
opinion, circumstances are 
such that a different or 
amended target would be a 
fairer measure of performance, 
such amended or different 
target can be set provided that 
it is not materially more or less 
difficult to satisfy than was the 
original target at the time it 
was set.

Shareholding requirement 
To ensure alignment between 
Executive Directors and 
shareholders’ interests over 
a longer time horizon.

The Committee operates 
a system of shareholder 
guidelines to encourage 
long-term share ownership 
by the Executive Directors.

Executive Directors may not 
sell any shares acquired via 
any share-based incentive 
plan if the sale would take  
their shareholding below the 
shareholding requirement.

The Executive Directors are 
expected to acquire shares 
equal to at least 300% of their 
salary. At the Committee’s 
discretion this may be 
acquired over a timeframe 
determined by the Committee.

Assura plc Annual Report 2016  67

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

The composition and total value of 
the Executive Directors’ remuneration 
package for the financial year 2016/17 
at minimum, on-target and maximum 
performance scenarios are set out in 
the charts below.

1,400

1,200

1,000

0
0
0
’
£

800

600

400

200

0

£899

27%

27%

46%

100%£410

100%

£1,225

40%

27%

33%

Minimum

On-target

Maximum

Chief Executive – Graham Roberts

■ Multiple reporting periods
■ Annual variable
■ Fixed elements

1,400

1,200

1,000

0
0
0
’
£

800

600

400

200

0

£590
30%
22%

48%

£282

100%

£810

43%

22%

35%

Minimum

On-target

Maximum

Financial Director – Jonathan Murphy

■ Multiple reporting periods
■ Annual variable
■ Fixed elements

Notes to the future policy 
for Executive Directors
Performance measures 
and targets
The annual bonus plan measures are 
selected to provide direct alignment 
with the short-term operational targets 
of the Company. Care is taken to ensure 
that short-term targets are always 
supportive of the long-term objectives. 
This is especially important in a business 
which has a long-term investment horizon. 
Short-term targets are stretching and 
geared to encourage outstanding 
performance, which if delivered can 
earn the Executive up to the maximum 
under the plan.

Differences in Remuneration Policy 
for all employees
Any differences in the types of reward 
between Directors and staff reflect 
common practice. All employees are 
entitled to base salary, benefits and 
defined contribution pension payments 
and are eligible for annual bonuses and 
to participate in the PSP (although actual 
participation in the PSP will be limited to 
the most senior executives within the 
Company). The bonus targets for staff are 
more focused on specific personal goals 
that further the Company’s interests. The 
maximum bonus opportunity available is 
based on the seniority and responsibility 
of the role.

The PSP targets are selected to ensure 
that the Executives are encouraged to, 
and appropriately rewarded for, delivering 
against the Company’s key long-term 
strategic goals so as to ensure a clear 
and transparent alignment of interests 
between Executives and shareholders 
and the generation of sustainable 
long-term returns.

Discretion
The Committee has discretion in several 
areas of policy as set out in this report. 
The Committee may also exercise 
operational and administrative discretions 
under relevant plan rules approved by 
shareholders. In addition, the Committee 
has the discretion to amend policy with 
regard to minor or administrative matters 
where it would be, in the opinion of the 
Committee, disproportionate to seek or 
await shareholder approval. In addition, 
for the avoidance of doubt, in approving 
this Policy, authority is given to the 
Company to honour any commitments 
entered into with current or former 
Directors prior to the adoption of 
this Policy. 

Travel and hospitality
While the Committee does not consider 
it to form part of benefits in the normal 
usage of that term, it has been advised 
that corporate hospitality, whether paid 
for by the Company or another, and 
business travel for Directors and in 
exceptional circumstances their families 
may technically come within the 
applicable rules and so the Committee 
expressly reserves the right for the 
Committee to authorise such activities 
within its agreed policies.

Illustrations of application 
of Remuneration Policy
The policy of the Committee is to 
align Executive Directors’ interests 
with those of shareholders and to 
give the Executive Directors incentives 
to perform at the highest levels. To 
achieve this, the Committee seeks to 
ensure that a significant proportion of 
the remuneration package varies with 
the performance of the Company 
and that targets are aligned with the 
Company’s stated business objectives.

68  Assura plc Annual Report 2016

www.assuraplc.comAssumptions used in determining the level of pay-out under given scenarios are as follows:

Minimum
 ■ Consists of base salary, benefits and pension.

 ■ Base salary is the salary to be paid in 2016/17.

 ■ Benefits measured as benefits paid in the year ended 31 March 2016.

 ■ Pension measured as the defined contribution or cash allowance in lieu of Company contributions of 20% – 13.5% of salary.

2016/17

Graham Roberts

Jonathan Murphy

Base salary  

£’000

Benefits  
£’000

Pension 
£’000

Total fixed  

£’000

326

235

19

15

65

32

410

282

On-target
Based on what the Director would receive if performance was on-target (excluding share price appreciation and dividends):

 ■ Annual bonus: consists of the on-target bonus (75% of maximum opportunity used for illustrative purposes).

 ■ Long-term incentive: consists of the midpoint level of vesting (50% vesting) under the PSP. 

Maximum
Based on the maximum remuneration receivable (excluding share price appreciation and dividends):

 ■ Annual bonus: consists of maximum bonus of 100% of base salary for Graham Roberts and 75% for Jonathan Murphy.

 ■ Long-term incentive: consists of the face value of awards (at 150% of salary for Messrs Roberts and Murphy) under the PSP.

Approach to recruitment remuneration and promotions
The Committee’s approach to recruitment remuneration is to pay no more than is necessary to attract candidates of the 
appropriate calibre and experience needed for the role. The remuneration package for any new recruit would be assessed 
following the same principles as for the Executive Directors, as set out in the remuneration Policy table. The Committee will have 
regard to guidelines and shareholder sentiment regarding one-off or enhanced short or long-term incentive payments made on 
recruitment and the appropriateness of any performance measures associated with an award.

Where an existing employee is promoted to the Board, the Policy set out above would apply from the date of promotion but 
there would be no retrospective application of the Policy in relation to existing incentive awards or remuneration arrangements. 
Accordingly, prevailing elements of the remuneration package for an existing employee would be honoured and form part of 
the ongoing remuneration of the employee. These would be disclosed to shareholders in the following year’s Annual Report 
on Remuneration.

Assura plc Annual Report 2016  69

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

The table below summarises our key policies with respect to recruitment remuneration:

Element

Fixed remuneration

Policy

The salary level, benefits and pension entitlement will be set taking into account 
a number of factors including market practice, the individual’s experience and 
responsibilities and the policies for salary, benefits and pensions for existing 
Executive Directors as set out in the Remuneration Policy table.

In certain circumstances the Committee may choose to recruit unproven Executive 
Directors at a salary below the market rate with a view to providing above average 
increases in salary until an appropriate salary positioning is achieved, subject to 
performance, experience and the individual proving themselves in the role.

Performance-based variable 
remuneration

The recruited Executive Director will be eligible to participate in the annual bonus plan 
and the PSP as set out in the Remuneration Policy table.

The maximum annual variable remuneration that an Executive Director can receive is 
limited to 400% of salary (i.e. the annual bonus plan maximum of 100% of salary plus 
the overriding PSP maximum of 300%). 

Share buyouts/replacement awards The Committee’s policy is not to provide buyouts as a matter of course. However, 

should the Committee determine that the individual circumstances of a recruitment 
justified the provision of a buyout, the value of any incentives that will be forfeited on 
cessation of an Executive Director’s previous employment will be calculated taking  
into account the following:

 ■ The proportion of the performance period completed on the date of the Director’s 

cessation of employment.

 ■ The performance conditions attached to the vesting of these incentives and the 

likelihood of them being satisfied.

 ■ Any other terms and conditions having a material effect on their value  

(“lapsed value”).

The Committee may then grant up to the estimated equivalent value as the lapsed 
value, where possible, under the Company’s incentive plans. To the extent that it was 
not possible or practical to provide the buyout within the terms of the Company’s 
existing incentive plans, a bespoke arrangement would be used to grant up to the 
estimated equivalent value.

In instances where the new Executive is relocated from one work-base to another, the 
Company may provide compensation to reflect the cost of relocation for the Executive 
at the discretion of the Committee.

The level of the relocation package will be assessed on a case by case basis but will 
take into consideration any incremental cost of living differences and/or housing and 
schooling costs.

Relocation policies

Non-Executive Directors would be recruited on the terms set out herein in respect of the main Policy for such Directors.

70  Assura plc Annual Report 2016

www.assuraplc.comApproach to service contracts and cessation of employment
Service contracts
Each of the Executive Directors has a service contract with the Company which is terminable by the Company on six months’ 
notice and by the Director on six months’ notice. The Company’s practice is to appoint the Non-Executive Directors, including the 
Chairman, under letters of appointment. Their appointment is usually for a term of three years subject to annual re-election by the 
shareholders at the Company’s AGM. When setting notice periods, the Committee has regard for market practice and Corporate 
Governance best practice.

Executive Director

Date of contract 

Unexpired term

Notice period by 
Company or Director

Graham Roberts

29 March 2012

Jonathan Murphy

2 January 2013

Rolling contract

Rolling contract

6 months

6 months

Non-Executive Director

Date of letter  
of appointment 

Unexpired term 
as at 31 March 2016

David Richardson 

28 January 2015

Jenefer Greenwood

28 January 2015

22 months

22 months

Executive Chairman

Date of letter  
of appointment 

Unexpired term 
as at 31 March 2016

Simon Laffin

28 January 2015

22 months

All service contracts and letters of appointment are available for viewing at the Company’s registered office.

When determining any loss of office payment for a departing Director, the Committee will always seek to minimise cost to 
the Company whilst complying with the contractual terms and seeking to reflect the circumstances in place at the time. The 
Committee reserves the right to make additional payments where such payments are made in good faith in discharge of an 
existing legal obligation (or by way of damages for breach of such an obligation); or by way of settlement or compromise of 
any claim arising in connection with the termination of an Executive Director’s office or employment.

Good leaver status
The Committee has discretion to determine whether an individual is a “good leaver” under the Company’s incentive plans. Where 
the Committee uses its general discretion to determine that an Executive Director is a good leaver, it will provide a full explanation 
to shareholders of the basis for its determination. The table below sets out, for each element of total remuneration, the Company’s 
policy on payment for loss of office in respect of Executive Directors and any additional discretion available to the Committee:

Assura plc Annual Report 2016  71

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Element

Cessation of employment

Change of control

Base salary, benefits, pension

Bonus plan

PSP 
The treatment of awards granted under 
the PSP will be governed by the rules, 
as approved by shareholders.

72  Assura plc Annual Report 2016

No special provisions.

On a change of control triggering the 
Executive’s termination of contract, 
the extent to which the performance 
requirements are satisfied will determine 
the annual bonus which is earned.

Note that this excludes a reorganisation 
or reconstruction where ownership does 
not materially change.

The Committee will take into account 
such factors as it consider relevant in 
relation to the bonus plan payment for 
the year in which the event occurs.

On a change of control (takeover, 
reconstruction, amalgamation, winding-
up or demerger), unvested awards will 
vest subject to the application of the 
performance conditions and subject to 
time pro-rating. The Committee will also 
retain a standard discretion to vary/waive 
time pro-rating on a takeover. There will 
be compulsory roll-over of awards on an 
internal reconstruction.

There will be no compensation for normal 
resignation or in the event of termination by 
the Company due to misconduct. In other 
circumstances, Executive Directors will be 
entitled to receive payment in lieu of notice.

Salary, benefits and pension contributions/
salary supplement will normally be paid 
over the notice period. The Company has 
discretion to make a lump sum payment on 
termination for the salary, value of benefits 
and pension amounts payable during the 
notice period. In all cases the Company 
will seek to mitigate any payments due.

Where an Executive Director’s employment 
is terminated after the end of a performance 
year but before the payment is made, the 
Executive may be eligible for an annual 
bonus award for that performance year 
subject to an assessment based on 
performance achieved over the period.

Where an Executive Director’s employment 
is terminated during a performance year 
and provided the individual is a “good 
leaver”, a pro-rata annual bonus award for 
the period worked in that performance year 
may be payable at the Committee’s 
discretion subject to an assessment based 
on performance achieved over the period. 
No award will be made in the event of gross 
misconduct.

Normally, on termination of employment 
before the end of the performance period, 
awards lapse in full. However, in good leaver 
situations (e.g. death, injury, ill-health, 
disability, retirement with agreement of 
employer, sale of business/subsidiary, or 
otherwise in the Committee’s discretion), 
awards will not lapse but will instead continue 
and will vest at the normal vesting date 
or on cessation, subject in both cases to 
satisfaction of the performance conditions 
and a pro-rata reduction as the Committee 
determines to reflect the shortened length 
of service. In addition, reflecting standard 
practice, the Committee can waive pro-rating 
in its discretion. Any awards subject to a post 
vesting holding period will vest on cessation, 
save in a case of summary dismissal.

www.assuraplc.comElement

Cessation of employment

Change of control

On a change of control (takeover, 
reconstruction, amalgamation, winding-up 
or demerger before the MD) there will be 
a new MD deemed to be the date of the 
change of control. 

In determining the value created, the 
Measurement Price will be the offer price 
for the Company’s shares. The calculation 
of the number of Company shares to be 
allocated to a participant will be as at any 
other MD. 

All accrued nil-cost options will vest on 
a change of control and be exercisable 
together with any other vested nil-cost 
options immediately for a set period of 
up to six months.

VCP1 
The treatment of awards granted under 
the VCP is governed by the rules, as 
approved by shareholders.

On termination of employment before a 
Measurement Date (“MD”), all unvested 
awards will lapse, unless the following 
circumstances apply:

 ■ Death, injury, ill-health or disability. 

 ■ Retirement or redundancy.

 ■ Any other circumstances if the Committee 

decides in any particular case. 

Where an Executive Director is deemed a 
good leaver prior to the MD, the Committee 
will have discretion to allow some or all of 
the awards to vest by deeming: 

 ■ There to be a new MD at the date of 
cessation and the number of nil-cost 
options to be accrued will be calculated 
as at any other MD; or

 ■ That the nearest normal MD to the date 

of cessation of employment can be used.

All accrued nil-cost options will then vest 
and be immediately exercisable (including 
any other vested nil-cost options) for 
a period of six months. 

Anyone who is not a good leaver will be a 
bad leaver. Where a bad leaver ceases to 
be employed prior to the awards becoming 
exercisable all awards will lapse (including 
accrued unvested nil-cost options).

Note
1.  No futher awards are to be made under the VCP. Therefore the above summary solely relates to the treatment of VCP awards already made.

Assura plc Annual Report 2016  73

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Future policy table – Non-Executive Directors

Objective and link 
to strategy 

The Company sets fee levels 
necessary to attract and retain 
experienced and skilled Non- 
Executive Directors to advise 
and assist with establishing 
and monitoring the strategic 
objectives of the Company.

Performance  
measurement 
and assessment

None.

Operation

Maximum opportunity

Fees will take account of 
fee levels of comparable 
companies within the FTSE 
Real Estate Investment 
Trusts and FTSE Real Estate 
Investment Services sectors, 
and companies of comparable 
size and complexity.

The aggregate fees and any 
benefits of Non-Executive 
Directors will not exceed 
the limit from time to time 
prescribed within the 
Company’s Articles of 
Association for such fees 
(currently £700,000 p.a. 
in aggregate).

Fee levels are sufficient 
to attract individuals with 
appropriate knowledge 
and experience.

Non-Executive Directors are 
paid a base fee and additional 
fees for Chairmanship of 
Committees and/or acting as the 
Senior Independent Director.

Fees are reviewed periodically 
with any changes generally 
effective from 1 April.

In exceptional circumstances, 
fees may also be paid for 
additional time spent on the 
Company’s business outside  
of the normal duties.

Non-Executive Directors do 
not receive a bonus, do not 
participate in awards under 
the Company’s share plans, 
and are not eligible to join the 
Company’s pension scheme.

The Company reserves 
the right to provide benefits 
(including travel and office 
support) to the Non-Executive 
Directors.

74  Assura plc Annual Report 2016

www.assuraplc.comConsideration of employment 
conditions elsewhere in Assura 
when developing the Policy
In setting the Remuneration Policy for 
Directors, the pay and conditions of 
other employees of Assura are taken 
into account, including any base salary 
increases awarded. The Committee is 
provided with data on the remuneration 
structure for all staff and uses this 
information to ensure consistency of 
approach throughout the Company.

The Company has a small number 
of employees and applies the same 
broad policy in relation to incentive 
compensation throughout the 
organisation. All employees are eligible 
for annual bonuses and to participate 
in the PSP (although, in practice, 
participation in the PSP is likely to 
be limited to senior management).

Although the Committee takes into 
account the pay and conditions of other 
employees, the Company did not consult 
with employees when drawing up the 
Policy report.

Consideration of 
shareholder views
The Committee takes the views of 
the shareholders seriously and these 
views are taken into account in shaping 
Remuneration Policy and practice. 
Shareholder views are considered when 
evaluating and setting remuneration 
strategy and the Committee commits 
to consulting with key shareholders 
prior to any significant changes to its 
Remuneration Policy (as has been the 
case in relation to the establishment of 
the new PSP and related Policy changes). 

External appointments
The Company’s policy is to permit an 
Executive Director to serve as a Non-
Executive Director elsewhere when this 
does not conflict with the individual’s 
duties to the Company, and where an 
Executive Director takes such a role they 
may be entitled to retain any fees which 
they earn from that appointment.

 ■ Attributable to management’s 

performance/achievement of the 
VCP performance conditions (i.e. an 
8% p.a. return to shareholders must 
be achieved before any value is 
created for participants)

 ■ Aligned with the value created for 
shareholders during the relevant 
measurement period.

Total equity exposure of 
Executives at 31 March 2016 
The Chief Executive and Finance 
Director together owned 4,957,517 million 
shares as at 31 March 2016 (31 March 
2015: 3,788,281 million) representing 
0.3% of the Company’s share capital.  
A table summarising their interests is 
included in the Annual Report on 
Remuneration (Part B below) on page 82. 

During the year Graham Roberts 
sold 2,500,000 shares at 52.33 pence 
per share and Jonathan Murphy sold 
1,064,354 shares at 55.0 pence per share.

Key reward decisions relating 
to incentive pay in 2015/16 
2015/16 annual bonus outturn
A table showing the full details on the 
2015/16 bonus assessment is set out 
on page 78.

First vesting under the VCP
As reported last year, to take account  
of three significant capital raising events, 
certain adjustments were made to the 
VCP pay-out algorithm to ensure the 
potential VCP benefit created at each 
Measurement Date is:

Full details of the actual adjustments 
made can be found on page 80. 

The first Measurement Date under the 
VCP occurred on 20 August 2015. As a 
consequence of the Company’s strong 
performance, the VCP units converted 
effectively in full into nil-cost options 
over 24,999,950 shares (out of the total 
25 million pool). This resulted in Graham 
Roberts’ units converting into 11,779,255 
nil-cost options, and Jonathan Murphy’s 
units into 5,153,423 nil-cost options.

Under the rules, 50% of any shares that 
accrued at the first Measurement Date 
(in the form of nil-cost options) became 
exercisable at that date, 50% become 
exercisable at the second Measurement 
Date and 100% of accrued nil-cost 
options at the third Measurement Date 
provided the minimum return thresholds 
for each Tranche are achieved at each 
Measurement Date. On 25 September 2015 
Messrs Roberts and Murphy exercised the 
first 50% of their nil-cost options resulting in 
them receiving (after the payment of income 
tax and NICs) 3,121,503 and 1,365,657 
shares respectively.

Assura plc Annual Report 2016  75

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

PART B: ANNUAL REPORT ON 
REMUNERATION – UNAUDITED 
UNLESS STATED
This Annual Report on Remuneration 
contains details of how the Company’s 
Remuneration Policy for Directors was 
implemented during the financial year 
ended 31 March 2016. This report has 
been prepared in accordance with the 
provisions of the Companies Act 2006 
and the Regulations. An advisory 
resolution to approve this report will  
be put to shareholders at the AGM. 

Consideration by the 
Committee of matters relating 
to Directors’ remuneration
The members of the Committee during 
2015/16 were Jenefer Greenwood 
(Committee Chairman), Simon Laffin  
and David Richardson. The members of 
the Committee have no personal financial 
interest, other than as shareholders,  
in matters to be decided, and no potential 
conflicts of interest arising from cross-
directorships. Other than Mr Laffin, the 
Non-Executives have no day to day 
involvement in running the business.

The Committee is responsible for 
recommending to the Board the 
remuneration policy for Executive 
Directors and the senior management and 
for setting the remuneration packages for 
each Executive Director. The Committee 
sets the fees of the Chairman and the fees 
for the Non-Executive Directors are set 
by the Chairman in conjunction with the 
Chief Executive. The Committee also has 

oversight of the remuneration policy and 
packages for other senior members of 
staff. The written Terms of Reference of 
the Committee are available on the 
Company’s website and from the 
Company on request. 

The Committee held five meetings during 
the year. Its activities during and for the 
financial year 2015/16 included:

 ■ Reviewing salary levels for the 

Executive Directors and Chairman

 ■ Considering objectives and targets 
for 2015/16 annual bonus payments 
and determining the bonus payments 
at year end

 ■ Calculating vesting of VCP awards at the 
first Measurement Date in August 2015

 ■ Confirming the third and final vesting 
of the ERP for Jonathan Murphy in 
January 2016 

 ■ Conducting a full review of the existing 

Remuneration Policy

 ■ Preparing this report.

Advisors to the Committee
During 2015/16 the Committee received 
external advice initially from PwC, which  
had previously been appointed by the 
Committee and was considered objective 
and independent. PwC is a member of  
the Remuneration Consultants Group  
and, as such, voluntarily operates under  
the code of conduct in relation to executive 
remuneration consulting in the UK. The 
Committee reviewed the nature of the 
services provided by PwC and was 

satisfied that no conflict of interest exists  
or existed in the provision of these services. 
The total fees paid to PwC in respect of 
services to the Committee during the year 
were £58,000. Fees were determined 
based on the scope and nature of the 
projects undertaken for the Committee.

Also during 2015/16 the Committee 
appointed FIT Remuneration Consultants 
LLP (“FIT”) as its new independent 
advisors. FIT is also a member of the 
Remuneration Consultants Group and, 
as such, voluntarily operates under the 
code of conduct in relation to executive 
remuneration consulting in the UK. 
The Committee reviewed the nature 
of the services provided by FIT and was 
satisfied that no conflict of interest exists  
or existed in the provision of these services. 
The total fees paid to FIT in respect of 
services to the Committee during the year 
were £30,000. Fees were determined 
based on the scope and nature of the 
projects undertaken for the Committee.

The Committee also sought the views 
of the Chief Executive, Graham Roberts, 
during the year. The Chief Executive is 
given notice of all meetings and, at the 
request of the Chairman of the Committee, 
attends part of the meetings. The Chief 
Executive may request that he attends and 
speaks at Committee meetings. In normal 
circumstances, the Chief Executive will be 
consulted on general policy matters and 
matters concerning the other Executive 
Director and employees.

76  Assura plc Annual Report 2016

www.assuraplc.comSingle total figure of remuneration – Executive Directors (audited)
The remuneration of Executive Directors showing the breakdown between components with comparative figures for the prior year 
is shown below. Figures provided have been calculated in accordance with the Regulations:

Executive Director (£’000)

Graham Roberts

Jonathan Murphy2

Year 

Salary

Taxable
benefits

Bonus Pensions

2015/16

2014/15

2015/16

2014/15

322

315

215

180

19

15

15

11

228

284

108

84

64

63

29

24

Long-
term
incentives1

3,114

–

Total

3,747

677

1,445

1,812

84

383

Notes
1.  The long-term incentives column includes the value of the VCP awards that vested during the year as described more fully below.
2. Jonathan Murphy’s long-term incentive figure includes the value of vested ERP awards.

Benefits
Taxable benefits comprised health insurance, death in service benefits, critical illness, Group Income Protection and company  
car allowance.

2015/16 annual bonus plan outcome
In determining the award for 2015/16, the Committee took into account the Company’s financial performance and achievements 
against key short-term objectives established at the beginning of the year. 

This involved establishing in advance what would constitute success for good, strong or outstanding performance. The performance 
targets and performance are summarised on page 78. 

It is the Committee’s approach to view the performance in the round at the end of the year, taking into account extraneous events 
and changing priorities, where relevant. 

The requirement to achieve a step change in scale and to reduce leverage at the same time were identified as the key critical 
success factors.

Assura plc Annual Report 2016  77

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

For 2015/16 the maximum potential bonus awards were 100% of salary for the Chief Executive and 50% of salary for the Finance Director.

Performance measures

Actual targets set at the beginning of the year

Grow the scale of the portfolio

Good £90 million additions, Strong £135 million, 
Outstanding £180 million

Actual performance 
outcome

Strong £141 million

Grow income through extensions 
(annualised)

Good £100,000 additional rent, Strong £150,000, 
Outstanding £200,000

Nil 

Let vacant space

Good 15%, Strong 20%, Outstanding 25%

Outstanding 34%

Deliver underlying budget

Good 100%, Strong 105%, Outstanding 110%

Strong 106%

Reduce average cost of debt

Good 30 basis points reduction, Strong 40 basis 
points, Outstanding 50 basis points

Strong 44 basis points

Increase the percentage of tenants asserting 
they would recommend Assura to others

Good 75%, Strong 80%, Outstanding 85%

Outstanding 90%

In addition to the above financial targets, the Committee agreed personal objectives for both Executive Directors at the start of the 
year. The Chief Executive was asked to pursue all possible lobbying activities; to secure the British Property Federation’s status as 
a strong policy contributor to both the NHS and the Government on primary care issues; and to open development opportunities  
in London. He was expected to keep the Board fully appraised of the lobbying programme, its successes and failures.

The Committee reviewed performance against the above targets and took into consideration that the overall performance on 
financial targets was Strong. The Chief Executive has contributed greatly to the BPF’s growing status. The Board had felt fully 
informed, although progress on opening up the London market was limited. The Committee also took account of the success 
of the equity issue in the year that has transformed Assura’s balance sheet. Overall, it was felt that great progress had been 
achieved by the Chief Executive, despite being unwell, culminating in a leave of absence towards the end of the year. Accordingly, 
taking all factors into account, the Committee awarded 71% of the maximum award, equivalent to 71% of annual base salary.

The Committee also reviewed the performance of the Finance Director. His financial targets were as above, overall being rated 
Strong. His individual targets were to: enhance his own understanding of current capital market conditions and macro-economic 
influences; identify opportunities and formulate a comprehensive medium-term financing strategy; review funding alternatives; 
identify alternatives and opportunities; and keep the Board fully appraised. The Committee concluded that the Finance Director 
had performed in an outstanding manner on all these objectives, culminating in the equity issuance and subsequent repayment 
of debt. It also noted that the Finance Director had played a growing role in leading communications with shareholders, not least 
in the equity raise. When the Chief Executive became unwell, the Finance Director took on more responsibility and helped to 
ensure that the business continued to operate effectively. As a result, the Committee decided to award the Finance Director 
100% of his bonus, equivalent to 50% of annual base salary.

Total pension entitlements
No Executive Director or any member of staff is entitled to a defined benefit pension arrangement. Graham Roberts and Jonathan 
Murphy received payments in lieu of pension contributions equivalent to 20.0% and 13.5% of salary respectively for 2015/16.

78  Assura plc Annual Report 2016

www.assuraplc.comVesting of long-term incentive awards (audited)
Value Creation Plan 
Description of adjustments 
As reported last year, to take account of three significant capital raising events, certain adjustments were made to the VCP 
pay-out algorithm to ensure the potential VCP benefit created at each Measurement Date is:

 ■ Attributable to management’s performance/achievement of the VCP performance conditions (i.e. an 8% p.a. return 

to shareholders must be achieved before any value is created for participants

 ■ Aligned with the value created for shareholders during the relevant measurement period.

More particularly, the Committee amended the Threshold Price applicable to the first Measurement Date (i.e. 20 August 2015), 
whereby, for each capital raising event (to be known as “Tranches”), a Threshold Price was set which must be exceeded before 
any value could be earned by participants. The paragraphs below summarise the alterations.

The Threshold Price applicable to each Tranche of shares at the first Measurement Date was set as follows:

Share capital at the start of the VCP 

Capital issued for MP Reality Holdings Ltd acquisition

Capital issued following placing/offer to shareholders

Capital issued for Metro MRI Ltd acquisition

Original 
Threshold 
Price 
(pence)

New
Threshold 
Price 
(pence) 

39.37

39.37

39.37

39.37

39.37

44.95

45.06

51.29

Shares 
(m)

529.5

44.3

414.3

18.8

Tranche

1

2

3

4

The Threshold Price for each new capital event (i.e. Tranches 2–4) was calculated by using the price at which new capital was 
raised (i.e. the Offer Price for Tranche 3) or the price on the day of issue (Tranches 2 and 4) and increasing this by the 8% p.a. 
compound threshold return rate from the date of the event to the first Measurement Date. The original Threshold Price of 
39.37 pence would continue to apply to Tranche 1 (“Base Price”).

Each Tranche under the VCP was tested on the first Measurement Date and was subject to the original terms and conditions  
of the VCP, except that as above each Tranche had its own Threshold Price.

At subsequent Measurement Dates (i.e. one and two years after the first Measurement Date), it was determined that the 
methodology for determining the Threshold Price for each Tranche will be the same whereby the Threshold Price for each 
Tranche will be the higher of:

 ■ The highest return achieved at any previous Measurement Date (treated as separate Tranches); or

 ■ 8% p.a. TSR from the Base Price for Tranche 1 or the capital raising price/price on the day of issue  

for Tranches 2, 3 and 4 (and others if further capital raising events occur).

Assura plc Annual Report 2016  79

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Each Tranche has its own minimum return threshold which must be achieved before any awards earned and deferred at previous 
Measurement Dates vest at the second or third Measurement Dates. This means that awards rolled over (i.e. accrued but not 
vested) from previous Measurement Dates must sustain an 8% p.a. TSR from the Base Price for Tranche 1 or the capital raising 
price/price on the day of issue for Tranches 2, 3 and 4.

It was the Committee’s view that these adjustments:

 ■ Were in the best interests of our shareholders on the basis that they ensured that shareholders were protected from any 

immediate value transfer as a result of the capital raising events

 ■ Would provide participants with the opportunity to share in any value created for shareholders on the new capital, in line with 
the rules of the VCP, provided the minimum level of return on all new shares (i.e. the 8% p.a. return threshold) is achieved.

The maximum aggregate number of shares that can be issued to satisfy awards under the VCP to all participants remained 
limited to 25 million. Therefore, no adjustments were made to the cap on the number of shares that could be earned under 
the VCP as a result of the changes to the share capital. 

Vesting at first Measurement Date
As noted above, the first Measurement Date occurred on 20 August 2015. The table below sets out the actual value creation 
under the VCP as calculated at the first Measurement Date, using (as prescribed in the plan rules) the average share price over 
three months following the announcement of the Company’s financial results for the 2014/15 financial year plus dividends paid  
on shares in issue: 

Average share price at first Measurement Date 

Dividends paid per share in issue

Measurement Price

Threshold Price 

Value created 

Tranche 1 
(pence 
per share)

Tranche 2 
(pence 
per share)

Tranche 3 
(pence 
per share)

Tranche 4 
(pence 
per share)

A

B

56.27

5.0625

C=A+B

61.3325

T

39.37

C-T

21.9625

56.27

2.40

58.67

44.95

13.72

56.27

1.95

58.22

45.06

13.16

56.27

1.50

57.77

51.29

6.48

As per the VCP performance condition, the total participant benefit available was 10% of the above value created for each 
Tranche multiplied by the number of shares in each Tranche, which amounts in total to £17.8 million. As a consequence of the 
Company’s strong performance up to the first Measurement Date, the VCP units converted virtually in full into nil-cost options 
over 24,999,950 shares (out of the total 25 million pool). This resulted in Graham Roberts’ units converting into 11,779,255 
nil-cost options, and Jonathan Murphy’s into 5,153,423 options.

Under the rules, 50% of any shares that accrued at the first Measurement Date (in the form of nil-cost options) became exercisable 
at the first Measurement Date, 50% of the remainder become exercisable at the second and 100% of accrued nil-cost options at 
the third Measurement Date provided the minimum return thresholds for each Tranche are achieved at each Measurement Date. 
On 25 September 2015 Messrs Roberts and Murphy exercised the first 50% of their nil-cost options resulting in them receiving 
(after the payment of income tax and NICs) 3,121,503 and 1,365,657 shares respectively.

80  Assura plc Annual Report 2016

www.assuraplc.comThe impact of the conversion of Messrs Roberts’ and Murphy’s units into nil-cost options and the above exercises is set out in the 
table below: 

Name

Graham Roberts

Graham Roberts

Graham Roberts

Jonathan Murphy

Jonathan Murphy

Jonathan Murphy

Year of  
grant

Awards 
outstanding 
at 31/3/15

Granted 
during the 
year

Lapsed 
during the 
year

Exercised 
during the 
year

Awards 
outstanding 
at 31/3/16

Exercise 
price

Exercisable 
between

2015

2015

2015

2015

2015

2015

–

–

–

–

–

–

5,889,628

2,944,814

2,944,813

2,576,712

1,288,356

1,288,355

–

–

–

–

–

–

5,889,628

–

Nil-cost

Aug ’15–23

–

–

2,944,814

Nil-cost

Aug ’16–23

2,944,813

Nil-cost

Aug ’17–23

2,576,712

–

Nil-cost

Aug ’15–23

–

–

1,288,356

Nil-cost

Aug ’16–23

1,288,355

Nil-cost

Aug ’17–23

Jonathan Murphy’s ERP
As previously reported, awards were made under the ERP to Jonathan Murphy in 2013 to facilitate his recruitment. The awards 
have no performance criteria and vest in three equal instalments on the first, second and third anniversary of their award. The final 
instalment vested in January 2016:

Award

ERP awards

Performance measures

Number of nil-cost 
options vested

Value of vested awards £’0001

None

153,334

83.5

Note
1.  The value of nil-cost options is calculated using the closing middle market share price on 29 January 2016 of 54.5 pence per share, the date the final 

instalment of awards became exercisable. 

Single total figure of remuneration – Non-Executives (audited)
The remuneration of Non-Executive Directors showing the breakdown between components, with comparative figures for the 
prior year, is shown below. Figures provided have been calculated in accordance with the Regulations: 

Non-Executive Director (£’000)

Simon Laffin

David Richardson

Jenefer Greenwood

Basic fees

Additional 
fees1

Total fees

2015/16

2014/15

2015/16

2014/15

2015/16

2014/15

128.5 

126.0

36.1

35.5

36.1

36.0

–

–

16.4

16.0

8.2

8.0

128.5

126.0

52.5

51.5

44.3

44.0

Note
1.  Additional fees represent Senior Independent Director and Chairman of Board Committee fees.

Assura plc Annual Report 2016  81

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Statement of Directors’ shareholding and share interests (audited)
Directors’ share interests and, where applicable, achievement of shareholding requirements are set out below. In order that  
their interests are aligned with those of shareholders, Executive Directors are expected to build up and maintain a personal 
shareholding equal to 100% of their basic salary in the Company. It is proposed that this threshold be increased to 300% in  
the revised Remuneration Policy to be presented at this year’s AGM. 

Shareholding and other interests at 31 March 2016

Director

Executive

Graham Roberts

Jonathan Murphy

Non-Executive

Simon Laffin

David Richardson

Jenefer Greenwood

Shares 
required 
to be held
(percentage 
of salary)

Number of 
shares
 required to
 hold1

Number of
 beneficially 
owned 
shares2

Total 
interests
 held at 
31 March
 2016

Shareholding
 requirement
 met?

100

100

–

–

–

605,461

4,000,000

4,000,000

404,896

957,517

957,517

–

–

–

3,338,578

3,338,578

414,835

117,256

414,835

117,256

Yes

Yes

n/a

n/a

n/a

Notes
1.  Shareholding requirement calculation is based on the share price at the end of the year (53.1 pence at 31 March 2016). 
2.  Beneficial interests include shares held directly or indirectly by connected persons.

The Company funds its share incentives through a combination of new issue and market purchased shares. The Company 
monitors the levels of share grants and the impact of these on the ongoing requirement for shares. In accordance with guidelines 
set out by the Investment Association the Company can issue a maximum of 10% of its issued share capital in a rolling 10-year 
period to employees under all its share plans, with an inner 5% limit applying to discretionary plans.

Other than the Executive Chairman Simon Laffin, who was allocated 33,803 Ordinary Shares via the scrip dividend alternative, 
there has been no movement in Directors’ shareholdings since the year end.

Performance graph and table
The Committee believes that the Executive Directors’ Remuneration Policy and the supporting reward structure provide clear 
alignment with the Company’s performance. The Committee believes it is appropriate to monitor the Company’s performance 
against the FTSE All Share Real Estate Investment Trusts index for these purposes. 

The graph below sets out the TSR performance of the Company compared to the FTSE Real Estate Investment Trusts index and 
for comparison, the FTSE All Share index over a seven-year period as required by the Regulations:

350

300

250

200

150

100

50

0

March
2009 

March
2010

March
2011

March
2012

March
2013

March
2014

March
2015

March
2016

 ■ Assura  ■ FTSE Real Estate Investment Trusts  ■ FTSE All Share

82  Assura plc Annual Report 2016

www.assuraplc.comThe table below shows the Chief Executives’ remuneration packages over the past seven years:

Year

2015/16

2014/15

2013/14

2012/13

2011/12

2010/11

2009/10

2009/10

Name

Graham Roberts

Graham Roberts

Graham Roberts

Graham Roberts

Nigel Rawlings2

Nigel Rawlings

Nigel Rawlings (from 16/03/10)

Richard Burrell3, 4 (until 15/03/10)

Single figure 
of total 
remuneration 
 (£’000)1

Bonus
pay-out
(as percentage
maximum
opportunity)

3,747

677 

680

674

395

314

11

487

71

90 

95

100

85

75

–

–

Long-term
incentive
vesting rates
(as percentage
maximum
opportunity)

100

–

–

–

–

–

–

–

Notes
1.  Includes base salary, taxable benefits, bonus payments for the relevant financial year, long-term incentive awards that vested for performance related to 

the financial year and cash in lieu of pension.

2.  Nigel Rawlings ceased to be a Director with effect from 30 April 2012. The bonus of £100,000 was a one-off award reflecting his contribution to selling 

the Pharmacy business.

3. Richard Burrell ceased to be a Director on 15 March 2010.
4.  During the financial year 2009/10 Richard Burrell was Chief Executive from 1 April 2009 until 15 March 2010 when Nigel Rawlings assumed the position. 

The amounts above are therefore reflective of the relative lengths of service.

Percentage change in the Chief Executive’s remuneration
The table below compares the percentage increase in the Chief Executive’s pay (including salary and fees, taxable benefits and 
annual bonus) with the wider employee population. The Company considers the 34 full-time employee population, excluding the 
Executive Board, to be an appropriate comparator group:

Chief Executive

Total employee pay

Average employee pay

Salary % 
increase 

Taxable 
benefits %  
increase

Bonus % 
increase/
(decrease)

1.5

2.6

4.1

26.7

20.9

51.0

(24.6)

(11.6)

(27.9)

Relative importance of spend on pay
The table below sets out the overall spend on pay for all employees compared with the returns distributed to shareholders: 

Significant distributions

Overall spend on pay for employees including Executive Directors

Distributions to shareholders by way of dividends 

2014/15 
(£m)

2015/16 
(£m)

3.0 

14.4 

3.3

27.2

% 
change

10.0 

88.9

Assura plc Annual Report 2016  83

Strategic reportFinancial statements Governance www.assuraplc.comRemuneration Report continued

Payments to past Directors or for loss of office
During the year there were no payments to past Directors, and no payments for loss of office. 

Statement of shareholder voting
The table below shows the advisory vote on the 2014/15 Directors’ Remuneration Report at the AGM held on 21 July 2015.

2015 AGM resolution

Votes for

% Votes against

%

Votes 
withheld

Annual Report on Remuneration

746,691,664

99.45

4,131,501

0.55

5,409,352

Statement of implementation of Remuneration Policy for 2016/17
Executive Directors
Salary
In setting salary levels for 2016/17 for the Executive Directors, the Committee considered a number of factors, including individual 
performance and experience, pay and conditions for employees across the Group, the general performance of the Company, pay 
levels in other comparable companies and the economic environment. The salaries for 2016/17 and the relative increases are set 
out below:

Executive Director

Graham Roberts

Jonathan Murphy

2015/16 
 salary
 (£’000)

322

215

2016/17
salary
 (£’000)

326

235

% change

1.5

9.3 

As noted above, for 2016/17 Graham Roberts’ salary will be increased by 1.5% to £326,400, with Jonathan Murphy’s salary 
increased by 9.3% to £235,000. Jonathan’s higher increase reflects the fact that, despite increases made over recent years, his 
salary remained significantly below the average commanded by similar post-holders. The Committee is entirely comfortable that 
this increase is appropriate, given Jonathan’s continued strong performance, together with the fact that even his new salary 
remains in line only with lower quartile comparators, and is, therefore, consistent with the existing policy.

Pension and benefits
As was the case last year, Graham Roberts and Jonathan Murphy will receive payments in lieu of pension contributions equivalent 
to 20% and 13.5% of salary respectively. Benefits will be provided in line with the Remuneration Policy.

Annual bonus
The maximum bonus opportunity for 2016/17 will be 100% of salary for Graham Roberts and (if the new Policy is approved by 
shareholders) 75% for Jonathan Murphy.

The performance objectives under the annual bonus plan for 2016/17 relate to value-added opportunities, within the portfolio and 
from market activity, financial targets and customer satisfaction. The Committee is of the opinion that the precise performance 
targets for the bonus plan are commercially sensitive and that it would be detrimental to the interests of the Company to disclose 
them before the start of the financial year. Appropriate levels of disclosure of the actual targets, performance achieved and 
awards made will be published at the end of the performance period so shareholders can fully assess the basis for any pay-outs. 
The Committee will also follow the same practice of previous years and view the weightings for bonus purposes at the end of the 
year, having regard to all known factors. Noting best/market practice, a deferred share element will be introduced into the annual 
bonus plan going forward, under which up to 50% of any bonus earned by an Executive Director will be deferred into shares for 
two years to the extent that the Executive Director does not already hold shares worth at least 300% of salary.

84  Assura plc Annual Report 2016

www.assuraplc.comLong-term incentives
Subject to formal shareholder approval being obtained for the new PSP at the forthcoming AGM, the Committee intends to 
make the first grant of awards under this new plan following the AGM. It is currently intended that both Graham Roberts and 
Jonathan Murphy will be granted awards over shares worth 150% of salary which will vest subject to the extent to which the 
following performance conditions are satisfied:

Absolute TSR growth: 50% of award
Absolute average annual compound TSR growth over 
performance period 

Percentage of this portion of award that vests

Below 5%

5%

15%

0%

0%

100%

NAV per share growth (including the value of dividends paid): 50% of award
Absolute average annual compound NAV per share  
growth over performance period 

Percentage of this portion of award that vests

Below 5%

5%

15%

0%

0%

100%

Straight-line vesting would occur between each target.

Non-Executive Directors
The following table sets out the fee rates for the non-Executive Directors from 1 April 2016:

Chairman fee

Non-Executive Director base fee

Additional fee for Chairmanship of Audit and Remuneration Committee

Additional fee for Senior Independent Director

By order of the Board

JENEFER GREENWOOD 
CHAIRMAN OF THE REMUNERATION COMMITTEE
17 May 2016

2015/16 
£’000

2016/17 
£’000

% change

128.5

36.2

8.2

8.2

130.5

36.9

8.3

8.3

1.6

1.9

1.2

1.2

Assura plc Annual Report 2016  85

Strategic reportFinancial statements Governance www.assuraplc.comDirectors’ Report

Financial and business reporting
The Directors present their Annual 
Report and Accounts on the affairs of 
the Group, together with the financial 
statements and auditor’s report, for the 
year ended 31 March 2016. The Corporate 
Governance Statement set out on page 
52 forms part of this report.

The Group has facilities from a number 
of financial institutions, none of which 
are repayable before May 2021 other 
than modest annual amortisation. In 
addition to surplus available cash of  
£43.7 million at 31 March 2016 (2015: 
£65.3 million), the Group has undrawn 
facilities of £75 million at the date of 
this report.

Internal controls and 
risk management
The Board accepts and acknowledges 
that it is both accountable and responsible 
for ensuring that the Group has in place 
appropriate and effective risk management 
and internal control systems including 
financial, operational and compliance 
control systems.

The Directors’ Report and the other 
sections of this Annual Report contain 
forward-looking statements. The extent 
to which the Company’s shareholders or 
anyone may rely on these forward-
looking statements is set out in the 
Glossary on page 124.

Principal activities
Assura plc is a leading primary care 
property investor and developer. It owns 
and procures good quality primary care 
properties across the UK.

The subsidiary and associated 
undertakings are listed in Note 9 
to the accounts.

Business review
The Group is required to include a 
business review in this report. The 
information that fulfils the requirements 
of the business review can be found on 
pages 38 to 43, which are incorporated 
in this report by reference. 

Going concern 
Assura’s business activities together 
with factors likely to affect its future 
performance are set out in the business 
review on pages 38 to 43. In addition, 
Note 23 to the accounts includes 
the Group’s objectives, policies and 
processes for managing its capital, its 
financial risk management objectives, 
details of its financial instruments and its 
exposure to credit risk and liquidity risk.

The Group’s primary care property 
developments in progress are all 
substantially pre-let.

The Board monitors these systems on 
an ongoing basis and this year’s review 
found them to be operating effectively. 

The Group has adequate headroom in its 
banking covenants. The Group has been 
in compliance with all financial covenants 
on its loans throughout the year.

The Group’s properties are substantially 
let with rent paid or reimbursed by the 
NHS and they benefit from a weighted 
average lease length of 14.0 years. They 
are diverse both geographically and 
by lot size and therefore represent 
excellent security.

The Group’s financial forecasts show 
that borrowing facilities are adequate 
and the business can operate within 
these facilities and meet its obligations 
when they fall due for the foreseeable 
future. The Directors believe that the 
business is well placed to manage its 
current and reasonably possible future 
risks successfully.

Accordingly, the Board considers it 
appropriate that the financial statements 
have been prepared on a going concern 
basis of accounting and there are no 
material uncertainties to the Company’s 
ability to continue to prepare them on this 
basis over a period of at least 12 months.

Long-term viability statement 
The Company’s viability statement is on 
page 32.

Dividends
Details of the dividend can be found 
in Note 19 to the accounts. The Group 
benefits from brought forward tax losses 
which results in all dividends paid during 
the year being paid as ordinary dividends 
with an associated tax credit.

Supplier payment policy
The Group has not signed up to any 
specific supplier payment code; it is 
Assura’s policy to comply with the terms 
of payment agreed with its suppliers. 
Where specific payment terms are not 
agreed, the Group endeavours to adhere 
to the suppliers’ standard payment 
terms. As at 31 March 2016, the average 
number of days taken by the Group to 
pay its suppliers was 22 days (2015: 
23 days). 

Post balance sheet events
On 17 May 2016 the Group signed a new 
£200 million revolving credit facility with 
a club of four banks. This replaced an 
existing £120 million facility. 

Directors’ liability insurance
The Company has arranged insurance 
cover in respect of legal action against 
its Directors.

86  Assura plc Annual Report 2016

www.assuraplc.comCompany share scheme
The Assura plc Employee Benefit Trust 
holds 1,256,714 (0.1%) of the issued share 
capital of the Company in trust for the 
benefit of employees of the Group and 
their dependants. The voting rights in 
relation to these shares are exercised by 
the Trustees who will take into account 
any recommendation made to them by 
the Board of Assura plc.

Donations
In the year to 31 March 2016 Assura 
donated £29,520 to charities (2015: 
£26,962), all of which were UK registered 
charities, and no contributions were 
made for political purposes (2015: nil). 
More details of our chosen charities can 
be found on pages 46 and 47.

Employees
Employees are encouraged to maximise 
their individual contribution to the Group. 
In addition to competitive remuneration 
packages, they participate in an annual 
bonus scheme which links personal 
contribution to the goals of the business. 
Outperformance against the annual 
targets can result in a bonus award 
proportionate to the individual’s 
contribution. Employees are provided 

Gender ratios 
Board

1 4

Senior management team

2 5

Employee workforce

regularly with information regarding 
progress against the budget, financial 
and economic factors affecting the 
business’s performance and other 
matters of concern to them. In addition, 
all staff are eligible to participate in a 
defined contribution pension scheme. 
The views of employees are taken into 
account when making decisions that 
might affect their interests. Assura 
encourages openness and transparency, 
with staff having regular access to the 
Directors and being given the opportunity 
to express views and opinions.

The Group is committed to the promotion 
of equal opportunities, supported by its 
Equal Opportunity and Valuing Diversity 
Policy. The policy reflects both current 
legislation and best practice. It highlights 
the Group’s obligations to race, gender 
and disability equality. Full and fair 
consideration is given to applications for 
employment from disabled persons and 
appropriate training and career 
development are provided. 

Share capital
The issued share capital of the Company 
is 1,637,706,738 Ordinary Shares of 
10 pence each. 

18 17

as at 17 May 2016

Interests in voting rights
As at 1 May 2016 the Company had been notified of the following interests representing 3% or more of its issued Ordinary 
Share Capital:

Name of shareholder

Invesco Limited

Artemis Investment Management

Aberdeen Asset Management

BlackRock (BGI)

Cohen & Steers Capital Management

Investec Wealth & Investment

Legal & General

Troy Asset Management

31 March 2016 

1 May 2016

Number
of shares 

Percentage 
of Ordinary
Shares

Number
of shares

Percentage 
of Ordinary
Shares

352,848,325

21.55 352,848,325

187,028,735

11.42 174,519,607

64,856,216

81,967,814

57,804,597

64,293,423

56,259,018

55,602,002

3.96

82,606,987

5.01

79,427,446

3.53

64,117,695

3.93

62,624,873

3.44

56,655,043

3.40

55,602,002

21.52

10.64

5.04

4.84

3.91

3.82

3.45

3.39

Assura plc Annual Report 2016  87

Strategic reportFinancial statements Governance www.assuraplc.comDirectors’ Report continued

The technical non-compliance with 
the Companies Act 2006 could, in theory, 
result in a right for the Company to claim 
repayment of the Dividend from certain 
shareholders and/or the Directors who 
approved the payments. Clearly it is not 
the intention of the Company that any 
such claims should be made by the 
Company against either its shareholders 
or its Directors. In order to put the 
shareholders and the Directors into 
the position in which they were always 
intended to be, the Company proposes 
to release and waive any such claims. 
Resolutions will be put to shareholders 
at the AGM to approve such release and 
waiver and to protect the shareholders 
and Directors against any future claims. 

Annual General Meeting
The AGM of the Company will be held 
at the offices of Addleshaw Goddard, 
60 Chiswell Street, London EC1Y 4AG 
on 19 July 2016 at 11am.

Both the Directors’ Report and the 
Strategic Report were approved by 
the Board and signed on its behalf.

ORLA BALL 
COMPANY SECRETARY
17 May 2016

Price risk, credit risk, liquidity 
risk and cash flow risk
Full details of how these risks are 
mitigated can be found in Note 23 
to the accounts.

Future developments
Details of future developments are 
discussed on pages 38 to 41 in the 
business review.

Greenhouse gas emissions
The greenhouse gas emissions from 
operating activities and property 
occupied by the Company represented 
74.5mt CO2e (2015: 71.7mt CO2e). These 
reported levels exclude investment 
properties where we are not the occupier.

Competition and Markets 
Authority (CMA) Order
The Company confirms that it has 
complied with the Statutory Audit Services 
for Large Companies Market Investigation 
(Mandatory Use of Competitive Tender 
Processes and Audit Committee 
Responsibilities) Order 2014 published 
by the CMA on 26 September 2014.

Auditor
Each of the persons who is a Director at 
the date of approval of this Annual Report 
confirms that:

 ■ So far as the Director is aware, there is 
no relevant audit information of which 
the Company’s auditor is unaware; and

 ■ The Director has taken all the steps 
that he/she ought to have taken as 
a Director in order to make himself/
herself aware of any relevant audit 
information and to establish that 
the Company’s auditor is aware 
of that information.

This confirmation is given and should 
be interpreted in accordance with 
the provisions of section 418 of the 
Companies Act 2006.

The Directors, on recommendation from 
the Audit Committee, intend to place a 
resolution before the AGM to re-appoint 
Deloitte LLP as auditor for the year 
ending 31 March 2017.

Amendments to the Articles 
of Incorporation
The Articles of Incorporation of the 
Company may be amended by special 
resolution of the Company.

Interim dividend payment
The Board has recently become aware of 
a technical irregularity with regard to the 
payment by the Company of the interim 
dividend to shareholders in April 2016 
(“the Dividend”). 

Distributions made by a company must not 
exceed the distributable profits as reported 
in the last set of “relevant accounts” of 
the company. For the purposes of the 
Companies Act the “relevant accounts” 
are either a company’s last annual audited 
accounts or its last interim accounts. In 
order to rely on interim accounts to pay a 
dividend a company must file those interim 
accounts with the Registrar of Companies. 
When the Company paid the Dividend, 
although it had sufficient distributable 
reserves to make the payment at the 
payment date, interim accounts showing 
the requisite level of distributable profits 
had not been filed with the Registrar of 
Companies and as a result, the Dividend 
was paid in technical infringement of the 
Companies Act 2006. 

88  Assura plc Annual Report 2016

www.assuraplc.com 
Directors’ Responsibility Statement

The Directors are responsible for 
preparing the Annual Report and the 
financial statements in accordance 
with applicable law and regulations.

Company law requires the Directors 
to prepare financial statements for 
each financial year. Under that law the 
Directors are required to prepare the 
Group financial statements in accordance 
with International Financial Reporting 
Standards (“IFRSs”) as adopted by the 
European Union (“EU”) and Article 4 of 
the IAS Regulation and have also chosen 
to prepare the Parent Company financial 
statements under IFRSs as adopted by 
the EU. Under company law the Directors 
must not approve the financial 
statements unless they are satisfied that 
they give a true and fair view of the state 
of affairs of the Company and of the profit 
or loss of the Company for that period.

In preparing these financial statements, 
IAS 1 requires that Directors:

 ■ Properly select and apply accounting 

policies

 ■ Present information, including 

accounting policies, in a manner that 
provides relevant, reliable, comparable 
and understandable information

 ■ Provide additional disclosures when 

compliance with the specific 
requirements in IFRSs are insufficient 
to enable users to understand the 
impact of particular transactions, other 
events and conditions on the entity’s 
financial position and financial 
performance; and

 ■ Make an assessment of the Company’s 
ability to continue as a going concern.

enable them to ensure that the financial 
statements comply with the Companies 
Act 2006. They are also responsible for 
safeguarding the assets of the Company 
and hence for taking reasonable steps for 
the prevention and detection of fraud and 
other irregularities.

The Directors are responsible for the 
maintenance and integrity of the corporate 
and financial information included on 
the Company’s website. Legislation in 
the United Kingdom governing the 
preparation and dissemination of financial 
statements may differ from legislation 
in other jurisdictions.

We confirm that to the best of our 
knowledge:

 ■ The financial statements, prepared 

in accordance with IFRSs as adopted 
by the EU, give a true and fair view of 
the assets, liabilities, financial position 
and profit of the Company and the 
undertakings included in the 
consolidation taken as a whole

 ■ The strategic report includes a fair 
review of the development and 
performance of the business and 
the position of the Company and 
the undertakings included in the 
consolidation taken as a whole, 
together with a description of the 
principal risks and uncertainties 
that they face; and

 ■ The Annual Report and financial 

statements, taken as a whole, are fair, 
balanced and understandable and 
provide the information necessary for 
shareholders to assess the Company’s 
position and performance, business 
model and strategy.

The Directors are responsible for 
keeping adequate accounting records 
that are sufficient to show and explain 
the Company’s transactions and disclose 
with reasonable accuracy at any time the 
financial position of the Company and 

By order of the Board

ORLA BALL
COMPANY SECRETARY
17 May 2016

Assura plc Annual Report 2016  89

Strategic reportFinancial statements Governance www.assuraplc.comIndependent Auditor’s Report

Opinion on financial 
statements of Assura plc

In our opinion the financial statements:

 ■ give a true and fair view of the state of the Group’s and of the Parent Company’s affairs 
as at 31 March 2016 and of the Group’s and the Parent Company’s profit for the year 
then ended;

 ■ have been properly prepared in accordance with International Financial Reporting 

Standards (“IFRSs”) as adopted by the European Union; and

 ■ have been prepared in accordance with the requirements of the Companies Act 2006 and, 

as regards the Group financial statements, Article 4 of the IAS Regulation.

The financial statements comprise the Consolidated and Parent Company Income 
Statements, the Consolidated and Parent Company Statements of Comprehensive Income, 
the Consolidated and Parent Company Balance Sheets, the Consolidated and Parent 
Company Cash Flow Statements, the Consolidated and Parent Company Statements of 
Changes in Equity and the related Notes 1 to 26 and A to F. The financial reporting framework 
that has been applied in their preparation is applicable law and IFRSs as adopted by the 
European Union.

As required by the Listing Rules we have reviewed the Directors’ statement regarding the 
appropriateness of the going concern basis of accounting contained within the Directors’ 
Report and the Directors’ statement on the longer-term viability of the Group contained within 
the strategic report on page 32. 

We have nothing material to add or draw attention to in relation to:

 ■ the Directors’ confirmation on page 30 that they have carried out a robust assessment of 

the principal risks facing the Group, including those that would threaten its business model, 
future performance, solvency or liquidity;

 ■ the disclosures on pages 33 to 37 that describe those risks and explain how they are being 

managed or mitigated;

 ■ the Directors’ statement in the Directors’ Report about whether they considered it 

appropriate to adopt the going concern basis of accounting in preparing them and their 
identification of any material uncertainties to the Group’s ability to continue to do so over 
a period of at least 12 months from the date of approval of the financial statements; and

 ■ the Directors’ explanation on page 32 as to how they have assessed the prospects of 

the Group, over what period they have done so and why they consider that period to be 
appropriate, and their statement as to whether they have a reasonable expectation that the 
Group will be able to continue in operation and meet its liabilities as they fall due over the 
period of their assessment, including any related disclosures drawing attention to any 
necessary qualifications or assumptions.

We agreed with the Directors’ adoption of the going concern basis of accounting and we 
did not identify any such material uncertainties. However, because not all future events or 
conditions can be predicted, this statement is not a guarantee as to the Group’s ability to 
continue as a going concern. 

We are required to comply with the Financial Reporting Council’s Ethical Standards for 
Auditors and we confirm that we are independent of the Group and we have fulfilled our other 
ethical responsibilities in accordance with those standards. We also confirm we have not 
provided any of the prohibited non-audit services referred to in those standards. 

Going concern and the 
Directors’ assessment  
of the principal risks  
that would threaten the  
solvency or liquidity  
of the Group

Independence

Our assessment of risks  
of material misstatement

The assessed risks of material misstatement described below are those that had the greatest 
effect on our audit strategy, the allocation of resources in the audit and directing the efforts 
of the engagement team:

90  Assura plc Annual Report 2016

www.assuraplc.comRisk

How the scope of our audit responded to the risk

Valuation of property 
portfolio 
The Group owns and 
manages a portfolio of 
primary care properties 
(including a number of 
development properties). The 
valuation of the portfolio is 
underpinned by a number of 
judgements and assumptions 
which creates significant 
estimation uncertainty. 

The properties are valued 
at six-monthly intervals 
by professionally qualified 
external valuers using the 
investment method of 
valuation. Development 
properties are valued by 
the same method with a 
deduction of all costs 
necessary to complete the 
development together with 
a developer’s margin.

The closing fair value of the 
portfolio as at 31 March 2016 
is £1,109.4 million (2015: 
£925.3 million). See accounting 
policies in Note 2 and Note 10 
to the financial statements.

Accounting for acquisitions 
During the current year, 
the Group has undertaken 
a number of significant 
acquisitions of companies 
which own one or more 
properties.

We assessed management’s process for reviewing and challenging the work of the external valuers.

We reviewed the external valuation reports to assess whether the approach taken is in 
accordance with the Royal Institution of Chartered Surveyors (“RICS”). 

We performed data analysis, stratifying the properties into sub-categories and identifying a 
range of average yields for each category. We then benchmarked these ranges both internally 
and against relevant external data where available. 

We held calls with the third party valuers, Savills and Jones Lang LaSalle, appointed by 
management for the valuation of the property portfolio and we challenged and evaluated the 
significant judgements and assumptions applied in their valuations including outstanding rent 
reviews and yields. We also challenged and discussed any outliers identified through our analysis.

Further, our in-house property specialists were integrated into the audit of the property 
portfolio in order to provide sector specific knowledge as part of our evaluation and challenge 
of the valuations.

We assessed the competence, independence and integrity of the external valuers, by 
consideration of their professional qualifications and market standing as valuers of primary 
care properties. We verified the integrity of a sample of information provided to valuers by 
management relating to rental income, occupancy and life of the lease.

We assessed the forecast costs to complete and developer’s margin on development 
properties, agreeing any committed amounts to underlying contracts and agreeing a sample 
of costs incurred in the year to supporting documentation.

We challenged the assumption that the acquisitions constitute asset purchases rather than 
business combinations. 

We verified the fair value of consideration paid by reference to acquisition agreements and 
other external evidence. 

We performed procedures to assess the fair value of the assets and liabilities acquired and 
assessed the accounting treatment adopted, with reference to the significant judgements and 
estimates involved (as per Note 2).

We considered the date at which the transactions completed based on the acquisition or 
disposal agreements and considered the impact of these transactions on revenue recognition. 

We considered the adequacy of the disclosure of the transactions in the financial statements.

Assura plc Annual Report 2016  91

Strategic reportFinancial statements Governance www.assuraplc.comIndependent Auditor’s Report continued

The risks included within this audit report are consistent with those reported in the year ended 31 March 2015 audit report.

The description of risks above should be read in conjunction with the significant issues considered by the Audit Committee 
discussed on page 55.

These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion 
thereon, and we do not provide a separate opinion on these matters.

Our application  
of materiality

We define materiality as the magnitude of misstatement in the financial statements that 
makes it probable that the economic decisions of a reasonably knowledgeable person would 
be changed or influenced. We use materiality both in planning the scope of our audit work 
and in evaluating the results of our work.

An overview of the scope 
of our audit

Opinion on other matters 
prescribed by the 
Companies Act 2006

Matters on which we 
are required to report 
by exception

Adequacy of explanations 
received and accounting 
records

We determined materiality for the Group to be £1.5 million (2015: £1.5 million). In determining 
the materiality of the Group, we have considered a number of factors including net assets, 
underlying profit and profit before tax being the critical performance measures of the Group. 
The figure represents 5% of pre-tax profit and less than 0.5% of equity. We agreed with the 
Audit Committee that we would report to the Committee all audit differences in excess of 
£30,000 (2015: £30,000), as well as differences below that threshold that, in our view, 
warranted reporting on qualitative grounds. We also report to the Audit Committee on 
disclosure matters that we identified when assessing the overall presentation of the 
financial statements.

Our Group audit was scoped by obtaining an understanding of the Group and its 
environment, including Group-wide controls, and assessing the risks of material misstatement 
at the Group level. The Group is audited in its entirety by Deloitte LLP in Manchester. Our 
audit work on the individual subsidiary entities was executed at levels of materiality applicable 
to each individual entity which were lower than Group materiality.

At the parent entity level we also tested the consolidation process.

In our opinion:

 ■ the part of the Directors’ Remuneration Report to be audited has been properly prepared in 

accordance with the Companies Act 2006; and

 ■ the information given in the Strategic Report and the Directors’ Report for the financial year 
for which the financial statements are prepared is consistent with the financial statements.

Under the Companies Act 2006 we are required to report to you if, in our opinion:

 ■ we have not received all the information and explanations we require for our audit; or

 ■ adequate accounting records have not been kept by the Parent Company, or returns 
adequate for our audit have not been received from branches not visited by us; or

 ■ the Parent Company financial statements are not in agreement with the accounting records 

and returns. 

We have nothing to report in respect of these matters.

Directors’ remuneration

Under the Companies Act 2006 we are also required to report if, in our opinion, certain 
disclosures of Directors’ remuneration have not been made or the part of the Directors’ 
Remuneration Report to be audited is not in agreement with the accounting records and 
returns. We have nothing to report arising from these matters.

92  Assura plc Annual Report 2016

www.assuraplc.comCorporate Governance 
Statement

Under the Listing Rules we are also required to review part of the Corporate Governance 
Statement relating to the Company’s compliance with certain provisions of the UK Corporate 
Governance Code. We have nothing to report arising from our review.

Our duty to read  
other information  
in the Annual Report

Under International Standards on Auditing (UK and Ireland), we are required to report to you if, 
in our opinion, information in the Annual Report is:

Respective responsibilities 
of Directors and auditor

Scope of the audit of the 
financial statements

 ■ materially inconsistent with the information in the audited financial statements; or

 ■ apparently materially incorrect based on, or materially inconsistent with, our knowledge 

of the Group acquired in the course of performing our audit; or

 ■ otherwise misleading.

In particular, we are required to consider whether we have identified any inconsistencies 
between our knowledge acquired during the audit and the Directors’ statement that they 
consider the Annual Report is fair, balanced and understandable and whether the Annual 
Report appropriately discloses those matters that we communicated to the Audit Committee 
which we consider should have been disclosed. We confirm that we have not identified any 
such inconsistencies or misleading statements.

As explained more fully in the Directors’ Responsibility Statement, the Directors are 
responsible for the preparation of the financial statements and for being satisfied that they 
give a true and fair view. Our responsibility is to audit and express an opinion on the financial 
statements in accordance with applicable law and International Standards on Auditing (UK 
and Ireland). We also comply with International Standard on Quality Control 1 (UK and 
Ireland). Our audit methodology and tools aim to ensure that our quality control procedures 
are effective, understood and applied. Our quality controls and systems include our dedicated 
professional standards review team and independent partner reviews.

This report is made solely to the Company’s members, as a body, in accordance with 
Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so 
that we might state to the Company’s members those matters we are required to state to 
them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, 
we do not accept or assume responsibility to anyone other than the Company and the 
Company’s members as a body, for our audit work, for this report, or for the opinions we 
have formed.

An audit involves obtaining evidence about the amounts and disclosures in the financial 
statements sufficient to give reasonable assurance that the financial statements are free 
from material misstatement, whether caused by fraud or error. This includes an assessment 
of: whether the accounting policies are appropriate to the Group’s and the Parent Company’s 
circumstances and have been consistently applied and adequately disclosed; the 
reasonableness of significant accounting estimates made by the Directors; and the overall 
presentation of the financial statements. In addition, we read all the financial and non-financial 
information in the Annual Report to identify material inconsistencies with the audited financial 
statements and to identify any information that is apparently materially incorrect based on, or 
materially inconsistent with, the knowledge acquired by us in the course of performing the 
audit. If we become aware of any apparent material misstatements or inconsistencies we 
consider the implications for our report.

RACHEL ARGYLE (SENIOR STATUTORY AUDITOR)
for and behalf of Deloitte LLP
Chartered Accountants and Statutory Auditor
Manchester, UK
17 May 2016

Assura plc Annual Report 2016  93

Strategic reportFinancial statements Governance www.assuraplc.comConsolidated income statement
Consolidated income statement 
For the year ended 31 March 2016
For the year ended 31 March 2016 

Underlying 
£m 

Note 

2016 
Capital 
and other 
£m 

Total 
£m 

Underlying 
£m 

2015 
Capital  
and other 
£m 

Continuing operations 
Gross rental and related income 
Property operating expenses 
Net rental income 

Administrative expenses 
Revaluation gains 
Gain/(loss) on sale of property 
Share-based payment charge 
Finance revenue 
Finance costs 
Early repayment costs 
Gain on derivative financial instruments 
Profit before taxation 
Taxation 
Profit for the year attributable to 
equity holders of the parent 

Earnings per share 
from underlying profit  
on profit for year  

– basic  
– basic  
– diluted 

3 

4 
10 

20 
3 
5 
17 
5 

6 

7 
7 
7 

61.0 
(2.6) 
58.4 

(6.1) 
– 
– 
– 
0.2 
(24.2) 
– 
– 
28.3 

– 
– 
– 

– 
36.4 
0.1 
(1.9) 
– 
– 
(34.1) 
– 
0.5 

61.0 
(2.6) 
58.4 

(6.1) 
36.4 
0.1 
(1.9) 
0.2 
(24.2) 
(34.1) 
– 
28.8 
(0.9) 

27.9 

51.1 
(2.9) 
48.2 

(5.7) 
– 
– 
– 
0.4 
(27.0) 
– 
– 
15.9 

– 
– 
– 

– 
21.4 
(0.1) 
(0.7) 
– 
– 
– 
0.1 
20.7 

2.2p 

2.1p 

2.2p 
2.1p 

Total 
£m 

51.1 
(2.9) 
48.2 

(5.7) 
21.4 
(0.1) 
(0.7) 
0.4 
(27.0) 
– 
0.1 
36.6 
0.6 

37.2 

4.9p 
4.7p 

There were no items of other comprehensive income or expense and therefore the profit for the year also reflects the Group’s total 
comprehensive income. 

94 Assura plc Annual Report 2016  
94  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consolidated balance sheet
Consolidated balance sheet 
As at 31 March 2016
As at 31 March 2016 

Non-current assets 
Investment property 
Investments  
Property, plant and equipment 
Deferred tax asset 

Current assets 

Cash, cash equivalents and restricted cash 
Trade and other receivables 
Property assets held for sale  

Total assets 

Current liabilities 

Trade and other payables 
Borrowings 
Deferred revenue 
Provisions 

Non-current liabilities 

Borrowings 
Obligations due under finance leases 
Deferred revenue 
Provisions 

Total liabilities 
Net assets 

Capital and reserves 

Share capital 
Own shares held 
Share premium 
Merger reserve 
Reserves 
Total equity 

Net asset value per Ordinary Share  – basic 

 – diluted 

Adjusted (EPRA) net asset value per Ordinary Share – basic 

– diluted 

Note 

10 
9 
11 
22 

12 
13 
10 

14 
17 
15 
16 

17 
14 
15 
16 

18 
18 

8 
8 
8 
8 

2016 
£m 

1,109.4 
0.4 
0.2 
0.4 
1,110.4 

44.3 
7.5 
1.7 
53.5 
1,163.9 

16.5 
4.0 
14.2 
0.3 
35.0 

365.2 
3.0 
6.4 
– 
374.6 
409.6 
754.3 

163.8 
(0.6) 
241.9 
231.2 
118.0 
754.3 

46.1p 
45.7p 
46.1p 
45.8p 

2015 
£m 

925.3 
0.4 
0.1 
1.3 
927.1 

66.5 
8.3 
5.4 
80.2 
1,007.3 

18.9 
8.0 
12.7 
0.1 
39.7 

505.5 
3.0 
6.9 
0.3 
515.7 
555.4 
451.9 

100.7 
(1.8) 
– 
231.2 
121.8 
451.9 

44.9p 
44.0p 
44.9p 
44.0p 

The financial statements were approved at a meeting of the Board of Directors held on 17 May 2016 and signed on its behalf by: 

SIMON LAFFIN 
EXECUTIVE CHAIRMAN 

JONATHAN MURPHY
FINANCE DIRECTOR 

www.assuraplc.com

Assura plc Annual Report 2016  95 
Assura plc Annual Report 2016  95

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consolidated statement of changes in equity
Consolidated statement of changes in equity 
For the year ended 31 March 2016
For the year ended 31 March 2016 

1 April 2014 
Profit attributable to equity holders 
Total comprehensive income 
Issue of Ordinary Shares  
Issue costs 
Scheme of arrangement  
Dividends  
Own shares held 
Employee share-based incentives 
31 March 2015 

Profit attributable to equity holders 
Total comprehensive income 
Issue of Ordinary Shares  
Issue costs 
Dividends  
Employee share-based incentives 
31 March 2016 

Note 

18 

18 
19 

18 

19 

Share 
capital 
£m 
53.0 
– 
– 
47.7 
– 
– 
– 
– 
– 
100.7 

– 
– 
62.5 
– 
0.2 
0.4 
163.8 

Own  
shares  
held 
£m 
(1.9) 
– 
– 
– 
– 
– 
– 
0.1 
– 
(1.8) 

Share 
premium 
£m 
77.1 
– 
– 
160.8 
(6.7) 
(231.2) 
– 
– 
– 
– 

– 
– 
(0.3) 
– 
– 
1.5 
(0.6) 

– 
– 
250.7 
(9.5) 
0.7 
– 
241.9 

Merger 
reserve 
£m 
– 
– 
– 
– 
– 
231.2 
– 
– 
– 
231.2 

– 
– 
– 
– 
– 
– 
231.2 

Reserves 
£m 
98.4 
37.2 
37.2 
– 
– 
– 
(14.4) 
(0.1) 
0.7 
121.8 

27.9 
27.9 
– 
– 
(27.2) 
(4.5) 
118.0 

Total 
equity 
£m 
226.6 
37.2 
37.2 
208.5 
(6.7) 
– 
(14.4) 
– 
0.7 
451.9 

27.9 
27.9 
312.9 
(9.5) 
(26.3) 
(2.6) 
754.3 

96 Assura plc Annual Report 2016  
96  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consolidated cash flow statement
Consolidated cash flow statement 
For the year ended 31 March 2016
For the year ended 31 March 2016 

Operating activities 
Rent received 
Interest paid and similar charges 
Fees received 
Interest received 
Cash paid to suppliers and employees 
Net cash inflow from operating activities 

Investing activities 
Purchase of investment property 
Development expenditure 
Proceeds from sale of property 
Expenditure on property, plant and equipment 
Net loans received from associated companies 
Net cash outflow from investing activities 

Financing activities 
Issue of Ordinary Shares 
Issue costs paid on issuance of Ordinary Shares 
Dividends paid 
Repayment of loans 
Long-term loans drawdown 
Early repayment costs 
Cash settlement of loan fair value adjustments 
Swap cash settlement 
Loan issue costs 
Net cash inflow from financing activities 

(Decrease)/increase in cash and cash equivalents 

Opening cash and cash equivalents 
Closing cash and cash equivalents 

Note 

21 

19 
17 
17 
17 

12 

2016 
£m 

62.7 
(25.9) 
0.8 
0.2 
(14.9) 
22.9 

(122.5) 
(17.7) 
1.5 
(0.2) 
– 
(138.9) 

308.6 
(9.5) 
(26.3) 
(188.5) 
45.0 
(34.1) 
– 
– 
(1.4) 
93.8 

(22.2) 

66.5 
44.3 

2015 
£m 

50.8 
(26.9) 
1.0 
0.4 
(8.4) 
16.9 

(64.3) 
(14.0) 
4.2 
– 
0.1 
(74.0) 

180.2 
(6.7) 
(14.4) 
(64.1) 
– 
– 
(7.8) 
(1.7) 
(0.5) 
85.0 

27.9 

38.6 
66.5 

www.assuraplc.com

Assura plc Annual Report 2016  97 
Assura plc Annual Report 2016  97

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts
Notes to the accounts 
For the year ended 31 March 2016
For the year ended 31 March 2016 

1. Corporate information and operations 
Assura plc (“Assura”) is incorporated in England and Wales and the Company’s Ordinary Shares are listed on the London 
Stock Exchange. 

As of 1 April 2013, the Group has elected to be treated as a UK REIT. See Note 6 for further details. 

2. Significant accounting policies 
Basis of preparation 
The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments 
and investment properties, including investment properties under construction and land which are included at fair value. The 
financial statements have also been prepared in accordance with IFRSs and interpretations adopted by the European Union 
and in accordance with the Companies Act 2006. 

Standards affecting the financial statements 
The following standards and amendments became effective for the Company in the year ended 31 March 2016. The 
pronouncements either had no material impact on the financial statements or resulted in changes in presentation and 
disclosure only: 

—  Annual improvements 2010 – 2012 cycle 
—  Annual improvements 2011 – 2013 cycle 

Standards in issue not yet effective 
The following standards and amendments are in issue as at the date of the approval of these financial statements, but are not yet 
effective for the Company. The Directors do not expect that the adoption of the standards listed below will have a material impact 
on the financial statements of the Company in future periods but are continuing to assess the potential impact (effective for periods 
beginning on or after the date in brackets): 

– IFRS 9 Financial Instruments (not yet endorsed in the EU) 
– IFRS 15 Revenue from Contracts with Customers (not yet endorsed in the EU) 
– IFRS 16 Leases (not yet endorsed in the EU) 
– Clarification of Acceptable Methods of Depreciation and Amortisation – Amendments to IAS 16 and IAS 38 (1 January 2016)  
– Equity Method in Separate Financial Statements – Amendments to IAS 27 (1 January 2016)  
– Disclosure Initiative – Amendments to IAS 1 (1 January 2016) 
– Annual improvements 2012 – 2014 cycle 

The financial statements are prepared on a going concern basis as explained in the Directors’ Report on page 86 and are presented 
in sterling. 

The accounting policies have been applied consistently to the results, other gains and losses, liabilities and cash flows of entities 
included in the consolidated financial statements. All intragroup balances, transactions, income and expenses are eliminated 
on consolidation. 

Significant judgements and key estimates 
The preparation of the financial statements requires management to make judgements, estimates and assumptions that may affect 
the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. 

Property valuations 
The key source of estimation and uncertainty relates to the valuation of the property portfolio, where a valuation is obtained 
twice a year from professionally qualified external valuers. The evidence to support these valuations is based primarily on recent, 
comparable market transactions on an arm’s length basis. However, the assumptions applied are inherently subjective and so 
are subject to a degree of uncertainty. Property valuations are one of the principal uncertainties of the Group.  

98 Assura plc Annual Report 2016  
98  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
2. Significant accounting policies continued 
Accounting for acquisitions  
A degree of judgement is required in relation to acquisitions to determine whether they should be accounted for as business 
combinations under IFRS 3 or as asset purchases. Consideration is taken of all the facts, including whether business processes 
or employees have been assumed, concerning the transaction in making the appropriate judgement. In addition, the fair value 
of assets and liabilities acquired as part of the transaction must be determined, which is based on external market evidence 
where available. 

Basis of consolidation 
Subsidiaries  
Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtains control, and continue to 
be consolidated until the date that such control ceases. Control comprises the power to govern the financial and operating policies 
of the investee so as to obtain benefit from its activities. 

In the Company financial statements, investments in subsidiaries are held at cost less any provision for impairment. 

Where properties are acquired through the purchase of a corporate entity but the transaction does not meet the definition of a 
business combination under IFRS 3, the purchase is treated as an asset acquisition. Where the acquisition is considered a business 
combination, the excess of the consideration transferred over the fair value of assets and liabilities acquired is held as goodwill, 
initially recognised at cost with subsequent impairment assessments completed at least annually. Where the initial calculation of 
goodwill arising is negative, this is recognised immediately in the income statement. 

Property portfolio 
Properties are externally valued on an open market basis as at the balance sheet date and are recorded at valuation. 

Any surplus or deficit arising on revaluing investment properties and investment property under construction (“IPUC”) is recognised 
in the income statement. 

All costs associated with the purchase and construction of IPUC are capitalised including attributable interest. Interest is calculated 
on the expenditure by reference to specific borrowings where relevant and otherwise on the average rate applicable to short-term 
loans. When IPUC are completed, they are classified as investment properties.  

In determining whether leases and related properties represent operating or finance leases, consideration is given to whether the 
tenant or landlord bears the risks and rewards of ownership. 

Leasehold properties that are leased out to tenants under operating leases are classified as investment properties or development 
properties, as appropriate, and included in the balance sheet at fair value. 

Where an investment property is held under a head lease it is initially recognised as an asset as the sum of the premium paid on 
acquisition and the present value of minimum ground rent payments. The corresponding rent liability to the head leaseholder is 
included in the balance sheet as a finance lease obligation.  

The market value of investment property as estimated by an external valuer is increased for the unamortised pharmacy lease 
premium held at the balance sheet date. 

Net rental income 
Rental income is recognised on an accruals basis and recognised on a straight line basis over the lease term. A rent adjustment 
based on open market estimated rental value is recognised from the rent review date in relation to unsettled rent reviews. Pharmacy 
lease premiums received from tenants are spread over the lease term, even if the receipts are not received on such a basis. 
The lease term is the non-cancellable period of the lease.  

Property operating expenses are expensed as incurred and property operating expenditure not recovered from tenants through 
service charges is charged to the income statement. 

www.assuraplc.com 

Assura plc Annual Report 2016  99 
Assura plc Annual Report 2016  99

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

2. Significant accounting policies continued 
Gains on sale of properties 
Gains on sale of properties are recognised on the completion of contract, and are calculated by reference to the carrying value 
at the end of the previous reporting period, adjusted for subsequent capital expenditure. 

Financial assets and liabilities 
Trade receivables and payables are initially recognised at fair value and subsequently measured at amortised cost and discounted 
as appropriate.  

Other investments are shown at amortised cost and held as loans and receivables. Loans and receivables are measured at 
amortised cost using the effective interest method, less any impairment. Interest income is recognised by applying the effective 
interest rate.  

Debt instruments are stated at their net proceeds on issue. Finance charges including premiums payable on settlement or 
redemption and direct issue costs are spread over the period to redemption at a constant rate on the carrying amount of the liability.  

Financial instruments 
Where the Group uses derivative financial instruments, in the form of interest rate swaps, to hedge its risks associated with interest 
rate fluctuations they are initially recognised at fair value on the date a derivative contract is entered into and are subsequently  
re-measured at their fair value by reference to market values for similar instruments. The resulting gains or losses are recognised 
through the income statement.  

Cash equivalents are limited to instruments with a maturity of less than three months. 

Tax 
Current tax is expected tax payable on any non-REIT taxable income for the period and is calculated using tax rates that have been 
enacted or substantively enacted at the balance sheet date. Taxable profit differs from net profit as reported in the income 
statement because it excludes items of income or expense that are not taxable (or tax deductible). 

Deferred tax is provided on items that may become taxable at a later date, on the difference between the balance sheet value and 
tax base value, on an undiscounted basis.  

Income statement definitions 
Underlying profit represents adjusted earnings, with further Company adjustments to exclude items such as property revaluations, 
exceptional items and share-based payment charges. These adjustments have been made on the basis they are non-recurring or 
non-cash fair value adjustments, which are not reflective of the underlying performance of the business. 

Capital and other represents all other statutory income statement items that are not considered underlying, including 
exceptional items. 

Employee costs 
Defined contribution pension plans 
Obligations for contributions to defined contribution pension plans are charged to the income statement as incurred. 

Share-based employee remuneration 
Share-based employee remuneration is determined with reference to the fair value of the equity instruments at the date at which 
they are granted and charged to the income statement over the vesting period on a straight line basis. The fair value of share 
options is calculated using the Black Scholes option pricing model or the Monte Carlo Model and is dependent on factors including 
the exercise price, expected volatility, option life and risk free interest rate. IFRS 2 Share-based Payments has been applied to share 
options granted. 

Segmental information 
The Group is run as one business and as such no segmental analysis is presented for the current or prior year results. 

100 Assura plc Annual Report 2016  
100  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
3. Revenue 

Rental revenue  
Other related income  
Gross rental and related income 

Finance revenue 
Bank and other interest 

Total revenue 

4. Administrative expenses 

Wages and salaries 
Social security costs 

Auditor’s remuneration 
Directors’ remuneration and fees 
Other administrative expenses 

a) Auditor’s remuneration 

Fees payable to auditor for audit of Company’s annual accounts 
Fees payable to auditor for audit of Company’s subsidiaries  
Total audit fees 
Reporting accountant services 
Tax services – advisory 

2016 
£m 
60.2 
0.8 
61.0 

0.2 
0.2 

2015 
£m 
50.1 
1.0 
51.1 

0.4 
0.4 

61.2 

51.5 

Note 

4(a) 

2016 
£m 
1.9 
0.4 
2.3 
0.2 
1.2 
2.4 
6.1 

2016 
£m 
0.1 
0.1 
0.2 
– 
– 
0.2 

2015 
£m 
1.6 
0.3 
1.9 
0.3 
1.3 
2.2 
5.7 

2015 
£m 
– 
0.1 
0.1 
0.1 
0.1 
0.3 

2015 
£m 

1.7 
0.7 
0.3 
2.7 

The Audit Committee considers the level of non-audit fees prior to work commencing to ensure independence is maintained. 
Detail of considerations during the year is provided on page 56. 

The average monthly number of employees during the year was 33 (2015: 30). 

Key management are the Executive Directors and other key management personnel. 

Key management staff 
Salaries, pension, holiday pay, payments in lieu of notice and bonus 
Cost of employee share-based incentives (including related social security costs) 
Social security costs 

2016 
£m 

1.8 
1.8 
0.3 
3.9 

www.assuraplc.com

Assura plc Annual Report 2016  101 
Assura plc Annual Report 2016  101

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

5. Finance costs 

Interest payable 
Interest capitalised on developments 
Amortisation of loan issue costs 
Amortisation of loan fair value adjustments 

Early repayment costs (Note 17) 
Change in fair value of interest rate swaps 

Interest was capitalised on property developments at 5% (2015: 5%). 

6. Taxation 

Consolidated income tax 
Deferred tax 
Relating to origination and reversal of temporary differences 
Income tax charge/(credit) reported in consolidated income statement 

The differences from the standard rate of tax applied to the profit before tax may be analysed as follows: 

Profit before taxation 
UK income tax at rate of 20% (2015: 21%) 
Effects of: 
Non-taxable income (including REIT exempt income) 
Expenses not deductible for tax purposes 
Movement in unrecognised deferred tax 

2016 
£m 
24.1 
(0.5) 
0.6 
– 
24.2 
34.1 
– 
58.3 

2016 
£m 

0.9 
0.9 

2016 
£m 
28.8 
5.8 

(6.0) 
0.6 
0.5 
0.9 

2015 
£m 
27.1 
(0.4) 
0.6 
(0.3) 
27.0 
– 
(0.1) 
26.9 

2015 
£m 

(0.6) 
(0.6) 

2015 
£m 
36.6 
7.7 

(8.9) 
2.2 
(1.6) 
(0.6) 

The Group elected to be treated as a UK REIT with effect from 1 April 2013. The UK REIT rules exempt the profits of the Group’s 
property rental business from corporation tax. Gains on properties are also exempt from tax, provided they are not held for 
trading or sold in the three years post completion of development. The Group will otherwise be subject to corporation tax at 20% 
(2016: 20%). 

The Group tax charge/(credit) relates to its non-property income. As the Group has sufficient brought forward tax losses, no tax is 
due and so the amount represents the movement in deferred tax. The movement in part relates to brought forward losses that have 
been utilised during the year, with the remainder representing a change in the estimated losses that will be utilised in the future.  

As a REIT, the Group is required to pay Property Income Distributions (“PIDs”) equal to at least 90% of the Group’s rental profit 
calculated by reference to tax rules rather than accounting standards. In the year to 31 March 2016 the taxable rental profit of the 
Group was £nil as a result of capital allowances available, and consequently no PID was required. 

To remain as a UK REIT there are a number of conditions to be met in respect of the principal company of the Group, the Group’s 
qualifying activities and the balance of business. The Group remains compliant at 31 March 2016. 

Further reductions in the main rate of corporation tax have been substantively enacted; the rate will reduce to 19% from 1 April 2017 
and 18% from 1 April 2020. These changes have been reflected in the calculation of deferred tax.  

102 Assura plc Annual Report 2016  
102  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Earnings per Ordinary Share  

Profit for the year  

Early repayment costs 
Revaluation gains 
Revaluation of derivative financial instruments 
(Gain)/loss on sale of property 
Adjusted (EPRA) earnings 

Earnings 
2016 
£m 
27.9 

Earnings 
2015 
£m 
37.2 

Adjusted 
(EPRA) 
earnings 
 2016 
£m 
27.9 

34.1 
(36.4) 
– 
(0.1) 
25.5 

Adjusted 
(EPRA) 
earnings 
2015 
£m 
37.2 

– 
(21.4) 
(0.1) 
0.1 
15.8 

Weighted average number of shares in issue – basic  
Potential dilutive impact of VCP 
Weighted average number of shares in issue – diluted 

1,300,338,908  1,300,338,908 
11,243,261 
1,311,582,169  1,311,582,169 

11,243,261 

763,163,756  763,163,756 
20,723,772 
783,887,528  783,887,528 

20,723,772 

Earnings per Ordinary Share – basic 
Earnings per Ordinary Share – diluted 

2.2p 
2.1p 

2.0p 
2.0p 

4.9p 
4.7p 

2.1p 
2.0p 

Underlying profit per share of 2.2 pence (2015: 2.1 pence) has been calculated as underlying profit for the year as presented 
on the income statement of £28.3 million (2015: £15.9 million) divided by the weighted average number of shares in issue of 
1,300,338,908 (2015: 763,163,756). Based on the diluted weighted average shares, underlying profit per share is 2.2 pence 
(2015: 2.0 pence). 

As set out on pages 79 and 80, the current estimated number of shares over which nil-cost options may be issued to participants 
is 12.5 million (2015: 24.6 million). After allowing for shares held by the Employee Benefit Trust, this would amount to a potential 
issuance of a further 11.2 million (2015: 20.7 million) shares over the course of the next three years.  

www.assuraplc.com

Assura plc Annual Report 2016  103 
Assura plc Annual Report 2016  103

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

8. Net asset value per Ordinary Share 

Net assets 

Own shares held  
Deferred tax 
NAV in accordance with EPRA 

Number of shares in issue 
Potential dilutive impact of VCP (Note 7) 
Diluted number of shares in issue 

NAV per Ordinary Share – basic 
NAV per Ordinary Share – diluted 

EPRA NAV 
Mark to market of fixed rate debt 
EPRA NNNAV 

Net asset 
value 
2016 
£m 
754.3 

Adjusted 
(EPRA)  
net asset 
value 
2016 
£m 
754.3 

0.6 
(0.4) 
754.5 

Net asset 
value 
2015 
£m 
451.9 

Adjusted 
(EPRA) 
 net asset 
value 
2015 
£m 
451.9 

1.8 
(1.3) 
452.4 

1,637,706,738  1,637,706,738 
11,243,261 
1,648,949,999  1,648,949,999 

11,243,261 

1,006,900,141  1,006,900,141 
20,723,772 
1,027,623,913  1,027,623,913 

20,723,772 

46.1p 
45.7p 

46.1p 
45.8p 

44.9p 
44.0p 

44.9p 
44.0p 

Adjusted  
net asset value 
2016 
£m 
754.5 
(60.2) 
694.3 

Adjusted  
net asset value 
2015 
£m 
452.4 
(90.7) 
361.7 

EPRA NNNAV per Ordinary Share 

42.4p 

35.9p 

The EPRA measures set out above are in accordance with the Best Practices Recommendations of the European Property Real 
Estate Association dated December 2014. 

Mark to market adjustments have been provided by the counterparty or by reference to the quoted fair value of financial instruments. 

104 Assura plc Annual Report 2016  
104  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. Investments 
Below is listing of all subsidiaries of Assura plc:  

Property investment companies 
Abbey Healthcare Group Ltd* 
Abbey Healthcare Property Investments Ltd* 
Assura Aspire Ltd* 
Assura Aspire UK Ltd* 
Assura CVSK Ltd* 
Assura HC Ltd* 
Assura HC UK Ltd* 
Assura Health Investments Ltd* 
Assura Medical Centres Ltd* 
Assura PCP UK Ltd* 
Assura Primary Care Properties Ltd* 
Assura Properties plc* 
Assura Properties UK Ltd* 
Assura Trellech Ltd* 
BHE (Heartlands) Ltd* 
BHE (St James) Ltd* 
Malmesbury Medical Enterprise Ltd* 
Medical Properties Ltd* 
Metro MRH Ltd* 
Metro MRI Ltd* 
Metro MRM Ltd* 
Newton Healthcare Ltd* 
Park Medical Services Ltd* 
Pentagon HS Ltd* 
SPCD (Silsden) Ltd* 
Trinity Medical Properties Ltd* 

Holding or dormant companies 
AH Medical Properties Ltd* 
Assura (AHI) Ltd* 
Assura Aylesham Ltd* 
Assura Banbury Ltd* 
Assura CS Ltd* 
Assura Financing Ltd* 
Assura Grimsby Ltd* 
Assura Group Ltd (Guernsey) 
Assura HC Holdings Ltd* 
Assura IH Ltd 
Assura Investments Ltd* 
Assura Kensington Ltd* 
Assura Management Services Ltd* 
Assura Pharmacy Holdings Ltd* (Guernsey) 
Assura Pharminvest Ltd* 
Assura Property Ltd* (Guernsey) 
Assura Property Management Ltd* 
Assura Retail York Ltd* 
Assura Services Ltd* 
Assura Southampton Ltd* 
Assura Stanwell Ltd* 
Assura Todmorden Ltd* 
Assura Tunbridge Wells Ltd* 
MP Realty Holdings Ltd* 
PCI Management Ltd* 
PH Investment (No. 1) Ltd* 
Primary Care Initiatives (Macclesfield) Ltd* 
Riddings Pharmco Ltd* 
South Kirkby Property Ltd* 
SPCD (Balsall Common) Ltd* 
SPCD (Crawcrook) Ltd* 
SPCD (Davyhulme) Ltd* 
SPCD (Didcot) Ltd* 
SPCD (Kincaidston) Ltd* 
SPCD (Rugeley) Ltd* 
SPCD (Sutton in Ashfield) Ltd* 
Trinity Medical Developments Ltd* 

* Indicates subsidiary owned by intermediate subsidiary of Assura plc. 

All companies are wholly owned by the Group and registered in England unless otherwise indicated. Taking into consideration 
the facts of each transaction, acquisitions of companies owning property completed during the years ended 31 March 2016 
and 31 March 2015 have been accounted for as asset purchases as opposed to business combinations.  

The Group also holds the following investments: 

GB Partnerships Investments Limited; 15% equity holding (book value £0.4 million, 2015: £0.4 million). 

Virgin Healthcare Holdings Limited; made up of a 6% equity holding (book value £nil) and a £4 million loan note receivable 
(book value £nil, 2015: £nil). 

www.assuraplc.com 

Assura plc Annual Report 2016  105 
Assura plc Annual Report 2016  105

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

10. Property assets 
Investment property and investment property under construction (“IPUC”) 
Properties are stated at fair value, which has been determined for the Group by Savills Commercial Limited and Jones Lang LaSalle 
as at 31 March 2016. The properties have been valued individually and on the basis of open market value in accordance with RICS 
Valuation – Professional Standards 2014 (“the Red Book”). Valuers are paid on the basis of a fixed fee arrangement, subject to the 
number of properties valued. 

Initial yields mainly range from 4.65% to 5.25% (2015: 5.25% to 5.50%) for prime units, increasing up to 6.15% (March 2015: 
6.15%) for older units with shorter unexpired lease terms. For properties with weaker tenants and poorer units, the yields 
range from 6.15% to over 8.0% (March 2015: 6.25% and over 8.0%) and higher for those very close to lease expiry or those 
approaching obsolescence.  

A 0.25% shift of valuation yield would have approximately a £54.2 million (2015: £42.8 million) impact on the investment 
property valuation. 

Opening fair value  
Additions: 
– acquisitions 
– improvements 

Development costs  
Transfers  
Transfer from assets held for sale  
Capitalised interest 
Disposals 
Unrealised surplus/(deficit) 
on revaluation  
Closing market value 
Add finance lease obligations 
recognised separately 
Closing fair value of 
investment property 

Investment 
2016 
£m 
915.6 

124.5 
2.7 
127.2 
– 
16.4 
0.6 
– 
(0.6) 

35.7 
1,094.9 

IPUC 
2016 
£m 
6.7 

– 
– 
– 
17.7 
(16.4) 
3.1 
0.5 
(0.8) 

0.7 
11.5 

Total 
2016 
£m 
922.3 

124.5 
2.7 
127.2 
17.7 
– 
3.7 
0.5 
(1.4) 

36.4 
1,106.4 

Investment 
2015 
£m 
638.8 

229.8 
0.7 
230.5 
– 
24.5 
1.5 
– 
(2.0) 

22.3 
915.6 

3.0 

– 

3.0 

3.0 

1,097.9 

11.5 

1,109.4 

918.6 

Market value of investment property as estimated by valuer 
Add IPUC 
Add pharmacy lease premiums 
Add finance lease obligations recognised separately 
Fair value for financial reporting purposes 
Vacant property held for sale 
Land held for sale 
Total property assets held for sale 
Total property assets 

IPUC 
2015 
£m 
14.8 

0.5 
– 
0.5 
14.0 
(24.5) 
4.7 
0.4 
(2.3) 

(0.9) 
6.7 

– 

6.7 

2016 
£m 
1,088.0 
11.5 
6.9 
3.0 
1,109.4 
– 
1.7 
1.7 
1,111.1 

Total 
2015 
£m 
653.6 

230.3 
0.7 
231.0 
14.0 
– 
6.2 
0.4 
(4.3) 

21.4 
922.3 

3.0 

925.3 

2015 
£m 
908.3 
6.7 
7.3 
3.0 
925.3 
0.6 
4.8 
5.4 
930.7 

Three land sites are held as available for sale (2015: three property investments and eight land sites). 

Fair value hierarchy 
The fair value measurement hierarchy for all investment property and IPUC as at 31 March 2016 was Level 3 – Significant 
unobservable inputs (2015: Level 3). There were no transfers between Levels 1, 2 or 3 during the year. 

106 Assura plc Annual Report 2016  
106  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. Property assets continued 
Descriptions and definitions relating to valuation techniques and key unobservable inputs made in determining fair values are 
as follows: 

Valuation techniques: market comparable method 
Under the market comparable method (or market comparable approach), a property's fair value is estimated based on 
comparable transactions. 

Unobservable inputs 
These include: estimated rental value (“ERV”) based on market conditions prevailing at the valuation date; estimated average 
increase in rent based on both market estimations and contractual situations; equivalent yield (defined as the weighted average of 
the net initial yield and reversionary yield); and the physical condition of the property determined by inspections on a rotational basis. 

11. Property, plant and equipment 
The Group holds computer and other equipment assets with cost of £0.7 million (2015: £0.5 million) and accumulated depreciation 
of £0.5 million (2015: £0.4 million), giving a net book value of £0.2 million (2015: £0.1 million). 

Additions during the year were £0.2 million (2015: £nil) and depreciation charged to the income statement was £0.1 million 
(2015: £nil). 

12. Cash, cash equivalents and restricted cash 

Cash held in current account 

Restricted cash 

2016 
£m 

43.7 

0.6 

44.3 

2015 
£m 

65.3 

1.2 

66.5 

Restricted cash arises where there are rent deposits, interest payment guarantees, cash is ring-fenced for committed property 
development expenditure, which is released to pay contractors’ invoices directly, or under the terms of security arrangements 
under the Group’s banking facilities or its bond. 

13. Trade and other receivables 

Trade receivables 

Prepayments and accrued income 

Other debtors 

2016 
£m 

4.2 

1.2 

2.1 

7.5 

2015 
£m 

5.6 

1.1 

1.6 

8.3 

Trade and other receivables disclosed above are classified as loans and receivables and are therefore measured at amortised cost. 

The Group’s principal customers are invoiced and pay quarterly in advance, usually on the English quarter days. Other debtors are 
generally on 30–60 days’ terms. No bad debt provision was required during the year (2015: £nil).  

As at 31 March 2016 and 31 March 2015, the analysis of trade debtors that were past due but not impaired is as follows: 

2016 
2015 

Past due but not impaired 

Neither past 
due nor 
impaired 
£m 

>30 days 
£m 

>60 days 
£m 

>90 days 
£m 

>120 days 
£m 

3.8 
5.0 

0.2 
0.4 

0.1 
– 

0.1 
0.2 

– 
– 

Total 
£m 

4.2 
5.6 

The bulk of the Group’s income derives from the NHS or is reimbursed by the NHS, hence the risk of default is minimal.  

www.assuraplc.com

Assura plc Annual Report 2016  107 
Assura plc Annual Report 2016  107

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

14. Trade and other payables 

Trade creditors 

Other creditors and accruals 

VAT creditor 

2016 
£m 

2.8 

11.8 

1.9 

16.5 

2015 
£m 

2.5 

13.5 

2.9 

18.9 

Finance lease arrangements are amounts payable in respect of leasehold investment property held by the Group. The amounts 
due after more than one year, which total £3.0 million (2015: £3.0 million), have been disclosed in non-current liabilities on the 
consolidated balance sheet. The maturity of trade and other payables and the minimum payments due under finance leases 
are disclosed in Note 23. The fair value of the Group’s lease obligations is approximately equal to their carrying value. 

15. Deferred revenue 

Arising from rental received in advance 

Arising from pharmacy lease premiums received in advance 

Current 

Non-current 

16. Provisions 

At 1 April 

Utilisation of provision 
At 31 March  

Analysed as: 
Current 
Non-current 

2016 
£m 

13.7 

6.9 
20.6 

14.2 

6.4 
20.6 

2016 
£m 

0.4 

(0.1) 
0.3 

0.3 
– 
0.3 

2015 
£m 

12.3 

7.3 
19.6 

12.7 

6.9 
19.6 

2015 
£m 

0.5 

(0.1) 
0.4 

0.1 
0.3 
0.4 

Provisions relate to the onerous property lease on the former Pall Mall office and represent management’s best estimate of the 
Group’s liability. The lease expires in July 2016. 

108 Assura plc Annual Report 2016  
108  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17. Borrowings 

At 1 April  
Amount drawn down in year 
Amount repaid in year 
Assumed with acquisition of properties/subsidiaries 
Amortisation of loan fair value adjustments 
Cash settlement of loan fair value adjustments 
Loan issue costs 
Amortisation of loan issue costs  
At 31 March  

Due within one year 
Due after more than one year 
At 31 March  

The Group has the following bank facilities: 

2016 
£m 
513.5 
45.0 
(188.5) 
– 
– 
– 
(1.4) 
0.6 
369.2 

4.0 
365.2 
369.2 

2015 
£m 
450.3 
– 
(64.1) 
135.3 
(0.3) 
(7.8) 
(0.5) 
0.6 
513.5 

8.0 
505.5 
513.5 

1.  10-year senior secured bond for £110 million at a fixed interest rate of 4.75% maturing in December 2021. The secured bond 
carries a loan to value covenant of 75% (70% at the point of substitution of an investment property or cash) and an interest 
cover requirement of 1.15 times (1.5 times at the point of substitution).  

2.  Loans from Aviva Commercial Finance with an aggregate balance of £217.8 million at 31 March 2016 (2015: £406.6 million). 
The Aviva loans are partially amortised by way of quarterly instalments and partially repaid by way of bullet repayments falling 
due between 2024 and 2044 with a weighted average term of 13.8 years to maturity; £4.0 million is due within a year. These 
loans are secured by way of charges over specific medical centre investment properties with cross-collateralisation between 
the loans and security. The loans are subject to fixed all-in interest rates ranging between 4.11% and 6.66% and a weighted 
average of 5.43%. The loans carry a debt service cover covenant of 1.05 times and a loan to value covenant of 70%, 
calculated across all loans and secured properties. 

In November 2015, in line with the debt reduction plan announced in the Prospectus for the October 2015 equity raise, 
£182.0 million of loans were repaid along with associated early repayment costs of £34.1 million. 

3.  Five-year club revolving credit facility with RBS, HSBC and Barclays for £120 million at an initial margin of 1.70% above LIBOR, 
expiring in May 2020. The facility is subject to a historical interest cover requirement of at least 175% and a weighted average 
lease length of nine years. The facility attracts a non-utilisation fee equal to 40% of the applicable margin. As at 31 March 2016, 
£45.0 million of this facility was drawn (2015: undrawn). Subsequent to the year end, this facility has been replaced with a new 
unsecured revolving credit facility of £200 million. 

The Group has been in compliance with all financial covenants on all of the above loans as applicable throughout the year. 

www.assuraplc.com

Assura plc Annual Report 2016  109 
Assura plc Annual Report 2016  109

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

18. Share capital 

Ordinary Shares issued and fully paid 

At 1 April 

Issued 13 June 2014 

Issued 15 October 2014 

Issued 6 November 2014 

Issued 20 July 2015 

Issued 25 September 2015 

Issued 14 October 2015 

Issued 4 November 2015 

Issued 20 January 2016 

Issued 27 January 2016 

At 31 March  
Own shares held 

Total share capital 

Number of 
shares 
2016 

Share  
capital 
2016 
£m 

Number of 
shares 
2015 

1,006,900,141 

100.7 

529,548,924 

– 

– 

– 

4,545,455 

3,543,975 

618,000,000 

2,229,072 

1,611,873 

876,222 

– 

– 

– 

44,264,196 

414,252,873 

18,834,148 

0.4 

0.4 

61.8 

0.2 

0.2 

0.1 

– 

– 

– 

– 

– 

– 

Share  
capital 
2015 
£m 

53.0 

4.4 

41.4 

1.9 

– 

– 

– 

– 

– 

– 

1,637,706,738 
(1,256,714) 

163.8 
(0.6)

1,006,900,141 
(3,911,551) 

1,636,450,024 

163.2 

1,002,988,590 

100.7 
(1.8) 

98.9 

Ordinary Shares issued on 20 July 2015, 4 November 2015 and 27 January 2016 represent shares issued as part consideration 
for the acquisition of investment properties held in corporate vehicles. The shares were valued based on the closing share price 
the day before issuance with this amount appropriately allocated between share capital and share premium.  

On 25 September 2015, 3,543,975 Ordinary Shares were issued following employees exercising nil-cost options awarded under 
the VCP. Further information can be found in respect of the VCP in Note 20 and on pages 79 and 80 of the Remuneration Report.  

On 14 October 2015, 618,000,000 Ordinary Shares were issued by way of a Firm Placing, Placing and Open Offer and Offer for 
Subscription at a price of 50 pence per Ordinary Share. Gross proceeds to the Company were £309.0 million, which has been 
allocated appropriately between share capital (£61.8 million) and share premium (£247.2 million). Issue costs totalling £9.5 million 
were incurred and have been allocated against share premium.  

On 20 January 2016, 1,611,873 Ordinary Shares were issued to shareholders who elected to receive Ordinary Shares in lieu 
of a cash dividend under the Company scrip dividend alternative. This represented 9.9% of shareholders.  

On 28 January 2015, Assura plc replaced Assura Group Limited as the top company in the Group following a scheme of 
arrangement sanctioned by the Royal Court of Guernsey. This capital restructuring was accounted for under merger accounting 
principles meaning the consolidated accounts have been presented as though the Group had always been constructed this way. 
Movements in the above table prior to 28 January 2015 relate to Assura Group Limited, with all subsequent movements relating 
to Assura plc. 

Own shares held comprise shares held by the Employee Benefit Trust. 

110 Assura plc Annual Report 2016  
110  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
19. Dividends paid on Ordinary Shares 

Payment date 
23 April 2014 
23 July 2014 
5 November 2014 
21 January 2015 
30 April 2015 
22 July 2015 
4 November 2015 
20 January 2016 

Pence per 
share 
0.45 
0.45 
0.45 

Number of 
Ordinary 
Shares 
529,548,924 
573,813,120 
988,065,993 
0.5  1,006,900,141 
0.5  1,006,900,141 
0.5  1,006,900,141 
0.5  1,632,989,571 
0.55  1,635,218,643 

2016 
£m 
– 
– 
– 
– 
5.0 
5.0 
8.2 
9.0 
27.2 

2015 
£m 
2.4 
2.6 
4.4 
5.0 
– 
– 
– 
– 
14.4 

A dividend of 0.55 pence per share was paid to shareholders on 20 April 2016. Subsequent to the payment, it was brought to the 
attention of the Directors that the dividend payment was technically an infringement of the Companies Act due to interim accounts 
not having been filed at Companies House. Further information is provided in the Directors’ Report on page 88. 

A quarterly dividend for 2016/17 of 0.55 pence per share is currently planned to be paid on 20 July 2016 to shareholders on the 
share register at 16 July 2016.  

A scrip dividend alternative was introduced with effect from the January 2016 quarterly dividend. Details of shares issued in lieu 
of dividend payments can be found in Note 18. 

The dividends paid do not include any PIDs as defined under the REIT regime. 

20. Share-based payments 
As at 31 March 2016, the Group had two long-term incentive schemes in place – the Value Creation Plan (“VCP”) and the Executive 
Recruitment Plan (“ERP”). 

The long-term incentive arrangements are structured so as to align the incentives of relevant Executives with the long-term 
performance of the business and to motivate and retain key members of staff. To the extent practicable long-term incentives 
are provided through the use of share-based (or share-fulfilled) remuneration to provide alignment of objectives with the Group’s 
shareholders. Long-term incentive awards are granted by the Remuneration Committee which reviews award levels on a case 
by case basis. 

As at 31 March 2016 the Employee Benefit Trust held a total of 1,256,714 (2015: 3,911,551) Ordinary Shares of 10 pence each 
in Assura plc. Previous long-term incentive plans have lapsed without vesting. 

Value Creation Plan 
As at 31 March 2016, a total of 848,950 performance units (2015: 848,950) had been granted to employees (including 575,000 
units granted to Executive Directors as detailed in the Remuneration Committee Report).  

Participants have the opportunity to receive 10% of the total value created for shareholders above a threshold price determined 
at three Measurement Dates in a five-year measurement period. Before any awards vest, which are granted as nil-cost options on 
conversion of any value created, a minimum level of Total Shareholder Return of 8% per annum compound growth from the Base 
Price at each Measurement Date must be achieved.  

At the first Measurement Date in August 2015, nil-cost options over 24,999,450 Ordinary Shares were awarded to scheme 
participants. 50% of these were exercisable in September 2015 with the remainder exercisable in 2016 or 2017 subject to 
achievement of certain performance hurdles. Further details in respect of the VCP are provided in the Remuneration Committee 
Report on pages 79 and 80. 

Executive Recruitment Plan 
During a prior year, a nil-cost contingent award of 460,002 Ordinary Shares was made under the ERP. The scheme is in respect 
of one Executive Director and full details are provided in the Remuneration Committee Report on page 81. 

www.assuraplc.com

Assura plc Annual Report 2016  111 
Assura plc Annual Report 2016  111

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

20. Share-based payments continued 
All schemes 
The fair value of equity settled units granted during 2013 was estimated as at the date of grant using the Monte Carlo Model, taking 
into account the terms and conditions upon which units were granted. The following table lists the inputs to the models used for 
the year ended 31 March 2013, being the last point at which a valuation was required under IFRS 2: 

Dividend yield (%) 

Expected share price volatility (%) 

Risk free interest rate (%) 

Expected life of units (years) 

2013 

3.5 

20.7 

0.74 

4.5 

The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be 
the actual outcome. 

The fair value of the units granted in 2013 was £2,475,000 based on the market price at the date the units were granted. This cost 
is allocated over the vesting period. The cost allocation for all outstanding units in the period was a charge of £468,500 (2015: 
charge of £623,500) and an additional charge has been recorded during the year in respect of the employer national insurance 
contributions payable on the awards so that the total income statement charge was £1.9 million (2015: £0.7 million). 

No share options were outstanding as at 31 March 2016. For share options outstanding as at 31 March 2015, the weighted 
average remaining contractual life was 0.83 years. No share options were granted during 2016 (2015: none). 

21. Note to the consolidated cash flow statement 

Reconciliation of net profit before taxation to net cash inflow from operating activities: 

Net profit before taxation 

Adjustments for: 

Decrease in debtors 

(Decrease)/increase in creditors 

Decrease in provisions 

Revaluation gain 

Interest capitalised on developments 

Gain on revaluation of financial instrument 

(Gain)/loss on disposal of properties 

Amortisation of acquired loans fair value adjustment 

Depreciation 

Early repayment costs  

Employee share-based incentive costs 

Amortisation of loan issue costs 

Net cash inflow from operating activities 

2016 
£m 

2015 
£m 

28.8 

36.6 

0.5 

(1.5) 

(0.1) 

(36.4) 

(0.5) 

– 

(0.1) 

– 

0.1 

34.1 

(2.6) 

0.6 

22.9 

0.9 

0.3 

(0.1) 

(21.4) 

(0.4) 

(0.1) 

0.1 

(0.3) 

– 

– 

0.7 

0.6 

16.9 

112 Assura plc Annual Report 2016  
112  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
22. Deferred tax 
Deferred tax consists of the following: 

At 1 April 
Income statement movement 
At 31 March  

2016 
£m 
1.3 
(0.9) 
0.4 

The amount of deductible temporary differences and unused tax losses (which have not been recognised) are as follows: 

Tax losses 
Other timing differences 

2016 
£m 
213.4 
6.0 
219.4 

The majority of tax losses carried forward relate to capital losses generated on the disposal of former divisions of the Group. 

The following deferred tax assets have not been recognised due to uncertainties around future recoverability: 

Tax losses 
Other temporary differences 

2016 
£m 
38.4 

1.1 
39.5 

2015 
£m 
0.7 
0.6 
1.3 

2015 
£m 
212.0 
6.0 
218.0 

2015 
£m 
42.4 

1.2 
43.6 

23. Derivatives and other financial instruments 
The Group holds cash and liquid resources as well as having debtors and creditors that arise directly from its operations.  

The main risks arising from the Group's financial instruments and properties are credit risk, liquidity risk, interest rate risk and 
capital risk. The Board regularly reviews and agrees policies for managing each of these risks and these are summarised below. 

Credit risk 
Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet a commitment that it has entered into 
with the Group.  

In the event of a default by an occupational tenant, the Group will suffer a rental income shortfall and may incur additional costs, 
including legal expenses, in maintaining, insuring and re-letting the property. Given the nature of the Company’s tenants and 
enhanced rights of landlords who can issue proceedings and enforcement by bailiffs, defaults are rare and potential defaults are 
managed carefully by the credit control department. The maximum credit exposure in aggregate is one quarter’s rent of circa 
£16 million; however, this amount derives from all the tenants in the portfolio and such a scenario is hypothetical. The Group’s 
credit risk is well spread across circa 685 tenants at any one time. Furthermore the bulk of the Group’s property income derives 
from the NHS or is reimbursed by the NHS, which has an obligation to ensure that patients can be seen and treated and steps 
in when GPs are unable to practise, hence the risk of default is minimal. 

The maximum credit risk exposure relating to financial assets is represented by their carrying values as at the balance sheet date.  

www.assuraplc.com

Assura plc Annual Report 2016  113 
Assura plc Annual Report 2016  113

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

23. Derivatives and other financial instruments continued 
Liquidity risk 
Liquidity risk is the risk that the Group will encounter in realising assets or otherwise raising funds to meet financial commitments. 
Investments in property are relatively illiquid; however, the Group has tried to mitigate this risk by investing in modern purpose built 
medical centres which are let to GPs and NHS PropCo. In order to progress its property investment and development programme, 
the Group needs access to bank and equity finance, both of which may be difficult to raise notwithstanding the quality, long lease 
length, NHS backing and geographical and lot size diversity of its property portfolio. 

The Group manages its liquidity risk by ensuring that it has a spread of sources and maturities. 

The Group has entered into commercial property leases on its investment property portfolio. These non-cancellable leases have 
remaining terms of up to 30 years and have a weighted average lease length of 14.0 years. All leases are subject to revision of 
rents according to various rent review clauses. Future minimum rentals receivable under non-cancellable operating leases along 
with trade and other receivable as at 31 March are as follows: 

Receivables as at 31 March 2016 
Non-cancellable leases 
Trade and other receivables 

Receivables as at 31 March 2015 
Non-cancellable leases 
Trade and other receivables 

On 
demand 
£m 
– 
– 
– 

Less than 
3 months 
£m 
15.9 
7.5 
23.4 

On 
demand 
£m 
– 
– 
– 

Less than 
3 months 
£m 
14.0 
8.3 
22.3 

3 to 12 
months 
£m 
47.8 
– 

47.8 

3 to 12 
months 
£m 
41.9 
– 
41.9 

1 to 5 
years 
£m 
252.7 
– 

252.7 

1 to 5 
years 
£m 
223.9 
– 
223.9 

>5 years 
£m 
629.0 
– 

629.0 

>5 years 
£m 
573.2 
– 
573.2 

Total 
£m 
945.4 
7.5 
952.9 

Total 
£m 
853.0 
8.3 
861.3 

The table below summarises the maturity profile of the Group’s financial liabilities, including interest, at 31 March 2016 and 
31 March 2015 based on contractual undiscounted payments at the earliest date which the Group can be required to pay. 

The total contracted discounted payments are higher than the total minimum rentals receivable due to the rent receivable not 
including any residual values on properties at the end of the lease contract. In practice, the Group expects a significant renewal 
of leases at the end of the lease term. 

Payables as at 31 March 2016 
Non-derivative financial liabilities: 
Interest bearing loans and borrowings 
Trade and other payables 
Total financial liabilities 

Payables as at 31 March 2015 
Non-derivative financial liabilities: 
Interest bearing loans and borrowings 
Trade and other payables 
Total financial liabilities 

On 
demand 
£m 

Less than 
3 months 
£m 

3 to 12 
months 
£m 

– 
– 
– 

6.5 
13.3 
19.8 

14.4 
3.2 
17.6 

On 
demand 
£m 

Less than 
3 months 
£m 

3 to 12 
months 
£m 

– 
– 
– 

10.2 
14.2 
24.4 

25.4 
3.5 
28.9 

1 to 5 
years 
£m 

99.8 
0.2 
100.0 

1 to 5 
years 
£m 

172.5 
0.1 
172.6 

>5 years 
£m 

406.8 
2.8 
409.6 

>5 years 
£m 

650.0 
2.9 
652.9 

Total 
£m 

527.5 
19.5 
547.0 

Total 
£m 

858.1 
20.7 
878.8 

114 Assura plc Annual Report 2016  
114  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23. Derivatives and other financial instruments continued 
Interest rate risk 
The Group’s exposure to market risk for changes in interest rates relates primarily to the Group’s cash deposits and, as debt 
is utilised, long-term debt obligations. The Group’s policy is to manage its interest cost using fixed rate debt, or by interest rate 
swaps, for the majority of loans and borrowings although the Group will accept some exposure to variable rates where deemed 
appropriate and restricted to one third of the loan book. The swaps are revalued to their market value by reference to market 
interest rates at each balance sheet date. 

The ageing analysis of the financial assets and liabilities excluding trade receivables and payables of the Group at 31 March 2016 
was as follows: 

Floating rate asset 
Cash 

Liabilities (fixed rate unless stated) 
Long-term loans: 

Revolving credit facility (variable rate) 
Bond 
Aviva 

Payments due under finance leases 

Within  
1 year 
£m 

1 to 5  
years 
£m 

>5 years 
£m 

Total 
£m 

44.3 

– 

– 

44.3 

– 
– 
(4.0) 
– 

(45.0) 
– 
(18.6) 
(0.2) 

– 
(110.0) 
(195.2) 
(2.8) 

(45.0) 
(110.0) 
(217.8) 
(3.0) 

In November 2011 the Group issued a £110.0 million 10-year senior secured bond at 4.75%. 

Aviva loans decreased during the period to £217.8 million (2015: £406.6 million). The Aviva loans are partially amortised by way of 
quarterly instalments and partially repaid by way of bullet repayments falling due between 2024 and 2044. £4.0 million is due within 
a year. These loans are secured by way of charges over specific medical centre investment properties with cross-collateralisation 
between the loans and security. The loans are subject to fixed all-in interest rates ranging between 4.11% and 6.66%. 

The Group has a revolving credit facility of £120 million which expires in 2020. Interest is charged at an initial rate of LIBOR 
plus 1.7% 

The ageing analysis of the financial assets and liabilities excluding trade receivables and payables of the Group at 31 March 2015 
was as follows: 

Floating rate asset 
Cash 

Fixed rate (all liabilities) 
Long-term loans: 

Bond 
Aviva 

Payments due under finance leases 

Within  
1 year 
£m 

1 to 5  
years 
£m 

>5 years 
£m 

Total 
£m 

66.5 

– 

– 

66.5 

– 
(8.0) 
(0.1) 

– 
(37.2) 
(0.1) 

(110.0) 
(361.4) 
(2.8) 

(110.0) 
(406.6) 
(3.0) 

www.assuraplc.com

Assura plc Annual Report 2016  115 
Assura plc Annual Report 2016  115

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the accounts continued
Notes to the accounts continued 
For the year ended 31 March 2016
For the year ended 31 March 2016 

23. Derivatives and other financial instruments continued 
Sensitivity analysis 
As at 31 March 2016, 88% of debt drawn by the Group is subject to fixed interest rates. A 0.25% movement in interest rates would 
change underlying profit by £0.1 million based on the amount of variable rate debt drawn. 

Cash 
Long-term loans 
Payments due under finance leases 

Book value 

Fair value 

2016 
£m 
44.3 
(369.2) 
(3.0) 

2015 
£m 
66.5 
(513.5) 
(3.0) 

2016 
£m 
44.3 
(429.4) 
(3.0) 

2015 
£m 
66.5 
(604.2) 
(3.0) 

The Group is exposed to the valuation impact on investor sentiment of long-term interest rate expectations, which can impact 
transactions in the market and increase or decrease valuations accordingly. 

Capital risk 
The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions. To maintain 
or adjust the capital structure, the Group may make disposals, adjust the dividend payment to shareholders, return capital to 
shareholders or issue new shares.  

The Group monitors capital structure with reference to loan to value (“LTV”), which is calculated as net debt divided by total 
property. The LTV percentage on this basis is 30% at 31 March 2016 (48% at 31 March 2015).  

Investment property 
Investment property under construction 
Held for sale – investment property 
Held for sale – land 
Total property  

Loans 
Finance lease 
Cash 

Net debt 

LTV 

2016 
£m 
1,097.9 
11.5 
– 
1.7 
1,111.1 

2016 
£m 

369.2 
3.0 
(44.3) 
327.9 

2015 
£m 
918.6 
6.7 
0.6 
4.8 
930.7 

2015 
£m 

513.5 
3.0 
(66.5) 
450.0 

30% 

48% 

24. Commitments 
At the year end the Group had two (2015: five) developments on site with a contracted total expenditure of £13.5 million  
(2015: £22.2 million) of which £8.5 million (2015: £6.1 million) had been expended.  

25. Related party transactions 
Details of transactions during the year and outstanding balances at 31 March 2016 in respect of associates are detailed in Note 9. 

Details of payments to key management personnel are provided in Note 4. 

26. Post balance sheet events 
Subsequent to the year end, a subsidiary of the Group has replaced the existing revolving credit facility with a new unsecured 
revolving credit facility of £200 million with the potential to extend further to £300 million.  

116 Assura plc Annual Report 2016  
116  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Company income statement
Company income statement 
For the year ended 31 March 2016
For the year ended 31 March 2016 

Revenue 
Dividends received from subsidiary companies 
Group management charge 
Total revenue 
Administrative expenses 
Share-based payment charge 
Operating profit 

Profit before taxation 
Taxation 
Profit attributable to equity holders 

01/04/2015 
to 
31/03/2016 
£m 

01/01/2015 
to 
31/03/2015 
£m 

50.0 
1.2 
51.2 
(2.1) 
(1.9) 
47.2 

47.2 
– 
47.2 

30.0 
– 
30.0 
– 
– 
)
30.0  

30.0 
– 
30.0 

All amounts relate to continuing activities. There were no items of other comprehensive income or expense and therefore the profit 
for the period also reflects the Company’s total comprehensive income. 

www.assuraplc.com

Assura plc Annual Report 2016  117 
Assura plc Annual Report 2016  117

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Company balance sheet
Company balance sheet 
As at 31 March 2016
As at 31 March 2016 

Non-current assets 

Investments in subsidiary companies 

Current assets 

Cash and cash equivalents 
Other receivables 
Amounts owed by subsidiary companies 

Current liabilities 

Trade and other payables 

Net assets 

Represented by: 

Capital and reserves 

Share capital  
Share premium 
Own shares held 
Merger reserve 
Reserves 

Total equity 

Note 

B 

C 

D 

18 

2016 
£m 

396.7 
396.7 

5.2 
0.1 
345.8 
351.1 

(1.5) 
(1.5) 

2015 
£m 

396.7 
396.7 

1.0 
– 
26.6 
27.6 

– 
– 

746.3 

424.3 

163.8 
241.9 
(0.6) 
295.4 
45.8 

746.3 

100.7 
– 
(1.8) 
295.4 
30.0 

424.3 

The financial statements were approved at a meeting of the Board of Directors held on 17 May 2016 and signed on its behalf by: 

SIMON LAFFIN 
EXECUTIVE CHAIRMAN 

JONATHAN MURPHY
FINANCE DIRECTOR 

Company registered number: 9349441 

118 Assura plc Annual Report 2016  
118  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Company statement of changes in equity
Company statement of changes in equity 
For the period ended 31 March 2016
For the year ended 31 March 2016 

1 January 2015 
Profit attributable to equity holders 
Total comprehensive income 
Cancellation of opening shares 
Scheme of arrangement  
Share issue costs 
Own shares held 
31 March 2015 

Profit attributable to equity holders 
Total comprehensive income 
Issue of Ordinary Shares 
Share issue costs 
Dividends 
Employee share-based incentives 
31 March 2016 

Note 

18 

18 

19 

Share  
capital 
£m 
0.1 
– 
– 
(0.1) 
100.7 
– 
– 
100.7 

– 
– 
62.5 
– 
0.2 
0.4 
163.8 

Share 
premium 
£m 
– 
– 
– 
– 
– 
– 
– 
– 

– 
– 
250.7 
(9.5) 
0.7 
– 
241.9 

Own 
shares 
 held  
£m 
– 
– 
– 
– 
– 
– 
(1.8) 
(1.8) 

– 
– 
(0.3) 
– 
– 
1.5 
(0.6) 

Merger 
reserve 
£m 
– 
– 
– 
– 
296.0 
(0.6) 
– 
295.4 

– 
– 
– 
– 
– 
– 
295.4 

Reserves 
£m 
– 
30.0 
30.0 
– 
– 
– 
– 
30.0 

47.2 
47.2 
– 
– 
(27.2) 
(4.2) 
45.8 

Total 
equity 
£m 
0.1 
30.0 
30.0 
(0.1) 
396.7 
(0.6) 
(1.8) 
424.3 

47.2 
47.2 
312.9 
(9.5) 
(26.3) 
(2.3) 
746.3 

www.assuraplc.com

Assura plc Annual Report 2016  119 
Assura plc Annual Report 2016  119

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Company cash flow statement
Company cash flow statement 
For the period ended 31 March 2016
For the period ended 31 March 2016 

Operating activities 

Dividends received from subsidiaries 

Charges received from subsidiaries 

Amounts paid to suppliers and employees 

Net cash inflow from operating activities 

Investing activities 
Net loans advanced to subsidiaries 
Net cash outflow from investing activities 

Financing activities 
Issue of Ordinary Shares 
Issue costs paid on issuance of Ordinary Shares 
Dividends paid 
Net cash inflow/(outflow) from financing activities 

Increase in cash and cash equivalents 
Cash and cash equivalents at start of period  
Cash and cash equivalents at end of period 

01/04/2015 
to 
31/03/2016 
£m 

01/01/2015 
to 
31/03/2015 
£m 

Note 

50.0 

1.2 

(5.2) 

46.0 

30.0 

– 

– 

30.0 

(314.6) 
(314.6) 

(28.4) 
(28.4) 

308.6 
(9.5) 
(26.3) 
272.8 

4.2 
1.0 
5.2 

– 
(0.6) 
– 
(0.6) 

1.0 
– 
1.0 

C 

120 Assura plc Annual Report 2016  
120  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the Company accounts
Notes to the Company accounts 
For the period ended 31 March 2016
For the period ended 31 March 2016 

A. Accounting policies and corporate information 
The accounts of the Company are separate to those of the Group. 

The accounting policies of the Company are consistent with those of the Group which can be found in Note 2 to the 
Group accounts. 

B. Investments in subsidiary companies 

Cost 
Provision for diminution in value 

Details of all subsidiaries as at 31 March 2016 are shown in Note 9 to the Group accounts. 

C. Cash and cash equivalents 

Cash held in current account 

D. Loans to subsidiary companies – current 

Amounts owed by Group undertakings 

The above loans are unsecured, non-interest bearing and repayable upon demand. 

2016 
£m 
396.7 
– 
396.7 

2016 
£m 
5.2 

2016 
£m 
345.8 

2015 
£m 
396.7 
– 
396.7 

2015 
£m 
1.0 

2015 
£m 
26.6 

The recoverable amount of loans receivable from subsidiaries is reviewed annually by reference to the subsidiary balance sheet and 
expected future activities, with a provision recorded to the extent the loan is not considered recoverable. No provision has been 
deemed necessary. 

E. Related party transactions 

Group undertakings 

31 March 2016 

31 March 2015 

The above transactions are with subsidiaries. 

Charges 
received 
£m 

Dividends 
 received 
£m 

Amounts 
 owed by 
£m 

Amounts 
 owed to 
£m 

1.2 

– 

50.0 

30.0 

345.8 

26.6 

– 

– 

www.assuraplc.com

Assura plc Annual Report 2016  121 
Assura plc Annual Report 2016  121

Strategic reportFinancial statements Governance www.assuraplc.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes to the Company accounts continued
Notes to the Company accounts continued 
For the period ended 31 March 2016
For the period ended 31 March 2016 

F. Risk management 
Credit risk 
Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet a commitment that it has entered into with 
the Company.  

Credit risks within the Company derive from non-payment of loan balances. However, as the balances are receivable from 
subsidiary companies the risk of default is considered minimal. 

The maximum credit risk exposure relating to financial assets is represented by the carrying value as at the balance sheet date.  

The Company balance sheet largely comprises illiquid assets in the form of investments in subsidiaries and loans to subsidiaries, 
which have been used to finance property investment and development activities. Accordingly the realisation of these assets may 
take time and may not achieve the values at which they are carried in the balance sheet. 

The Company’s other assets are cash of £5.2 million (31 March 2015: £1.0 million). The Company had trade and other payables 
of £1.5 million at 31 March 2016 (31 March 2015: £nil). 

There are no differences between the book value of cash and trade payables, nor is there any meaningful interest rate sensitivity. 

122 Assura plc Annual Report 2016  
122  Assura plc Annual Report 2016

www.assuraplc.com

www.assuraplc.com  
 
 
 
 
 
Glossary

Adjusted Earnings per Ordinary 
Share from Continuing Operations 
(“Adjusted EPS”) is the profit attributable 
to equity holders of the parent adjusted 
for non-recurring items including goodwill 
impairment, revaluation losses on 
derivative financial instruments (including 
associates) and movements in deferred 
tax divided by the weighted average 
number of shares in issue during 
the period.

Average Debt Maturity is each 
tranche of Group debt multiplied by 
the remaining period to its maturity and 
the result divided by total Group debt 
in issue at the year end.

Average Interest Rate is the Group 
loan interest and derivative costs per 
annum at the year end, divided by total 
Group debt in issue at the year end.

BPF is the British Property Federation 
which is the membership organisation, and 
the voice, of the UK real estate industry.

Building Research Establishment 
Environmental Assessment Method 
(“BREEAM”) assesses the sustainability 
of buildings against a range of criteria.

Clinical Commissioning Groups 
(“CCGs”) are the groups of GPs and 
other healthcare professionals that took 
over commissioning of primary and 
secondary healthcare from PCTs in 
England with effect 1 April 2013.

Company is Assura plc.

Consumer Price Index (“CPI”) 
is an official measure of the general 
level of inflation as reflected in the 
weighted average of prices of a basket 
of consumer goods and services such 
as transportation, food, clothing, etc. 
CPI is commonly calculated on a monthly 
and annual basis.

Debt Service Cover is the number 
of times net interest payable plus debt 
amortisation is covered by underlying 
profit before net interest. 

Direct Property Costs comprise 
ground rents payable under head leases, 
void costs, other direct irrecoverable 
property expenses, rent review fees 
and valuation fees.

District Valuer (“DV”) is the District 
Valuer Service being the commercial arm 
of the Valuation Office Agency (“VOA”). 
It provides professional property advice 
across the public sector and in respect 
of primary healthcare represents NHS 
bodies on matters of valuation, rent reviews 
and initial rents on new developments.

Dividend Cover is the number of times 
the dividend payable (on an annual basis) 
is covered by underlying profit. 

Gross Rental Income is the gross 
accounting rent receivable. 

Group is Assura plc and its subsidiaries.

IFRS is International Financial 
Reporting Standards as adopted 
by the European Union.

Interest Cover is the number of 
times net interest payable is covered 
by underlying profit before net interest.

Interest Rate Swap is a contract to 
exchange fixed payments for floating 
payments linked to an interest rate, and 
is generally used to manage exposure 
to fluctuations in interest rates.

Earnings per Ordinary Share from 
Continuing Operations (“EPS”) is the 
profit attributable to equity holders of the 
parent divided by the weighted average 
number of shares in issue during the period.

IPD is the Investment Property Databank 
Limited which provides performance 
analysis for most types of real estate and 
produces an independent benchmark 
of property returns.

European Public Real Estate 
Association (“EPRA”) is the industry 
body for European REITs.

IPD Healthcare is the Investment 
Property Databank’s UK Annual 
Healthcare Property Index. 

EPRA Net Asset Value (“EPRA NAV”)  
is the balance sheet net assets excluding 
own shares held, mark to market 
derivative financial instruments (including 
associates) and deferred taxation.

EPRA NNNAV is the EPRA NAV 
adjusted to reflect the fair value of debt 
and derivatives.

Equivalent Yield (true and nominal) is 
a weighted average of the Net Initial Yield 
and Reversionary Yield and represents 
the return a property will produce based 
upon the timing of the income received. 
The true equivalent yield assumes rents 
are received quarterly in advance. The 
nominal equivalent assumes rents are 
received annually in arrears.

Estimated Rental Value (“ERV”) is 
the external valuers’ opinion as to the 
open market rent which, on the date of 
valuation, could reasonably be expected 
to be obtained on a new letting or rent 
review of a property.

IPD Total Return is calculated as the 
change in capital value, less any capital 
expenditure incurred, plus net income, 
expressed as a percentage of capital 
employed over the period, as calculated 
by IPD.

London Interbank Offered Rate 
(“LIBOR”) is the interest rate charged by 
one bank to another for lending money.

Local Improvement Finance Trusts 
(“LIFT”) are public-private consortia that 
develop primary care and community 
based facilities and services.

Loan to Value (“LTV”) is the ratio of 
net debt to the total value of property 
and LIFT assets.

Mark to Market (“MtM”) is the 
difference between the book value of 
an asset or liability and its market value.

Assura plc Annual Report 2016  123

Strategic reportFinancial statements Governance www.assuraplc.comGlossary continued

Net Initial Yield is the annualised 
rents generated by an asset, after 
the deduction of an estimate of annual 
recurring irrecoverable property outgoings, 
expressed as a percentage of the asset 
valuation (after notional purchaser’s costs). 
Development properties are not included.

Net Rental Income is the rental income 
receivable in the period after payment of 
direct property costs. Net rental income 
is quoted on an accounting basis. 

NHS Property Services Limited 
(“NHS PropCo”) is the company, wholly 
owned and funded by the Department 
of Health, which, as of 1 April 2013, has 
taken on all property obligations formerly 
borne by the PCTs. 

Primary Care Property is the property 
occupied by health services providers who 
act as the principal point of consultation 
for patients such as GP practices, dental 
practices, community pharmacies and high 
street optometrists.

Property Income Distribution (“PID”) 
is the required distribution of income 
as dividends under the REIT regime. 
It is calculated as 90% of exempted 
net income. 

Real Estate Investment Trust 
(“REIT”) is a listed property company 
which qualifies for and has elected into 
a tax regime, which exempts qualifying 
UK profits, arising from property rental 
income and gains on investment property 
disposals, from corporation tax, but 
requires the distribution of a PID.

Rent Reviews take place at intervals 
agreed in the lease (typically every three 
years) and their purpose is usually to 
adjust the rent to the current market 
level at the review date. 

Rent Roll is the passing rent being the 
total of all the contracted rents reserved 
under the leases.

Reversionary Yield is the anticipated 
yield, which the initial yield will rise to 
once the rent reaches the ERV and when 
the property is fully let. It is calculated 
by dividing the ERV by the valuation.

Retail Price Index (“RPI”) is an official 
measure of the general level of inflation 
asreflected in the retail price of a basket 
of goods and services such as energy, 
food, petrol, housing, household goods, 
travelling fares, etc. RPI is commonly 
computed on a monthly and annual basis.

RPI Linked Leases are those leases 
which have rent reviews which are linked 
to changes in the RPI.

Total Accounting Return is the overall 
return generated by the Group including 
the impact of debt. It is calculated as 
the movement on EPRA NAV for the 
year plus the dividends paid, divided 
by the opening EPRA NAV. 

Total Property Return is the overall 
return generated by properties on a debt 
free basis. It is calculated as the net rental 
income generated by the portfolio plus 
the change in market values, divided by 
opening property assets plus additions. 

Total Shareholder Return (“TSR”) 
is the combination of dividends paid 
to shareholders and the net movement 
in the share price during the year. It is 
calculated as the movement in the share 
price for the period plus the dividends 
paid, divided by the opening share price.

Underlying Profit is the pre-tax earnings 
measure adjusted for non-cash fair value 
adjustments and non-recurring items 
such as revaluation gains, revaluation 
of derivatives, share-based payment 
charge and gains on sale of property.

Weighted Average Unexpired Lease 
Term (“WAULT”) is the average lease 
term remaining to first break, or expiry, 
across the portfolio weighted by 
contracted rental income.

Yield on cost is the estimated annual 
rent of a completed development divided 
by the total cost of development including 
site value and finance costs expressed 
as a percentage return.

Yield shift is a movement (usually 
expressed in basis points) in the yield of 
a property asset, or like-for-like portfolio 
over a given period. Yield compression 
is a commonly-used term for a reduction 
in yields.

Forward-looking statements 
This document contains certain statements that are neither reported financial results nor other historical information. These statements 
are forward-looking in nature and are subject to risks and uncertainties. Actual future results may differ materially from those expressed in 
or implied by these statements. Many of these risks and uncertainties relate to factors that are beyond Assura’s ability to control or estimate 
precisely, such as future market conditions, the behaviour of other market participants, the actions of governmental regulators and other risk 
factors such as the Company’s ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory 
framework in which the Company operates or in economic or technological trends or conditions, including inflation and consumer confidence, 
on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak 
only as of the date of this document. Assura does not undertake any obligation to publicly release any revisions to these forward-looking 
statements to reflect events or circumstances after the date of this document. Information contained in this document relating to the Company 
should not be relied upon as a guide to future performance.

124  Assura plc Annual Report 2016

www.assuraplc.comCorporate information

Registered Office: 

The Brew House 
Greenalls Avenue 
Warrington 
Cheshire 
WA4 6HL

Company Secretary: 

Orla Ball

Auditor: 

Legal Advisors: 

Stockbrokers: 

Deloitte LLP 
2 Hardman Street 
Manchester 
M60 2AT

Addleshaw Goddard LLP 
100 Barbirolli Square 
Manchester 
M2 3AB

Stifel  
150 Cheapside 
London 
EC2V 6ET

Liberum Capital Limited 
Ropemaker Place 
25 Ropemaker Street 
London 
EC2Y 9LY

Bankers: 

Aviva plc

Barclays Bank plc

HSBC plc

Santander UK plc

The Royal Bank of Scotland plc

This report is printed on Galerie Satin which 
is made from pulp sourced from well managed 
forests and other controlled sources. Both 
the paper and the print factory are FSC® 
(Forest Stewardship Council®) certified. 

Design and production by Luminous
www.luminous.co.uk

www.assuraplc.com

Assura plc Annual Report 2016  125

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assura plc 
The Brew House 
Greenalls Avenue 
Warrington 
WA4 6HL

T: 01925 420660 
F: 01925 234503 
E: info@assura.co.uk

www.assuraplc.com

A

s

s

u

r

a

p

l

c

A

n

n

u

a

l

R

e

p

o

r

t

2

0

1

6